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Abstract 
Autism Spectrum Disorder (ASD) is a pervasive neurodevelopmental disorder 
characterised by social, communicative, and behavioural deficits. Despite decades of 
research in this field, effective pharmacological treatments for ASD are still lacking 
and better animal models for this disorder are urgently needed. Although it is now 
well understood that both genetic and environmental influences play a role in the 
aetiology of ASD, most existing animal models for this disorder only take into 
account one of these aetiological contributors and have largely ignored investigating 
an interaction. The main aim of this thesis was to develop a novel animal model for 
ASD that demonstrated higher construct validity than traditional models by using a 
gene-environment approach. To this aim, two previously established environmental 
risk factor-based models for ASD were each combined with a genetic rat model that 
mimicked a genotype associated with ASD. Specifically, a maternal immune 
activation model (modelled via prenatal administration of lipopolysaccharide) and a 
prenatal exposure to valproate model (modelled via prenatal administration of 
valproate) were both combined with a serotonin transporter (SERT) knockout rat 
model. Next, experimental rats were investigated in a variety of paradigms designed 
to detect behavioural, biochemical, and immunological outcomes related to ASD. 
This thesis tested the hypothesis that rats with a genetically compromised SERT 
function would be more vulnerable to the impacts of the two environmental risk 
factors. Collectively, the data from this thesis show that rats with a genetically 
compromised SERT function are not more vulnerable to the impacts of a maternal 
immune activation or prenatal exposure to VPA. In fact, at least with regards to 
prenatal exposure to valproate, rats with a compromised SERT function actually 
appeared more resilient to ASD-like outcomes. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
Parts of this chapter appear in “Perinatal influences of Valproate on Brain and 
Behaviour: An animal model for Autism” by Ranger and Ellenbroek (2015) (original 
copyright notice as given in the publication in which the material was originally 
published) with permission of Springer. 
 
Autism 
Autism (or Autism Spectrum Disorder, ASD) is a pervasive neurodevelopmental disorder 
characterised by a triad of behavioural symptoms: impaired social behaviour, impaired 
communication, and repetitive behaviour (Belzung, Leman, Vourc’h, & Andres, 2005). 
Clinical symptoms are expected by age 3 but signs of ASD have been observed as early 
as 6-12 months of age (Levy, Mandell, & Schultz, 2009). These deficits usually persist 
over the individual’s lifetime and only a small fraction of those with ASD function 
independently in adulthood (Kinney, Munir, Crowley, & Miller, 2008). Although this 
triad of symptoms forms the core of ASD, it is important to realise that many ASD 
patients also show a plethora of other symptoms. These auxiliary symptoms can be 
psychiatric (including depression and anxiety), behavioural (including aggression), 
intellectual (lower IQ in many cases), sensory (tactile hyperresponsiveness), and 
neurological (including pre-pulse inhibition deficits and epilepsy). Importantly, ASD is a 
spectrum disorder, showing a large heterogeneity with regards to its symptoms and 
severity (Hartley, Sikora, & McCoy, 2008; Levy et al., 2009; Perry, Minassian, Lopez, 
Maron, & Lincoln, 2007; Rogers, Hepburn, & Wehner, 2003; Simonoff et al., 2008; 
Tuchman & Rapin, 2002).  
Although estimates vary according to region, race, and sex, the most recent data on 
the prevalence of ASD suggests it affects 1 in 68 children (1.47%); a number that appears 
to have increased dramatically over the last 50 years (Wingate et al., 2014). The 
increasing prevalence is apparent even over the last few years: The Centres for Disease 
Control and Prevention (CDC) have been tracking prevalence data for ASD in the USA 
since the year 2000. The figures show a steady increase in prevalence over time; rising 
from 0.67% in the year 2000 to 1.47% in 2010. It is not yet clear whether the increasing 
prevalence reflects a true increase in the disorder or simply an increased awareness or 
broadening diagnostic criteria (Weintraub, 2011). Interestingly, a study investigating the 
ASD prevalence in England found that the prevalence in adults (0.98%) was comparable 
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with that in children at the time – a finding that would not be expected if there was a true 
increase in prevalence (Brugha et al., 2011). However, note that this 0.98% figure is still 
lower than the more recent estimates of prevalence provided by the CDC. Monitoring the 
prevalence of ASD is difficult for many reasons, including: the complexity of the disease, 
the lack of established biomarkers, and the ever-changing diagnostic criteria (Wingate et 
al., 2014). Interestingly, males are 4-5 times more likely to have ASD than females 
(Wingate et al., 2014). 
The impact of ASD is not only felt by its sufferers, but also by their families and 
society as a whole (Buescher, Cidav, Knapp, & Mandell, 2014; Cadman et al., 2012; 
Kinney et al., 2008). Families of individuals with ASD have to deal with significant 
emotional and financial burden (Barker et al., 2011; Cidav, Marcus, & Mandell, 2012; 
Stuart & McGrew, 2009). On average, families of ASD patients work less and earn less 
than families of healthy children (Cidav et al., 2012). These figures are, in part, 
presumably due to the time demands required in caring for a child with ASD. In fact, one 
Swedish study concluded that parents of individuals with ASD spend approximately 1000 
hours annually caring for their affected child (Järbrink, 2007).  
ASD is an extremely costly problem for society. The most recent research 
investigating the economic impact of ASD in the United Kingdom and the United States 
reported several key findings: first, the lifetime societal cost for one individual with ASD 
was approximately US$1.4 million in both countries. Second, this figure was significantly 
larger if the patient also had an intellectual disability. Third, when comparing the relative 
costs of children with ASD and adults with ASD, they found the aggregate societal cost 
for all children with ASD was US$4.5 billion annually in the United Kingdom and US$61 
billion annually in the USA; and the aggregate societal cost for all adults with ASD was 
US$43 billion annually in the United Kingdom, and US$175 billion annually in the USA. 
The major contributors to cost were specialised education and accommodation, and 
productivity loss (Buescher et al., 2014). These figures echo earlier findings from a 
Swedish study that estimated the societal cost of ASD in Sweden was approximately 
€50,000 annually per child; with the major contributors to cost stemming from 
community support and specialised schooling (Järbrink, 2007).  
Effective treatments for ASD are very limited – no pharmacological treatment 
currently exists that can cure ASD or ameliorate all of the core symptoms (Levy et al., 
2009; Vorstman et al., 2014). However, there is effective medication available to target 
many of the co-morbid problems associated with ASD such as irritability, aggression, 
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anxiety, and behavioural problems (Hsia et al., 2014; Murray et al., 2014; Politte & 
McDougle, 2014; Steckler, Spooren, & Murphy, 2014; Vorstman et al., 2014). In fact, it 
was reported that children and adolescents with ASD are 7 and 12 times more likely, 
respectively, to be prescribed psychostimulant medication, than healthy controls (Murray 
et al., 2014). Despite there being considerable world-wide variation in the way medical 
practitioners prescribe medication for those with ASD, anti-psychotics are the most 
commonly prescribed class of drug, with risperidone being the most commonly 
prescribed drug within this class. In fact, there are only two Food and Drug 
Administration (FDA)-approved drugs for ASD, both second generation antipsychotics: 
risperidone and aripiprazole (Hsia et al., 2014). The primary reason for the lack of 
effective medication for ASD is that the neurobiological underpinnings of this disorder 
are poorly understood, thus drug developers have few molecular targets to investigate 
(Vorstman et al., 2014). 
To reiterate: the exact causes of ASD are not well understood. However, results from 
twin and family studies suggest two important points: first, ASD is highly genetic with 
heritability estimates ranging from 50-95% (Colvert et al., 2015; Sandin et al., 2014). 
Second, as monozygotic twins do not have 100% concordance rates, environmental 
factors must also play a role in the aetiology of ASD (Bailey et al., 1995; Freitag, 2006; 
O'Roak & State, 2008; Ronald & Hoekstra, 2011; Steffenburg et al., 1989; Sykes & 
Lamb, 2007). The question of whether genetic or environmental influences play a bigger 
role in the aetiology of ASD is disputed; it has been claimed that environmental 
influences play a larger role than genetic factors, and that early estimates of the genetic 
liability to ASD were greatly overestimated (Hallmayer et al., 2011). However, the most 
recent evidence suggests genetic factors play a larger role than the environment in the 
development of ASD (Colvert et al., 2015). These conflicting results indicate that ASD 
may not just have heterogeneous symptomatology but also a heterogeneous aetiology 
(Tordjman et al., 2014). In other words, ASD patients with differing phenotypes may 
have developed ASD in differing ways. This hypothesis will be discussed in more detail 
in a later section. Together, the data suggest both genetic and environmental influences 
play a role in the aetiology of ASD, but the exact nature of this relationship remains 
unclear. 
Thus, there are four clear points that make ASD an important focus of research: first, 
the disastrous consequences for the individuals, their families, and society; second, the 
prevalence of this disorder appears to have increased over the last 50 years; third, the lack 
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of effective treatments; and finally, the complex and poorly understood nature of its 
aetiology.  
Two kinds of research are essential for the development of an effective treatment for 
ASD: first, clinical research aimed at identifying specific genetic and environmental 
factors that contribute to this disorder (Kinney et al., 2008; Vorstman et al., 2014); and 
second, preclinical research aimed at modelling these identified genetic and 
environmental risk factors in animals (Patterson, 2011). The current project is focused on 
the second kind of research. The objective is to develop a novel animal model for ASD by 
investigating the interaction between specific genetic and environmental risk factors that 
have been repeatedly linked to ASD. 
Unravelling the relationship between genetic and environmental risk factors can 
provide a deeper understanding of the aetiology of complex disorders (Caspi & Moffitt, 
2006; Di Forti, 2008; Rodier & Hyman, 1998). Research of this nature is achieved by 
examining the effect of an exposure to a particular environmental variable and observing 
how this same variable influences different genotypes (Caspi & Moffitt, 2006). Indeed, 
certain genotypes can make one more vulnerable or more resilient to the same 
environmental variable. Research investigating gene-environment interactions has shed 
light on disorders such as schizophrenia and depression, helping to answer questions like 
why only some people who experience negative life events become depressed (Caspi et 
al., 2005; Caspi et al., 2003). One of the objectives of the current project is to help 
improve the understanding of the aetiology of ASD through a gene-environment 
approach.  
Due to the complexity of ASD and the heterogeneity of its symptoms, multiple 
candidates have been identified as genetic and environmental risk factors (Betancur, 
2011; Kinney et al., 2008; Levy et al., 2009; Newschaffer et al., 2007; Sykes & Lamb, 
2007). The current research will focus on one genetic candidate and two environmental 
candidates. The genetic risk factor under investigation will be a genetic polymorphism in 
the promoter region of the serotonin transporter: the so-called serotonin transporter linked 
polymorphic region (5-HTTLPR). The environmental risk factors under investigation will 
be a maternal infection and prenatal exposure to valproate (VPA). The following sections 
of this paper will describe each risk factor in more detail, and outline why they are the 
focus of the current research. First the genetic risk factor will be discussed, followed by 
both the environmental risk factors. 
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Genetics and the 5-HTTLPR 
 
Serotonin 
Numerous studies suggest serotonin (5-HT) is involved in the pathophysiology of ASD 
(Cook Jr & Leventhal, 1996; Muller, Anacker, & Veenstra-VanderWeele, 2015). In fact, 
a seminal review of the neurochemical literature concluded that 5-HT was the 
neurochemical with the most empirical evidence for a role in ASD (Lam, Aman, & 
Arnold, 2006). Pioneering research on mental retardation and autistic disorder in children 
observed an elevated level of whole blood 5-HT (hyperserotonemia) in individuals with 
ASD (Schain & Freedman, 1961). Since then, hyperserotonemia has become the 
neurochemical finding most consistently replicated in patients with ASD (Devlin et al., 
2005). Interestingly, a recent study found that taking selective serotonin reuptake 
inhibitors (SSRIs: a class of drugs primarily used as antidepressants that produce a state 
of increased extracellular 5-HT) during pregnancy significantly increased the risk of ASD 
in the resulting children (Boukhris, Sheehy, Mottron, & Bérard, 2015). In addition, 
immunocytochemical analysis of post-mortem brain tissue revealed a dramatic increase in 
brain 5-HT axons in individuals with ASD relative to controls (Azmitia, Singh, & 
Whitaker-Azmitia, 2011). On the other hand, short-term dietary depletion of tryptophan, 
the precursor to 5-HT, was seen to exacerbate behavioural symptoms of autistic disorder 
in some adult patients (McDougle, Naylor, Cohen, Aghajanian, et al., 1996). Moreover, 
tryptophan hydroxylase 2 knock-out mice, lacking any brain 5-HT, exhibit the three 
major behavioural hallmarks of ASD and have been suggested as a promising model for 
this disorder (Kane et al., 2012; Mosienko, Beis, Alenina, & Wöhr, 2015). Combined, 
these findings suggest a dysregulation of 5-HT may be an important part of the aetiology 
of ASD. However, the question of how 5-HT levels play a role in autism remains unclear 
(Devlin et al., 2005; Lam et al., 2006).  
Dysregulation, as opposed to either too much or too little is a common pattern within 
the ASD literature. In fact, numerous individual genes, synaptic functioning, NMDA 
receptors, and mTOR pathway expression are just a few of the biological factors that have 
been found to lead to ASD-type deficits when normal functioning is altered in either 
direction (Lee, Choi, & Kim, 2015; Nicolini, Ahn, Michalski, Rho, & Fahnestock, 2015; 
Zoghbi & Bear, 2012).  
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Serotonin Transporter 
ASD research has focused primarily on the serotonin transporter gene (SLC6A4, located 
on chromosome 17q) for several reasons: first, it is the prime regulator of extra cellular 
5-HT levels and thus may play a role in the elevated levels of whole-blood 5-HT seen in 
autistic patients (Muller et al., 2015; Schain & Freedman, 1961). Second, there is some 
evidence that SSRIs have clinical benefits in autistic patients (McDougle, Naylor, Cohen, 
Volkmar, et al., 1996). In addition, more recent evidence implicated the serotonin 
transporter (SERT) in autism; specifically, autistic children were found to have decreased 
SERT binding capacity in the medial frontal cortex (Makkonen, Riikonen, Kokki, 
Airaksinen, & Kuikka, 2008).   
The SERT regulates the level of 5-HT in the synaptic cleft by transporting it back into 
the presynaptic neurons. This regulation leaves the SERT an integral part of serotonergic 
neurotransmission. In fact, this is the case from a particularly early stage of 
embryogenesis; SERT mRNA (messenger RNA) and protein begin to be expressed in the 
rat brain the same day as 5-HT itself, in the rostral raphe nuclei on embryonic day 12 
(Hansson, Mezey, & Hoffman, 1998; Zhou, Sari, & Zhang, 2000).  
 
The 5-HTTLPR 
Importantly, transcription of the SERT gene is modulated by, among others, a 
polymorphism in the promoter region of this gene: the 5-HTTLPR (Lesch et al., 1996). 
The allelic structure of the 5-HTTLPR is complex. Although technically up to 14 allelic 
variants have been identified (Nakamura, Ueno, Sano, & Tanabe, 2000), and convincing 
evidence has demonstrated it to be functionally triallelic in structure, much of the research 
investigating the 5-HTTLPR has done so treating it as though it is biallelic, considering 
only the two major alleles: the short (S) and the long (L) allele (Hu et al., 2006). In fact, 
in a recent meta-analysis, of the thirty different reports compiled that investigated the role 
of the 5-HTTLPR on developmental outcomes, only three used triallelic genotyping (van 
Ijzendoorn, Belsky, & Bakermans-Kranenburg, 2012). Thus, the bulk of research tends to 
consider only the following three genotypes as relevant: S/S (those homozygous for the S 
allele), S/L (those heterozygous for the S allele), and L/L (those homozygous for the L 
allele). Moreover, when examining the association between ASD and 5-HTTLPR 
genotype, there is a tendency for researchers to group the S/L genotypes with the S/S 
genotypes, thus creating a binary distinction between those that express the S allele and 
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those that do not. The reason for grouping these two genotypes is that the S allele seems 
to work in a dominant manner (Hu et al., 2006).  
The functional consequences of the allelic variation are what make the 5-HTTLPR an 
interesting focus of research. Relative to the L variant, the S variant reduces the 
transcriptional efficiency of the SERT gene and, theoretically, is associated with 
increased extracellular 5-HT levels (Kiser, SteemerS, Branchi, & Homberg, 2012; Lesch 
et al., 1996). Thus, an individual’s 5-HTTLPR genotype can reveal important information 
about their serotonergic transmission. Given that serotonin is implicated in ASD, the 
5-HTTLPR appears to be an excellent candidate for genetic research on this disorder. 
 
The 5-HTTLPR and ASD 
Human research investigating the genetic underpinnings of ASD has suggested a 
significant association between 5-HTTLPR genotype and ASD (Conroy et al., 2004; 
Cook et al., 1997; Devlin et al., 2005; Klauck, Poustka, Benner, Lesch, & Poustka, 1997; 
McCauley et al., 2004; Yirmiya et al., 2001). However, other studies have failed to 
replicate this significant association (Betancur et al., 2002; Huang & Santangelo, 2008; 
Maestrini et al., 1999; Persico et al., 2000; Ramoz et al., 2006; Zhong et al., 1999). The 
most notable aspect of the research investigating the association between 5-HTTLPR 
genotype and ASD is the large heterogeneity in the findings. Not only are studies divided 
on whether the 5-HTTLPR plays a role at all, but of the studies that do conclude the 5-
HTTLPR plays a role in ASD, there remains a controversy as to which allelic variant 
confers the risk for ASD, or if the allelic variants actually play a different role in ASD 
altogether. The number of studies indicating the S variant to be overtransmitted in ASD is 
almost equal to the number of studies indicating the L variant to be overtransmitted in 
ASD (Devlin et al., 2005). Furthermore, the degree of heterogeneity is even reflected in 
the results of different meta-analyses. When grouping the available findings, one research 
team found an overall preferential transmission of the S allele from parents to their 
affected children (Guhathakurta et al., 2006); whereas two years later another meta-
analysis failed to find an overall association between ASD and either of the allelic 
variants of the 5-HTTLPR (Huang & Santangelo, 2008). However, this latter study did 
observe an effect of ethnicity, with US mixed population samples showing a significant 
preferential transmission of the S variant while no transmission bias was seen in Asian or 
European samples (Huang & Santangelo, 2008).  
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The 5-HTTLPR is a good theoretical candidate for research. Although this notion is 
supported by numerous research groups, it is evident some research does not support this 
claim. However, failed replications of significant genetic associations with 
psychopathological conditions are by no means specific to ASD or the 5-HTTLPR 
(Burmeister, McInnis, & Zöllner, 2008; Trikalinos, Ntzani, Contopoulos-Ioannidis, & 
Ioannidis, 2004; Zöllner & Pritchard, 2007). The following sections of this paper will 
explain why such large heterogeneity in this field is possible, and why there is still reason 
to be optimistic that the 5-HTTLPR plays a role in ASD. There appear to be at least four 
major factors that may explain some of the large heterogeneity amongst research in this 
field. Each factor will be discussed in turn. 
 
Explanations for Heterogeneity  
The first possible explanation for these diverse findings is the hypothesis that perhaps the 
heterogeneity of 5-HTTLPR genotype research maps on to the clinical heterogeneity of 
ASD (Brune et al., 2006; Devlin et al., 2005). In other words, perhaps the S variant is 
associated with particular symptoms of ASD and the L variant associated with other 
symptoms of ASD. In fact, research investigating this idea provides support for such a 
hypothesis. In a sample of autistic children from the University of Chicago 
Developmental Disorders Clinic, the S variant was associated with more severe nonverbal 
communication deficits, whilst the L variant was associated with more severe stereotyped 
and repetitive behaviours (Brune et al., 2006). In addition, two recent studies found that 
within groups of ASD patients, the L variant was associated with increased tactile 
hyperresponsiveness (Schauder, Muller, Veenstra-VanderWeele, & Cascio, 2015), and 
self-injury (Kolevzon et al., 2014). It is possible these findings explain some of the reason 
why several research groups failed to find an association between 5-HTTLPR genotype 
and ASD. The clinical heterogeneity of ASD has also been used to explain the 
contradictory results found in the neuropathological underpinnings of ASD (Ciaranello & 
Ciaranello, 1995). 
The second possible explanation for the large heterogeneity in this field stems from 
the ethnic and racial diversity of the populations being investigated. It appears 
ethnicity/race may play a vital role in allelic frequency and which polymorphic variant 
confers a higher risk of ASD, if at all (Arieff, Kaur, Gameeldien, Van der Merwe, & 
Bajic, 2010; Huang & Santangelo, 2008). Following the omnipresent theme of research 
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on ASD, research comparing the S and L allelic frequencies and transmission rates of 
different autistic populations around the world has produced varying results.  
With regard to simple overall allelic frequency, there is a large difference between 
ethnic groups throughout the entire population (Hu et al., 2006). For example, people 
with northern European ancestry have a higher frequency of the L allele, whereas 
individuals of Asian and Indian ancestry have a higher frequency of the S allele (Cho, 
Yoo, Park, Lee, & Kim, 2007; Guhathakurta et al., 2006; Koishi et al., 2006; Tordjman et 
al., 2001). 
Research investigating the preferential transmission of 5-HTTLPR allelic variants in 
ASD among different ethnic groups is also heterogeneous. A study of French autistic 
patients found that when examining the patients as one group, there appeared to be a 
small overtransmission of the L allele, but not enough to confidently conclude that it 
conveyed risk. However, when examining autistic patients in sub-groups, grouped by 
severity of phenotype, it was found that severely affected individuals were more likely to 
express the S variant, whereas moderately affected individuals were more likely to 
express the L variant. It was concluded that 5-HTTLPR genotype did not convey risk of 
ASD but rather it influenced the phenotypic expression of ASD (Tordjman et al., 2001).  
In addition, although research conducted on a Korean population found that the L 
allele is preferentially transmitted in ASD, research on a predominantly Caucasian 
American population found that the S allele is preferentially transmitted (Cho et al., 2007; 
Cook et al., 1997). Despite this contrast, both samples support an association between 
5-HTTLPR genotype and ASD. However, research on Indian and Japanese populations 
found no preferential transmission of either allelic variant and thus does not support an 
association between 5-HTTLPR genotype and ASD (Guhathakurta et al., 2006; Koishi et 
al., 2006). 
One extreme example of the role that ethnicity/race plays in the relationship between 
5-HTTLPR and ASD comes from a study done in South Africa. Using a sample 
consisting of three groups: African, mixed race, and Caucasian, it was seen that relative to 
the L/L genotype, having the S/S genotype increased the odds of ASD by more than 
10,000 fold for Africans; 10.15 fold for those of mixed race and 2.74 fold for Caucasians 
(Arieff et al., 2010).  
The third possible explanation for the heterogeneity of research investigating the 
association between the 5-HTTLPR and ASD is the way in which the allelic structure of 
the 5-HTTLPR is characterised. As previously mentioned, most linkage studies have 
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treated the 5-HTTLPR as functionally biallelic, acknowledging only the S and L alleles. 
However, more recently the 5-HTTLPR has been described as functionally triallelic (Hu 
et al., 2006). Specifically, the L allele can actually be divided into two different alleles: 
the L(a), corresponding to what is commonly referred to as the normal L allele, and the 
new L(g) allele. This third allele, the L(g), results from a single base substitution (adenine 
 guanine) in the normal L allele. The L(g) allele creates a binding site for the 
transcription factor AP2 (activating protein 2), resulting in a reduced expression rate and 
thus making it functionally similar to the S allele (Hu et al., 2006). Although the L(g) 
allele is less common, it is by no means rare (present in 10-15% of Caucasians, and 
approximately 24% of African Americans) and it could possibly explain the moderate 
effect size of the 5-HTTLPR in some papers (Kiser et al., 2012). The reason for this is 
that there is now an additional variable that may mask the true effect of the 5-HTTLPR: 
previously unrecognised allelic variation of the 5-HTTLPR. As the L(g) allele functions 
almost the same as the S allele, studies that have included L(g) allele carriers within the 
S/L and L/L genotypes have possibly underestimated the true effect of the 5-HTTLPR 
(Hu et al., 2006). In fact, computer simulations based on actual allelic frequencies in 
different ethnic groups demonstrated that knowledge of the L(g) allele vastly improved 
prediction of SERT expression (Hu et al., 2006). In summary, the inconsistent manner in 
which the alleles of the 5-HTTLPR are studied results in a potentially meaningful source 
of variability between studies supposedly studying the same polymorphism.  
The fourth possible explanation for the heterogeneity in this field is the failure of the 
majority of linkage studies to take into account environmental influences. If research only 
examines the overall effect of genotype and a meaningful environmental influence is 
ignored then it is possible a significant gene-environment interaction can be missed and 
therefore the importance of the gene can be understated. One study investigating the 5-
HTTLPR and its association with ASD symptoms in children with attention deficit 
hyperactivity disorder (ADHD) demonstrated this well (Nijmeijer et al., 2010). Whilst no 
main effect of 5-HTTLPR genotype was found, further analysis revealed that there was 
significant interaction between the S allele of the 5-HTTLPR and maternal smoking 
during pregnancy and low birth weight. Specifically, carriers of the S allele had increased 
social and behavioural problems, but only when encountering these negative 
environmental influences (Nijmeijer et al., 2010). If this paper had not investigated these 
environmental influences the role of the 5-HTTLPR would have been underestimated or, 
at worst, dismissed.  
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In conclusion, human research investigating the 5-HTTLPR in ASD suggests this 
particular polymorphism may play a role in ASD, but exactly how remains unclear. There 
appear to be four major reasons that may explain some of the large heterogeneity within 
the research in this field: the clinical heterogeneity of ASD, the ethnic and racial diversity 
of the populations being investigated, the way the allelic structure of the 5-HTTLPR is 
characterised, and finally the influence the environment may play in such research.  
 
Animal Research and SERT  
Animal research investigating genetic variation in the SERT also suggests the SERT may 
play an important role in components of ASD. Studies from mice, rats, and non-human 
primates have all found compromised SERT function associated with deficits in social 
behaviour – one of the core symptoms of ASD. When compared with wild-type mice, 
SERT knockout mice performed differently on a social interaction test, including 
significant reductions in ‘initiating sniffing’ and ‘follows’ (Kalueff, Fox, Gallagher, & 
Murphy, 2007). In addition, when compared with wild-type rats, SERT knockout rats 
demonstrated a significant reduction in social play behaviour; specifically, a reduction in 
pinning, pouncing, and boxing/wrestling (Homberg, Schiepers, Schoffelmeer, Cuppen, & 
Vanderschuren, 2007). This last finding involving rats is of particular importance as, 
compared with mice, rats are more social and have a richer repertoire of social behaviour, 
making them a better model for human social behaviour (Wöhr & Scattoni, 2013).  
A study involving non-human primates also found that 5-HTTLPR genotype 
significantly influenced social behaviour and cognition. Specifically, rhesus macaques 
with the S/L genotype significantly differed from L/L genotyped macaques on several 
important dimensions: they spent less time staring at faces and eyes of conspecifics; they 
were less likely to take a risky gamble after being primed with a picture of a high-status 
conspecific, and were less likely to give up juice to see an image of a high-status male 
conspecific (Watson, Ghodasra, & Platt, 2009). The data from this rhesus macaque study 
support the idea that 5-HTTLPR genotype is associated with disorders of social behaviour 
and anxiety. Moreover, the authors concluded that 5-HTTLPR variation may be one of 
many genetic factors that contribute to a complex disorder like ASD (Watson et al., 
2009). 
In conclusion, animal research suggests that compromised SERT function may play a 
role in ASD. Thus, evidence from rodents, non-human primates, and humans suggest the 
5-HTTLPR/SERT is an ideal candidate for genetic research on ASD. Whereas human 
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research indicates both alleles may play a role, the animal studies described here would 
appear to indicate that it is the S allele which may confer risk for ASD.  
 
Other Genetic Candidates 
The genetic underpinnings of ASD are extremely complex, with a combination of genetic 
factors likely contributing to an individual’s susceptibility for developing ASD (Sykes & 
Lamb, 2007; Vorstman et al., 2014). It is important to note then, that there are many other 
plausible candidates for genetic research on ASD. In fact, over 100 genetic loci associated 
with ASD have been described and recent estimates of the total number of risk genes are 
even higher (Betancur, 2011; O’Roak et al., 2012). For instance: research has shown two 
single-nucleotide-polymorphisms in the SLC25A12 gene (located at chromosome 2q31.1) 
and a trinucleotide repeat polymorphism in the RELN gene (located at chromosome 
7q22) to be associated with ASD (Ramoz et al., 2004; Segurado et al., 2005). However, 
as is the case with the 5-HTTLPR, other studies have failed to replicate these findings 
(Blasi et al., 2005; Bonora et al., 2003; Devlin et al., 2004; Li et al., 2004; Rabionet et al., 
2006). In addition, genetic alterations in the Shank gene family, and alterations in genes 
encoding for neuroligins and neurexins (all related to synaptic functioning) have been 
associated with ASD (Jamain et al., 2003; Jiang & Ehlers, 2013; Kim et al., 2008; 
Leblond et al., 2014; Südhof, 2008; Yan et al., 2008). Although other genetic candidates 
exist, studying multiple candidates is beyond the scope of the current thesis. For reasons 
outlined above, the current project will focus only on the 5-HTTLPR/SERT. Moreover, 
many of these other genetic mutations (such as in the Shank genes, and in the genes 
encoding neuroligins and neurexins) are extremely rare; therefore, from a population 
point of view, the 5-HTTLPR may be much more relevant.  
The preponderance of evidence suggests that ASD has a heterogeneous aetiology 
(Ronald, Happe, Bolton, et al., 2006; Tordjman et al., 2014), which may go a long way 
towards explaining its heterogeneous symptomatology. Thus, it is no wonder the genetic 
architecture of ASD is so complex, as individuals with ASD may have entirely different 
genetic (or environmental) factors contributing to their disorder. When these individuals 
are clustered in one large study to search for unified genetic risks, inconsistencies, 
contradictory findings, and failed replications should be expected. Furthermore, the 
concept that ASD has several causal pathways may explain the continued pattern of 
dysregulation found in the literature. When ASD is investigated for an association with 
numerous biological factors such as synaptic functioning, levels of specific 
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neurochemicals, neurotrophins, or proteins, evidence in both directions is apparent. In 
fact, it is difficult to find consistently replicated associations with ASD. However, if the 
mechanisms underlying these patients’ pathologies are different, then these patterns are 
unsurprising. The issue of ASD’s heterogeneous aetiology and what it means for ASD 
research as whole will be discussed in more depth in the final chapter of this thesis.  
An important question to consider is whether the genetic complexity of ASD provides 
insurmountable problems for drug development and future treatment. According to 
Vorstman et al. (2014), although there may be hundreds of potential gene associations 
with ASD, many different genes often converge in networks and contribute to the same 
biological pathway or function. Thus, there are far fewer biological functions involved in 
ASD than there are candidate genes. As pharmacological therapies target the 
normalisation of these defective biological functions/pathways, rather than the risk genes 
themselves, it means the possibility of developing an effective pharmacological 
compound may be more promising than the genetic complexity would suggest (Vorstman 
et al., 2014).  
 
The Environment and ASD  
Although environmental influences are known to play a role in the aetiology of ASD, 
when and how they act is unclear. A wealth of evidence points to the prenatal period as a 
particularly sensitive period in which environmental agents may exert their effects on 
postnatal behaviour – a logical interpretation for a disorder that can show symptoms as 
early as 6 months of age. Therefore, both the environmental risk factors investigated in 
this thesis pertain to the prenatal developmental period.  
 
Maternal Infection and the Immune System 
The first environmental risk factor investigated in this thesis is a maternal infection and 
the corresponding maternal immune activation. In order to gain an understanding of the 
role of maternal infection in ASD, one must first understand the role of the immune 
system. Immune system dysregulation has been repeatedly associated with ASD (Ferretti 
& Hollander, 2015; Patterson, 2009; Sperner-Unterweger, 2005). The immune system, by 
which an organism protects against disease, has two main components: first, to recognise 
foreign material or pathogens, and second, to eliminate these from the host organism 
(Beck & Habicht, 1996). These two components are collectively known as an immune 
response (or immune activation) and can be achieved in multiple ways (Sperner-
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Unterweger, 2005). An important part of the immune response system is the group of 
proteins called cytokines, which are proteins that regulate a host’s reaction to immune 
responses, infection, and inflammation. Broadly speaking, cytokines can be divided into 
two types: pro-inflammatory cytokines that worsen disease, and anti-inflammatory 
cytokines that work to heal disease. There are several groups of cytokines, including 
tumor necrosis factor (TNF), macrophage chemoattractant protein (MCP) and interleukins 
(IL) (Dinarello, 2000). The human immune system is both sophisticated and remarkably 
complex, thus only a brief description is appropriate here; for more information see Beck 
and Habicht (1996). 
Numerous findings have indicated a possible role of immune dysregulation in the 
pathogenesis of ASD. Specifically, research has observed an increase of the pro-
inflammatory cytokine TNF-α in the cerebrospinal fluid of autistic children (Chez, 
Dowling, Patel, Khanna, & Kominsky, 2007); an increase of pro-inflammatory cytokines 
TNF-α, IL-6, and Granulocyte-macrophage colony-stimulating factor (GM-CFS) in the 
brains of ASD patients (Li et al., 2009); elevated levels of TNF-α, IL-6, and IL-1β in 
peripheral blood mononuclear cells of ASD patients (Jyonouchi, Sun, & Le, 2001); and 
increased activation of microglia and astroglia, along with a significant increase in MCP-
1 in autistic patients (Vargas, Nascimbene, Krishnan, Zimmerman, & Pardo, 2005). 
 
Maternal Infection and Human Research 
One environmental factor that can influence the foetal immune system is a maternal 
infection. (Libbey, Sweeten, McMahon, & Fujinami, 2005). In fact, maternal infection 
has been proposed as a leading candidate for initiating the immune changes seen in ASD, 
possibly via the production of cytokines during the maternal immune response (Libbey et 
al., 2005; Patterson, 2002, 2009; Smith, Li, Garbett, Mirnics, & Patterson, 2007). There 
are two major reasons for this hypothesis: first, the immune dysregulation in ASD is 
found in the adult and child autistic brain, indicating it is both a permanent state and that 
it begins at an early stage (Patterson, 2009). Second, there is strong evidence, from both 
human and animal research, for an association between maternal infection and ASD. In 
fact, some authors have even concluded that prenatal infections are the primary non-
genetic cause of ASD (Ciaranello & Ciaranello, 1995).  
Although few epidemiological studies have investigated the involvement of maternal 
infection with ASD, a recent landmark paper has provided exactly this type of research. 
Atladóttir et al. (2010) conducted a large-scale study in Denmark, investigating the link 
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between maternal infection and ASD diagnosis in over 1.6 million children. Using 
hospital records, a significant association was found between maternal infection in the 
first and second trimesters of pregnancy and ASD diagnoses in the resulting children. 
Specifically, pregnant mothers having a viral infection in their first trimester or a bacterial 
infection in their second trimester increased the odds of ASD in their children by 2.98 and 
1.42 fold, respectively (Atladóttir et al., 2010). These findings suggest several important 
points: first, they support the hypothesis that maternal infections are a risk factor for 
developing ASD. Second, the findings suggest the timing of exposure to such infections 
is a crucial factor in their risk association. Third, the fact that not all infected mothers had 
children with ASD suggests other factors such as genotype influence this environmental 
variable (Patterson, 2009).  
Maternal infection being associated with psychopathological outcomes is not specific 
to ASD. Numerous epidemiological studies have found a positive association between 
maternal infection and schizophrenia as well (Patterson, 2009). In fact, it was estimated 
that up to 14% of cases of schizophrenia would have been prevented if maternal infection 
had not occurred (Penner & Brown, 2007). Considering schizophrenia costs the USA 
alone approximately US$62.7 billion per annum (Wu et al., 2005), preventing 14% of the 
cases of schizophrenia would represent a remarkably significant sum every year (US$8.78 
billion).  
Interestingly, schizophrenia is a disorder where marked immune dysregulation has 
also been observed (Sperner-Unterweger, 2005). The numerous parallels between 
schizophrenia and ASD have led recent speculation that these disorders may actually be 
closer than traditionally believed. It has been proposed that a maternal infection leading to 
an acute inflammatory response can account for both the shared and differing 
symptomatology of ASD and schizophrenia. Specifically, the acute inflammation itself 
may account for the shared symptoms, whereas subsequent chronic or latent inflammation 
may lead to the unique phenotypes for ASD, and schizophrenia, respectively (Meyer, 
Feldon, & Dammann, 2011). More recently it has even been proposed that ASD and 
schizophrenia may indeed be one and the same disease but simply manifest at different 
developmental stages according to an individual’s interaction with the environment 
(Wang, 2015). 
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Maternal Infection and Animal Research 
In line with the human epidemiological data, animal research has suggested that maternal 
infection may play a role in ASD. Mice whose mothers were injected on gestational day 
(GD) 9.5 with a mouse-adapted human influenza virus, displayed significant behavioural 
changes and cerebellar abnormalities relating to ASD, including deficits in social 
interaction and pre-pulse inhibition, and a reduction in Purkinje cells (Shi, Fatemi, 
Sidwell, & Patterson, 2003; Shi et al., 2009). In addition, mice exposed to a prenatal 
influenza virus on GD 18 showed a reduction in 5-HT levels in adolescence (Fatemi et 
al., 2008). Finally, research with non-human primates found that rhesus macaques 
exposed prenatally to the influenza virus exhibited a reduction in overall brain volume 
that resembled the brain abnormalities found in schizophrenia, a disorder with numerous 
parallels to ASD (Short et al., 2010). The data from these studies demonstrated that 
maternal infection can have drastic behavioural, biochemical, and neuronal outcomes 
relating to ASD, on offspring that extend into adulthood.  
However, understanding the mechanism by which maternal infection influences 
offspring behaviour is also important (Ashdown et al., 2005). The two distinct 
possibilities appear to be either through a direct infection of the foetus, or through an 
interaction to the maternal immune response. It is the latter of these two possibilities that 
appears to be supported by the most evidence. The fact that various pathogens have been 
linked to both ASD and schizophrenia suggests that the particular type of pathogen may 
be irrelevant and instead the explanatory mechanism be one that underlies all infections – 
a maternal immune response/activation (Gilmore & Fredrik Jarskog, 1997; Libbey et al., 
2005). In addition, research using two immune activating agents that elicit a maternal 
immune activation but do not contain a live virus or bacterial pathogens, provide support 
for the hypothesis that the consequences of a maternal infection stem from a reaction to 
the maternal immune response (to be explained below). The primary reason for this 
support is that these agents produce many of the same ASD-related deficits created by 
prenatal influenza models, and appear sufficient for achieving these outcomes (Meyer, 
Feldon, & Fatemi, 2009).  
 
Poly (I:C) and LPS 
The first immunogen is polyriboinosinic-polyribocytidilic acid, or Poly (I:C); a synthetic 
substance that evokes an antiviral immune response but does not contain a virus. 
Offspring of pregnant mice injected with Poly (I:C) display behavioural deficits related to 
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ASD, including deficits in social behaviour, communication, repetitive behaviour, and 
pre-pulse inhibition (Malkova, Yu, Hsiao, Moore, & Patterson, 2012; Shi et al., 2003). In 
addition, offspring of Poly (I:C) injected mothers exhibited cerebellar pathology 
resembling that found in human patients with ASD (Shi et al., 2009), abnormalities in the 
hippocampus (Ohkawara, Katsuyama, Ida-Eto, Narita, & Narita, 2014; Zuckerman, 
Rehavi, Nachman, & Weiner, 2003), and atypical behavioural and pharmacological 
responses relevant to schizophrenia (Zuckerman & Weiner, 2005). These findings 
indicate that the ASD-related behavioural consequences of a maternal infection do not 
stem from direct viral infection of the foetus, but rather from a reaction to the maternal 
immune response.  
These results in rodents also extend to non-human primate models of maternal 
immune activation. An adapted version of Poly (I:C) for primates was administered to 
pregnant rhesus macaques and the behaviour of their offspring was extensively analysed. 
The offspring of mothers exposed to an immune activation displayed deficits relative to 
controls along numerous behavioural measures related to ASD, including social 
interaction, communication, and repetitive behaviour (Bauman et al., 2014).  
The second immunogen that has helped answer the question of how maternal 
infection influences offspring is lipopolysaccharide (LPS). LPS is an important 
component of the outer membrane of gram-negative bacteria and is used to mimic a 
bacterial infection without exposure to live bacteria. Among its varied biological effects, 
it causes the production and release of pro-inflammatory cytokines such as IL-1, IL-6 and 
TNF-α (Schletter, Heine, Ulmer, & Rietschel, 1995). Research has also found ASD-like 
outcomes in the offspring of rats administered LPS during pregnancy, including reduced 
play behaviour in juveniles, decreased social interaction in adults, reduced 
communication, increased repetitive behaviour, and deficits in pre-pulse inhibition 
(Baharnoori, Bhardwaj, & Srivastava, 2012; Borrell, Vela, Arévalo-Martin, Molina-
Holgado, & Guaza, 2002; Fortier, Luheshi, & Boksa, 2007; Kirsten et al., 2012; Kirsten, 
Taricano, Maiorka, Palermo-Neto, & Bernardi, 2010). Like the findings from Poly (I:C) 
research, the data from LPS research support the claim that maternal infection likely 
influences offspring behaviour through a maternal immune activation.  
Moreover, the impact of these immunogens is unlikely to be due to their direct action 
on the foetus. Indeed, when pregnant Sprague-Dawley rats were injected with LPS, 
maternal tissue examination detected LPS in the placenta, blood, liver, and kidney; and 
pro-inflammatory cytokines were detected in the maternal plasma and placenta. However, 
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foetal tissue examination detected no LPS or pro-inflammatory cytokine induction 
(Ashdown et al., 2005). Similarly, another study found maternal administration of LPS 
increased cytokine mRNA in the placenta but did not affect cytokine mRNA in the foetal 
brain (Gayle et al., 2004). These data suggest that the effects of maternal exposure to LPS 
on offspring are not a result of the direct action of LPS on the foetus, but rather a result of 
the indirect action of LPS and its downstream consequences that occur at placental sites. 
In summary, the fact that maternal infection seems to be mediated by a maternal immune 
activation and its downstream consequences suggests Poly (I:C) or LPS can serve as 
effective models in animals for mimicking the key aspect of a maternal infection, as it 
pertains to ASD.  
 
Maternal Immune Activation Mechanism 
The process of how maternal immune activation influences offspring has also been 
investigated. Using Poly (I:C) to model maternal immune activation, typical ASD-related 
deficits associated with maternal Poly (I:C) administration were observed in offspring 
(Smith et al., 2007). When the cytokine IL-6 from the maternal immune response system 
was blocked, through administration of an anti-IL-6 antibody or by using IL-6 knockout 
mice, the ASD-like behavioural abnormalities were not observed. In contrast, when 
administering blocking antibodies to other cytokines, such as IL-1β and IFNγ, the 
behavioural deficits were not prevented. These results indicate the cytokine IL-6 is central 
to the process of how a maternal immune response influences offspring (Smith et al., 
2007). Interestingly, a recent report found elevated plasma concentrations of IL-6 in 
autistic patients and argued that levels of IL-6, in combination with levels of 5-HT, hold 
great promise as a potential biomarker for ASD (Yang, Liu, Sang, Zhu, & Du, 2015).  
In summary, the data from human and non-human animals suggest maternal infection 
is a clear risk factor for the development of ASD, likely acting through the maternal 
immune response that releases pro-inflammatory cytokines. More specifically, it is 
possible that the crucial cytokine in this process is IL-6. In addition, considering the 
important role of genetics in the development of ASD, it is likely any effect of a maternal 
immune response does not work in isolation but rather in combination with a susceptible 
genotype.  
An interaction between genetic predisposition and environmental factors taking place 
during the sensitive perinatal period likely contributes to the development of ASD. Given 
the importance of 5-HT in ASD and the evidence linking a maternal immune activation to 
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this disorder, the current thesis aimed to combine a maternal immune activation model 
with a SERT knockout genetic animal model to assess whether the impact of a maternal 
immune activation depends on SERT genotype in rats.  
 
Prenatal Exposure to Valproate 
The second environmental risk factor investigated in this thesis is prenatal exposure to 
valproate. Valproic acid (valproate, VPA, 2 propylpentanoic acid), is an anti-convulsant 
and mood stabiliser used predominantly to treat epilepsy, bipolar disorder, and migraine 
(Lloyd, 2013; Mulleners, McCrory, & Linde, 2014; Trinka, Höfler, Zerbs, & Brigo, 
2014). However, its usefulness has also been trialled in Alzheimer’s disease, cancer, and 
HIV treatments (Avallone et al., 2014; Brodie & Brandes, 2014; Grishina et al., 2015; Hu 
et al., 2011; Lehrman et al., 2005; Qing et al., 2008). VPA exerts a broad range of 
activities via a multitude of different mechanisms, some known and some unknown, and 
for this reason the VPA literature is both remarkably complex and equivocal in nature 
(Douma et al., 2014; Kwan, Sills, & Brodie, 2001; Patterson, 2011).  
In addition to its prophylactic properties, VPA is a known teratogen (Diav-Citrin et 
al., 2008; Koren, Nava-Ocampo, Moretti, Sussman, & Nulman, 2006; Meador, Reynolds, 
Crean, Fahrbach, & Probst, 2008; Morrow et al., 2006; Wyszynski et al., 2005). A 
systematic review of the literature concluded that taking VPA during pregnancy was 
associated with a 3.77 fold increased risk of major congenital malformations in offspring 
relative to healthy women, a 2.59 fold increased risk relative to women treated with other 
anti-epileptic medication, and a 3.16 fold increased risk relative to those with untreated 
epilepsy (Koren et al., 2006). Together, the literature investigating VPA exposure and 
congenital malformations indicate an approximate 3 fold increase in major malformations 
in children exposed prenatally to VPA (Ornoy, 2009).  
A teratogen is predominantly defined as an agent that causes malformation to, and/or 
disrupts the development of, the embryo or foetus. What constitutes a teratogenic 
outcome is somewhat less clear. Typically, discussion of outcomes surrounds congenital 
malformations such as neural tube defects present from birth. However, in addition to the 
increased likelihood of congenital malformations, there is strong evidence that children 
exposed prenatally to VPA are significantly more likely to experience developmental 
delay and develop ASD, thus making it a key environmental risk factor for this disorder 
(Adab et al., 2004; Christensen et al., 2013; Christianson, Chester, & Kromberg, 1994; 
Dean et al., 2002; Moore et al., 2000; Rasalam et al., 2005; Roullet, Lai, & Foster, 2013; 
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Smith & Brown, 2014; Viinikainen et al., 2006; Williams & Hersh, 1997). Most recently, 
data from a Danish population-based study showed that prenatal exposure to VPA was 
associated with an almost 3 fold increased risk for ASD. Specifically, those exposed to 
VPA had an absolute risk factor of 4.42% for ASD, whereas controls not exposed to VPA 
had an absolute risk factor of 1.53% (Christensen et al., 2013). As will be discussed later 
in the chapter, there is convincing evidence to suggest that the congenital malformations 
and the ASD-like pathology depend, to a large degree, on similar mechanistic processes 
including alterations in epigenetics and oxidative stress (Dufour-Rainfray et al., 2011). 
 
Prenatal VPA as an Animal Model for ASD 
Prenatal exposure to VPA has been thoroughly assessed as an animal model for ASD. In 
fact, prenatal exposure to VPA is now a well-established model for ASD and has been 
used in cell-cultures, tadpoles, zebrafish, and rodents (Bauman, Crawley, & Berman, 
2010; Jacob et al., 2014; James et al., 2015; Kim et al., 2011; Miyazaki, Narita, & Narita, 
2005; Patterson, 2011; Rodier, Ingram, Tisdale, & Croog, 1997; Schneider & Przewlocki, 
2005). The typical method of creating this model is to inject pregnant rats with a single 
dose of VPA around the time of the foetal neural tube closure, approximately GD 12 
(Kim et al., 2011). However, the exact dose, method of injection, day of exposure, and 
whether the exposure is acute or chronic, can vary from study to study; often leading to 
varying outcomes (Cohen, Varlinskaya, Wilson, Glatt, & Mooney, 2013; Štefánik, 
Olexová, & Kršková, 2015). In fact, it has been proposed that the dose of VPA 
determines the mechanism of influence and thus the outcome (Johannessen & 
Johannessen, 2003). 
Numerous behavioural and biochemical outcomes associated with ASD in humans 
have been produced by this model. Importantly, these outcomes are observed in a variety 
of species, including ‘outbred’ genetically heterogeneous rodent strains with stronger 
translational validity to the genetically diverse human population.  
Specifically, prenatal exposure to VPA can produce the following behavioural 
abnormalities that are associated with ASD in humans: lower sociability, deficits in 
communication, increased repetitive behaviour/stereotypies, pre-pulse inhibition deficits, 
lowered sensitivity to pain, increased anxiety, and hyperlocomotor activity (Choi et al., 
2014; Dufour-Rainfray et al., 2010; Gandal et al., 2010; James et al., 2015; Mehta, 
Gandal, & Siegel, 2011; Schneider & Przewlocki, 2005; Schneider et al., 2008).  
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In addition, prenatal exposure to VPA produces the following biochemical, 
anatomical or neuronal deficits, many of which are associated with ASD in humans: a 
reduction in Purkinje cells, cerebellar and gastrointestinal abnormalities (Ingram, 
Peckham, Tisdale, & Rodier, 2000; Kim, Choi, et al., 2013; Rodier et al., 1997), deficits 
in the Akt/mTOR pathway (Nicolini et al., 2015), increased cortical thickness and number 
of neurons in the neocortex (Sabers, Bertelsen, Scheel-Krüger, Nyengaard, & Møller, 
2015), an increase in the basolateral nucleus of the amygdala (Loohuis et al., 2015), a 
reduction in spine density in the hippocampus (Takuma et al., 2014), and decreased 
cortical brain-derived neurotrophic factor (BDNF) mRNA (Roullet, Wollaston, 
Decatanzaro, & Foster, 2010).  
Of particular importance to the current study, prenatal exposure to VPA has also been 
demonstrated to significantly impact the serotonergic system. Specifically, exposure to 
VPA on GD 9 modified the normal migration of 5-HT neurons in the dorsal raphe nuclei 
of rats in one study (Miyazaki et al., 2005), and led to hyperserotonemia, the most 
consistently replicated neurochemical finding in human patients, in another study (Narita 
et al., 2002). Mimicking the non-specific dysregulation of 5-HT in ASD, both increased 
and decreased hippocampal 5-HT levels have been observed at postnatal day (PND) 50, 
following VPA exposure at GD 9 (Dufour-Rainfray et al., 2010; Narita et al., 2002). In 
addition, zebrafish models of foetal VPA exposure observed that VPA blocked 5-HT 
neuronal differentiation, but failed to effect cerebellar Purkinje neuronal differentiation, 
indicating a particular sensitivity to 5-HT (Jacob et al., 2014). (See Table 1 for a summary 
of these findings). 
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Table 1. Behavioural, biochemical, and neuroanatomical changes observed in animal models of prenatal 
exposure to VPA. 
Reference Effect Species 
(Choi et al., 2014) Hyperlocomotor activity Rat (Sprague-Dawley) 
(Gandal et al., 2010) ↓ social interaction 
↓USV 
↑rep. behav. 
Mice 
(Mehta et al., 2011) ↑ anxiety 
↑rep. behav. 
Mice 
(Schneider & Przewlocki, 
2005) 
↓ sensitivitity to pain 
↓ p.p.i 
↓ social behav. 
↑ stereotypies 
Rat (Wistar) 
(Schneider et al., 2008) ↓ sensitivity to pain 
↑ rep. behav. 
↑ anxiety 
↓ social behav. 
Rat (Wistar) 
(James et al., 2015) Abnormal social behaviour Xenopus laevis Tadpoles 
(Ingram et al., 2000) ↓ purkinje cells 
 
Rat (Long Evan) 
(Kim, Choi, et al., 2013) Gastrointestinal abnormalities Rat (Sprague-Dawley) 
(Rodier et al., 1997) Cerebellar abnormalities Rat 
(Nicolini et al., 2015) Deficits in the Akt/mTOR 
pathway 
Rat (Wistar Han) 
(Sabers et al., 2015) ↑ cortical thickness 
↑ neurons neocortex 
Rat (Wistar) 
(Loohuis et al., 2015) ↑ in the basolateral nucleus of the 
amygdala 
Rat (Wistar) 
(Takuma et al., 2014) ↓ spine density in hippocampus Mice 
(Roullet et al., 2010) ↓ BDNF mRNA Mice 
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(Miyazaki et al., 2005) Abnormal 5HT differentiation, 
migration and maturation 
Rat (Wistar) 
(Narita et al., 2002) Hyperserotonemia 
↑ 5HT in hippocampus 
Rat (Sprague-Dawley) 
(Dufour-Rainfray et al., 2010) ↓ 5HT in hippocampus Rat (Wistar) 
(Jacob et al., 2014) Failure of 5HT expression Zebrafish 
 
The VPA model has even been able to replicate the male-female imbalance found in 
ASD. VPA exposure in animals has a more detrimental impact on behaviour, morphology 
and the immune system in males than it does on females (Kataoka et al., 2013; Kim, Kim, 
et al., 2013; Mowery et al., 2015; Schneider et al., 2008). The reasons for this differential 
impact of VPA are uncertain (Mowery et al., 2015; Schneider et al., 2008). However, the 
preponderance of evidence suggests the likely answer is that natural differences between 
the sexes exacerbate or protect against the teratogenic impact of VPA. In other words, 
female-specific biochemical patterns during critical developmental periods may protect 
against VPA (Schneider et al., 2008). Indeed, female oestrogen has been described as 
protective against harmful toxins implicated in the onset of ASD (Geier, Kern, & Geier, 
2010). 
Despite the preponderance of evidence supporting VPA as a valid animal model for 
ASD, recent evidence has found that prenatal VPA administration actually increased 
social behaviour in VPA-treated rats, relative to controls (Cohen et al., 2013; Štefánik et 
al., 2015). These contrary findings suggest two important points: first, that more detailed 
analysis of the VPA model is needed and second, that the experimental details involved in 
the VPA model are of critical importance to the outcome. This second point is 
particularly important and will now be discussed in greater detail.  
 
Experimental Variables in VPA Models  
When a wider examination of the literature on the outcomes and mechanisms of VPA is 
undertaken (not just related to models of ASD) the most evident theme is the wide-scale 
heterogeneity in the data. It can be safely concluded that VPA is somewhat of a ‘dirty’ 
drug in that it potentially works via multiple mechanisms and leads to many different 
outcomes, making it very difficult to understand. It is therefore vitally important to 
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understand the factors contributing to the variability of the effects of VPA (Roullet et al., 
2013).  
Cell, animal, and human research on VPA has demonstrated several key points: first, 
response to VPA differs as a function of the developmental age, brain region, and sex 
investigated (Bittigau et al., 2002; Kataoka et al., 2013). For instance the apoptotic effects 
of VPA in 14 different brain regions was studied in rat pups exposed to VPA at various 
developmental stages. Results revealed the response to VPA differed as a function of both 
developmental age and brain region (Bittigau et al., 2002). Regional specific neuronal cell 
loss has also been observed in mouse models of VPA (Kataoka et al., 2013). In addition, 
mice administered VPA at GD 12.5 led to social interaction deficits in male, but not 
female mice, highlighting the importance of sex in VPA exposure (Kataoka et al., 2013). 
The second key point is that response to VPA is both differentiation stage and cell-
type dependent (Fujiki, Sato, Fujitani, & Yamashita, 2013; Wang et al., 2011). For 
instance, VPA was found to have a proapoptotic effect on embryonic stem cell-derived 
neural progenitor cells of glutamatergic neurons, but this effect was not observed in their 
neuronal progeny (Fujiki et al., 2013). Moreover, a neuron-astrocyte culture mix treated 
with VPA induced apoptotic effects that were not observed in a simple neuron-enriched 
culture, implicating the importance of cell-type in VPA-induced neurodegeneration 
(Wang et al., 2011).  
The third key point is that even seemingly small experimental changes can lead to not 
just different but opposing findings. A clear example of this comes from two different 
research groups investigating VPA exposure at GD 9 and measuring hippocampal 5-HT 
at PND 50 (Dufour-Rainfray et al., 2010; Narita et al., 2002). Whereas one paper found 
an increase in 5-HT in Sprague Dawley rats following 800 mg/kg VPA (Narita et al., 
2002), the other found a 46% decrease in 5-HT in Wistar rats following 600 mg/kg VPA 
(Dufour-Rainfray et al., 2010). The discrepant findings were hypothesised to be a result 
of the differences in the experimental procedure (Dufour-Rainfray et al., 2010).  
The final key point is that VPA-induced outcomes are highly dependent on dosage 
and timing, or the window of exposure, to the drug (Jeong et al., 2003; Johannessen & 
Johannessen, 2003; Takuma et al., 2014). The amount of VPA administered has been 
repeatedly shown to affect the outcome of the drug in humans, with higher doses 
associated with higher rates of teratogenicity (Diav-Citrin et al., 2008; Koren et al., 2006; 
Meador et al., 2008). When VPA is administered also has significant implications for the 
response to the drug. For instance, mice administered VPA at GD 12.5, but not GD 9 and 
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GD 14.5, exhibited ASD-like symptomatology, including deficits in social interaction 
(Kataoka et al., 2013). Another, particularly striking, example of the role of timing in 
VPA-induced-outcome was seen in a paper exposing mice prenatally to VPA and then 
treating these same mice with VPA postnatally. VPA exposed mice had deficits in novel 
object recognition, and decreased spine density in the hippocampus. Remarkably, 
postnatal chronic treatment of VPA attenuated both deficits (Takuma et al., 2014). In 
other words, the very drug that created the deficits prenatally attenuated the deficits when 
given postnatally. 
Taken together, the data suggest strongly that VPA has a particularly high sensitivity 
for experimental variables and therefore even slightly different experimental models can 
produce very different results. It is clear that the timing, dosage, cell-type, differentiation 
stage, strain-type, sex, and brain region studied can all have a meaningful impact on the 
outcome of research using VPA. These factors likely explain some of the diversity in the 
VPA literature.  
 
Mechanisms of Action 
We have seen that prenatal exposure to VPA is a well-established animal model for ASD, 
but by what mechanisms does VPA exert this ASD-related influence on animals? 
Although numerous research teams have investigated the mechanisms of action for VPA, 
a consensus remains elusive (Bollino, Balan, & Aurelian, 2015; Fathe, Palacios, & 
Finnell, 2014; Fujiki et al., 2013; Jeong et al., 2003). The following sections of this 
chapter will focus on the two major mechanisms for which there is the most compelling 
evidence: Histone Deacetylase-Inhibition (HDAC-I), and oxidative stress. A discussion of 
the mechanisms underlying VPA’s prophylactic properties is beyond the scope of this 
thesis. 
  
Histone Deacetylase Inhibition 
HDAC-I has been proposed as one of the major mechanisms through which VPA exerts 
its teratogenic influence (Eikel, Lampen, & Nau, 2006; Fujiki et al., 2013; Lloyd, 2013; 
Menegola et al., 2005; Phiel et al., 2001; Tung & Winn, 2010). Deoxyribonucleic-acid 
(DNA) molecules are surprisingly long. In order for DNA to fit within the small confines 
of the cell nucleus, it has to be dramatically compressed. This compression is 
accomplished by tightly wrapping the DNA molecule around proteins known as histones, 
to form nucleosomes: the repeating units of chromatin (Kornberg, 1977; Li & Reinberg, 
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2011). However, this high degree of compression makes it more difficult for gene 
transcription to occur, as this involves large proteins (such as transcription factors) 
binding to DNA before ribonucleic acid (RNA) polymerase can bind and initiate gene 
transcription. Thus, gene expression is regulated, among others, by how tightly DNA is 
wrapped around the core histones. Several different modifications of the core histones are 
known to influence this wrapping, including histone methylation, histone 
phosphorylation, and histone acetylation. This latter process is regulated by two classes of 
enzymes: histone acetyltransferases (HATs), and histone deacetylases (HDACs). Put 
simply, HATs attach acetyl groups to lysine residues on histones, leading to a slight 
uncoiling of the DNA around the histones, thus allowing transcription factors to bind 
more easily. HDACs, on the other hand, remove acetyl groups from histones, leading to a 
more compressed DNA-histone package and hence limit the binding of transcription 
factors. Functionally, histone acetylation enhances, while histone de-acetylation inhibits 
gene transcription (Ivanov, Barragan, & Ingelman-Sundberg, 2014; Lloyd, 2013). 
VPA has been shown to inhibit HDAC, (Fujiki et al., 2013; Menegola et al., 2005; 
Phiel et al., 2001), thus preventing HDACs from removing acetyl groups. Therefore, 
functionally HDAC-Is result in hyperacetylation and gene activation. By disturbing the 
natural HAT, HDAC dynamic process, VPA has the ability to impact many different 
genes at the same time (Lloyd, 2013). These HDAC-Inhibitory properties are thought to 
underlie the teratogenic influence of VPA. Indeed, like VPA, other HDAC-Is such as 
trichostatin A (TSA) and sodium butyrate demonstrate teratogenic effects. Interestingly, 
whereas VPA analogues that retain HDAC inhibitory activity also induce teratogenicity, 
analogues that lack this effect do not (Gurvich et al., 2005). 
Histone modifications that can alter gene expression come under the umbrella term of 
epigenetics. Epigenetics is defined as the study of changes of function to the genome that 
modify the expression of genes but do not change the nucleotide sequence (Ivanov et al., 
2014; Tordjman et al., 2014). It is now believed that specific environmental factors can 
induce changes in gene expression via epigenetic mechanisms. These changes in gene 
expression are functionally expressed by the affected organism and can be responsible for 
a variety of phenotypes, both positive and negative. Importantly, histone modifications 
can be long-lasting, thus affecting gene transcription for prolonged periods of time. 
Epigenetics plays an important role in the broader explanatory model of 
gene-environment interactions and therefore VPA can be viewed as an environmental 
 37 
 
agent that has the capability to interact with specific genes that lead to an ASD 
phenotype.  
The main question that follows from VPA’s influence on HDAC is: why does HDAC-
I induced gene activation lead to teratogenic effects? At the moment it is virtually 
impossible to answer this question for a number of reasons. First, depending on the type 
of histone that is acetylated (there are four basic histone (H2A, H2B, H3, and H4) that 
make up the nucleosome, plus H1 that connects nucleosomes together), histone 
acetylation can induce different effects. Second, the histone acetylation can occur in many 
different genes, thus leading to an increased transcription of many genes. Third, 
epigenetic changes, such as histone acetylation may be very local, i.e., differ between 
different brain regions, or within a single brain region, or even between different types of 
cells. Altogether, the puzzle of which genes are activated by VPA and when and where 
has not been solved. However, the types of genes that were activated can be inferred from 
the behavioural or biochemical outcomes. In other words, if we observe a teratogenic 
outcome, we can infer that the types of genes that lead to this outcome were the ones 
activated in this instance. The field of toxicogenomics has the potential to make 
significant strides in our understanding of VPA-responsive genes. 
  
Reactive Oxygen Species and Oxidative Stress 
Reactive Oxygen Species (ROS) may also play an important role in the mechanism of 
VPA-induced teratogenesis (Tung & Winn, 2011). ROS are highly reactive molecules 
that, in excess, have the capacity to damage many elements of a cell (Andersen, 2004; 
Wells et al., 2009). There are a variety of endogenous mechanisms by which ROS are 
generated, including mitochondrial respiration and the immune response system (Lloyd, 
2013; Wells et al., 2009), but ROS can also be enhanced exogenously by xenobiotics, 
including VPA (Defoort, Kim, & Winn, 2006; Kawai & Arinze, 2006; Na, Wartenberg, 
Nau, Hescheler, & Sauer, 2003; Tung & Winn, 2011; Wells et al., 2009). Although 
generation of ROS is both normal and beneficial, excessive generation of ROS can have 
major detrimental effects through either disruption of signal transduction and/or oxidative 
damage to lipids, DNA, RNA, proteins, and carbohydrates (Wells et al., 2009). A variety 
of defence mechanisms exist that help fight against the excess generation of ROS and 
regulate this environment, including: antioxidant enzymes and compounds, and direct and 
indirect repair systems (Davies, 2000; Sies, 1997). When the generation of ROS 
overwhelms the multi-tiered defence mechanisms a state of oxidative stress ensues and 
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deleterious effects to the host can occur. The balancing act of ROS generation vs. the 
host’s defence mechanisms to keep a regulated and healthy ROS environment reflects 
what is referred to as the oxygen paradox – the concept that although aerobic life requires 
oxygen to survive, oxygen is also intrinsically dangerous to its existence (Davies, 1995). 
Importantly, the embryo and foetus have lower antioxidant enzyme levels, and in turn, 
a lowered defence system against excess generation of ROS (Wells et al., 2009; Winn & 
Wells, 1999). This lowered defence system theoretically leaves the embryo and foetus 
with a higher susceptibility to the effects of ROS generating mechanisms or xenobiotics, 
such as VPA (Zaken, Kohen, & Ornoy, 2000). Numerous studies have demonstrated that 
exposure to VPA increases the production of ROS and has negative consequences for cell 
survival and development (Defoort et al., 2006; Na et al., 2003; Tung & Winn, 2011). 
One mechanism whereby this may be achieved is through enzymatic bioactivation (Winn 
& Wells, 1997). Xenobiotics can be bioactivated by certain enzymes that are highly 
prevalent in the embryo, such as prostaglandin H synthase (PHS) and lipoxygenase (LPO) 
and converted to free radical reactive intermediates which commence ROS generation 
(Wells et al., 1997). If the excess ROS generation overwhelms the host’s defence 
mechanisms and oxidative stress results, then adverse developmental effects may be 
produced (Wells, Lee, McCallum, Perstin, & Harper, 2010). Put simply, the teratogenic 
effect of VPA could result from a combination of an undeveloped defence mechanism 
and VPA’s ability to initiate ROS production.  
Furthermore, VPA has the ability to interfere with the defence mechanisms 
themselves. Superoxide dismutase (SOD) and glutathione (GSH) are two important 
antioxidants involved in the defence against ROS, and a downregulation of both SOD and 
GSH has been observed following VPA exposure (Hsieh, Wang, Tsai, Peng, & Peng, 
2012; Zhang, Wang, & Nazarali, 2010). GSSG (glutathione in its oxidised form) and its 
ratio with GSH can be used as a measure of oxidative stress, with increases in GSSG: 
GSH ratio indicative of increased oxidative stress. Dose-dependent increases in 
embryonic GSSG: GSH ratio have been observed following VPA exposure at doses ≥ 100 
μg/ml (Zhang et al., 2010). Together, these data suggest VPA’s ability to alter antioxidant 
homeostasis in the embryo may play an important role in VPA’s teratogenic influence.  
ROS can directly induce DNA double strand breaks (Winn, 2003). Homologous 
Recombination (HR) is a DNA repair mechanism that can repair DNA double strand 
breaks (Haber, 1999). However, HR is not an entirely error-free procedure and has the 
potential to contribute to detrimental genetic changes. Thus, increased levels of HR 
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theoretically would increase the odds of important genes in the developmental process 
being disrupted at critical time points, possibly resulting in teratogenesis (Defoort et al., 
2006). Interestingly, VPA has been demonstrated to cause oxidative stress and, in turn, 
increase HR levels in vitro. Furthermore, the antioxidative enzyme catalase, one of the 
cellular defence mechanisms against oxidative stress, completely blocked the increased 
HR following VPA treatment (Defoort et al., 2006). These data suggest HR could be an 
underlying mechanism of VPA-induced teratogenesis and that oxidative stress plays an 
important role (Defoort et al., 2006). 
Finally, the role of oxidative stress and ROS in the mechanism of VPA-induced 
teratogenesis is further supported by data demonstrating the attenuating effects of certain 
antioxidants in prenatal VPA animal models. For instance, green tea extract was found to 
exhibit neuroprotective effects, possibly due to its antioxidant properties (Banji et al., 
2011). Likewise, the antioxidant Vitamin E attenuated the VPA-induced teratogenic 
effects in mice (Al Deeb, Al Moutaery, Arshaduddin, & Tariq, 2000). Embryonic models 
have suggested the main mechanisms of Vitamin E in attenuating VPA-induced 
teratogenicity are through the inhibition of ROS and the restoration of GSH (Hsieh, Chen, 
Lin, Peng, & Peng, 2014). In addition, the neuroprotective antioxidant Astaxanthin (Liu 
& Osawa, 2009) was seen to improve ASD-related behavioural outcomes in mice, an 
effect also attributed to its antioxidant properties (Al-Amin, Rahman, Khan, Zaman, & 
Reza, 2015).  
Taken together, the data from human and non-human animals indicate that prenatal 
exposure to VPA is both an environmental risk factor and an established animal model for 
ASD that most likely exerts its influence through its HDAC-I and ROS-inducing 
properties. However, it appears no one has investigated this established animal model in 
combination with a genetic animal model in order to determine if the effects of VPA 
depend on a particular genotype. Conceptually, research of this nature has at least three 
particular end-goals: first, to understand at a theoretical level why only some foetuses 
exposed to VPA develop ASD. The second goal is to identify a biomarker that will assist 
doctors in identifying pregnant women at particular risk from taking VPA. Understanding 
which women are vulnerable, or indeed resistant, to the detrimental influence of VPA will 
allow safer prescription practices, and hopefully fewer cases of VPA-induced ASD. 
Finally, research of this nature aims for a better understanding of the pathological 
mechanisms of VPA in order to be able to test potential new drugs for ASD. The current 
thesis aimed to play a role in achieving these goals by combining the prenatal exposure to 
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VPA animal model with the SERT genetic animal model to assess whether the impact of 
VPA depends on SERT genotype.  
Animal Models 
Following this in-depth consideration of each of the three risk factors to be investigated in 
this thesis, the paper will now continue with an overview of animal modelling in general 
and, more specifically, how to model ASD in rats. Finally, in this section there will be a 
discussion on the benefits of combining these specific risk factors and investigating the 
interaction.  
Animal models play a major role in the research process of any disorder/disease, as 
they allow for the testing of specific hypotheses and the identification of novel therapies 
(Bauman et al., 2010). Although there is some disagreement on what constitutes a good 
animal model for a given disorder, a model’s suitability is most often evaluated for three 
kinds of validity: construct, face, and predictive validity (Nestler & Hyman, 2010; 
Willner, 1984). Construct validity is determined by the extent to which the construction 
of the animal model reflects the aetiological processes of the disorder in humans. Ideal 
construct validity would be obtained if you were modelling a disorder (X), with only one 
determinant (Y), and you created a model for X by replicating Y in an animal. Of course, 
when modelling complicated multi-factorial disorders such as ASD, achieving perfect 
construct validity is improbable, so instead investigators traditionally aim as high as 
possible. Ideal animal models of disorders should be constructed using evidence-based, 
plausible risk factors and/or agents believed to play a causal role in the disorder in 
humans (Nestler & Hyman, 2010). It has been argued that construct validity is the most 
important kind of validity for animal models as it relates to the underlying theory of the 
entire model (van der Staay, Arndt, & Nordquist, 2009).  
Face validity is determined by the extent to which the model produces behavioural, 
biochemical, and neuronal outcomes relevant to the disorder in question. When modelling 
neuropsychiatric disorders, achieving suitable face validity poses several challenges. 
First, few neuropsychiatric disorders in humans have well understood neurobiological 
hallmarks of the disorder. Second, some neuropsychiatric disorders such as depression 
have an extremely diverse set of symptoms; in fact, two humans can be clinically 
depressed whilst sharing no common symptoms, or even expressing opposing symptoms 
such as weight gain vs. weight loss. The diverse nature of symptoms can make modelling 
certain disorders troublesome. Third, many symptoms of disorders do not appear to be 
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easily modelled in animals, for example an animal model of schizophrenia would have 
difficulty modelling hallucinations. Fortunately, modelling ASD in animals has 
significantly less difficulty with this last problem than some other disease models, such as 
depression or schizophrenia. The reason for this is that the core symptoms of ASD 
(impaired social behaviour, impaired communication, and repetitive behaviour) can be 
reasonably mimicked in animals, even if their correlates are only an approximation 
(Nestler & Hyman, 2010; Patterson, 2011). Assessing face validity in an animal model 
must be done with caution, as inferences surrounding animal behaviour are often clouded 
with anthropomorphic reasoning (Holmes, 2003; van der Staay et al., 2009). 
Finally, predictive validity is determined by the extent to which an animal model 
responds to pharmacological treatments in a way that would be expected in humans with 
the disorder. Ideal predictive validity would be obtained if a model produced behavioural 
outcomes relevant to a human disorder, and administering a proven treatment in humans 
for that disorder reversed these behaviours in the animal model. Achieving suitable 
predictive validity is problematic when generating an animal model for ASD as there are 
no known effective treatments (Nestler & Hyman, 2010).  
In conclusion, an ideal animal model for ASD would possess three characteristics: 
first, it would be generated by mimicking both genetic and environmental causation; 
second, it would produce behavioural and biochemical outcomes relevant to ASD; and 
finally, pharmaceutical options beneficial in humans would also reduce symptomatology 
in the animals. However, there are several major challenges for developing an ideal ASD 
animal model, including the complex aetiology, the heterogeneity of the symptomatology, 
a lack of diagnostic biomarkers, and no existing pharmacological treatment, leaving it 
difficult to achieve ideal construct, face, and predictive validity. In fact, creating an ideal 
animal model of any human disease and especially in the field of brain disorders has been 
notoriously difficult, so a ‘best-we-can-do’ approach is traditionally taken. Whether this 
traditional approach is appropriate or indeed desirable will be discussed in the final 
chapter of this thesis.  
 
Modelling ASD in Rats 
It is now possible to model a variety of autistic features in rodents, including both 
symptoms and risk factors (Patterson, 2011). The current thesis aims to take advantage of 
a unique genetic animal model in order to mimic the 5-HTTLPR in Wistar rats. The 
SERT knockout rat was developed via ENU (N-ethyl-N-nitrosourea) mutagenesis and 
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resulted in a rat model with a premature stop-codon in the SERT. The resulting rat model 
is now a powerful tool for researchers studying a variety of diseases in which 5-HT plays 
an important role (Smits et al., 2006). Whereas homozygous SERT knockout rats have a 
100% reduction in SERT function, heterozygous SERT knockout rats have an 
approximately 40% reduction in SERT function (Homberg, Olivier, et al., 2007), making 
the heterozygous SERT knockout rat ideal for modelling the S variant of the 5-HTTLPR 
human polymorphism. In addition, as wild-type rats have normal SERT function they are 
ideal for modelling the L variant of the 5-HTTLPR. Thus, there is now a way to 
investigate the 5-HTTLPR genotype using rats: by comparing heterozygous SERT 
knockout rats with wild-type rats; and this is exactly the method the current research will 
employ. Homozygous SERT knockout rats have no human equivalent and for this reason 
are not the main focus of this research (Kalueff, Ren-Patterson, & Murphy, 2007). The 
two environmental risk factors under investigation: maternal infection and prenatal 
exposure to VPA will be mimicked via administration of LPS or VPA to pregnant 
mothers at relevant gestational periods. The process of modelling ASD’s aetiology in this 
way, combined with the plausibility of the theoretical underpinnings previously described 
will determine the construct validity of this model.  
 
Combining the Risk Factors  
Although animal models for each of these environmental risk factors exist in isolation, no 
one has ever combined these two risk factors with a genetic rat model of any kind. 
Despite the knowledge that ASD is caused by both genetic and environmental factors, 
most existing animal models mimic only one part of the aetiology for this disorder and 
have largely ignored combining a multitude of aetiological contributors (Belzung et al., 
2005; Ranger & Ellenbroek, 2015). The current investigation attempts to combine the 
multiple risk factors previously described with the aim of identifying a possible gene-
environment interaction.  
There are four reasons to investigate a possible gene-environment interaction in these 
circumstances. First, we know that ASD is caused by both genetic and environmental 
determinants. Second, the data suggest 5-HTTLPR genotype likely plays a role, but not in 
a well understood manner; and it seems one of the major reasons for this ambiguity is the 
failure of the majority of linkage studies to take into account environmental influences. 
Third, prenatal exposure to a maternal infection or VPA increases the risk of ASD, but 
not all exposed individuals develop ASD. Fourth, an interaction between these particular 
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environmental and genetic risk factors seems plausible as both LPS and VPA have been 
shown to interact with the serotonergic system (De Theije et al., 2014; Hrupka & 
Langhans, 2001; Jacob et al., 2014; Macchi et al., 2013; Miyazaki et al., 2005; 
MohanKumar, MohanKumar, & Quadri, 1999; Narita et al., 2002). The primary objective 
in aiming to develop an animal model using both genetic and environmental determinants 
is that it could provide a novel model for ASD with superior construct validity and 
explanatory power than older models, as the generation of this novel model would more 
closely reflect the aetiological process that occurs in humans. 
The fact that existing models have already demonstrated ASD-like effects with each 
of these risk factors in isolation provides an important question in need of solving: how 
can we identify an interaction whilst at the same time rule out that it is just the combined 
impact of two main effects? The key to identifying an interaction (if there is one to be 
found), is in using the right degree of genetic and environmental insult. Many previous 
animal studies have used VPA and LPS doses that may simply be too high to identify an 
interaction because of a ceiling effect – in other words, the environmental insult is simply 
too large. In addition, previous studies involving the SERT genetic animal model have 
used animals with a complete ablation of the SERT (i.e., a homozygous knockout), 
possibly making the genetic effect too large and masking any effect of the environment. 
Conversely, in order to avoid a floor effect, neither the genetic nor environmental effect 
can be too small. Thus, in order to be able to detect an interaction the environmental 
insult and genetic effect should both be moderate. Therefore, the current experiments 
used moderate doses of VPA and LPS, and focused on heterozygous knockout rats, rather 
than homozygous knockout rats.  
 
Objectives and Hypotheses  
There is a distinct lack of research investigating the interaction between genetic and 
prenatal environmental risk factors in ASD, making these types of investigations a critical 
priority for research in this field (Chaste & Leboyer, 2012; Kinney et al., 2008; Tordjman 
et al., 2014). In fact, when investigations of this kind have been performed, their results 
have been informative (Schwartzer et al., 2013). Data from human and animal research 
indicate that three particularly good candidates for investigation are the 5-HTTLPR 
polymorphism, a maternal infection that generates a maternal immune response, and 
prenatal exposure to VPA. It is now possible to model these three risk factors in rodents. 
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Overall, the goal of the current thesis was to develop a novel animal model for ASD 
with construct validity superior to traditional models. In turn, this thesis investigated the 
hypothesis that rats with a genetically compromised SERT function will be more 
vulnerable to the impacts of different environmental risk factors. Specifically, chapter 2 
investigated whether the association between a maternal immune response and ASD-like 
behaviour previously observed in animal models was influenced by SERT genotype. In 
addition, chapters 3 and 4 investigated whether the association between prenatal exposure 
to VPA and ASD-like symptomatology previously observed in animal models was 
influenced by SERT genotype. In these endeavours, the aforementioned genetic and 
environmental risk factors were modelled in Wistar rats and their behaviour was 
investigated in multiple behavioural paradigms designed to detect the core symptoms of 
ASD. These risk factors were modelled using the SERT knockout rat model in 
combination with prenatal administration of LPS or VPA. In addition to these behavioural 
experiments, biochemical changes in the BDNF gene and immunological changes in IL-6 
were investigated. Together, these investigations sought to identify if the proposed 
manipulations resulted in behavioural, biochemical, or immunological profiles in 
accordance with those observed in humans with ASD. 
There existed one overriding hypothesis in this thesis: rats with a genetically 
compromised SERT function would show an increased vulnerability to the impacts of 
both a maternal immune activation and prenatal VPA exposure. On the basis of human 
and animal research, it was expected that rats exposed to the environmental risk factors in 
this study would display behaviour in accordance with ASD symptomatology on one or 
more of the behavioural or biochemical assays, and that these effects would be 
exaggerated if they also had a compromised SERT genotype. 
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CHAPTER 2: MATERNAL IMMUNE ACTIVATION AND SOCIAL 
BEHAVIOUR 
 
Data from both humans and non-human animals suggest maternal infection is a risk factor 
for the development of ASD (Atladóttir et al., 2010; Bauman et al., 2014; Shi et al., 
2003). Maternal infection most likely exerts its influence via the maternal immune 
response and the corresponding release of pro-inflammatory cytokines such as IL-6 
(Smith et al., 2007). Thus, maternal immune activation appears to be the principle 
mechanism underlying maternal infection and its association with ASD.  
LPS is an immunogen used to mimic a bacterial infection without exposure to live 
bacteria. LPS evokes strong immune responses when administered to animals and has 
been used to model ASD in animals (Kirsten et al., 2012). In this chapter subcutaneous 
administration of LPS to a pregnant rat was used to induce a maternal immune response.  
The three major behavioural hallmarks of ASD are deficits in social behaviour and 
communication, and an increase in repetitive behaviour (Levy et al., 2009). The purpose 
of this chapter was to conduct an extensive investigation of the effects of LPS on social 
behaviour in particular; more specifically, to analyse the behavioural consequences of a 
0.5 mg/kg dose of LPS administered subcutaneously at GD 10 and again at GD 11 and to 
see if the behavioural response was dependent on SERT genotype. Multiple social 
behaviour paradigms were performed throughout various points of the animals’ lives, 
namely: juvenility, adolescence, and adulthood. These experiments were designed to 
assess the presence of ASD-like social deficits in rats.  
When evaluating an animal model for its validity, it is good practice to evaluate each 
domain of interest (in this case social behaviour) in more than one paradigm. The 
underlying theory is that if there truly is a behavioural deficit of importance to ASD it 
should be robust enough to be detected across a variety of experiments designed to 
measure the same concept but in different ways. In addition, behaviour such as social 
behaviour is complex and different paradigms can assess different aspects of this 
construct; thus by using more than one paradigm one can obtain a better understanding 
about which aspect(s) are affected. The data from these experiments helped determine the 
face validity of a SERT reduction-maternal immune activation gene-environment model 
for ASD. These experiments tested the hypothesis that rats with a genetically 
compromised SERT function would show an increased vulnerability to the impact of a 
maternal immune activation encountered during foetal development. 
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Animals 
All experimental animals were Wistar rats, bred in the animal laboratory on the 7
th
 floor 
of Easterfield building, Victoria University. The experimental animals varied according to 
their SERT genotype. The genotypes of interest were wild-type and heterozygous SERT 
knockout animals. All animals were group housed in a temperature-controlled room 
(temperature: 21± 2
o
C; 55% humidity) and kept on 12 hr light-dark cycles (lights on at 
07:00) with food and water available ad libitum. All pups were weaned at PND 21, and 
then housed with sex-matched littermates. For most experiments males were kept for the 
behavioural experiments, whilst females were euthanized; however, females were used 
when breeding difficulties resulted in low numbers of males. There were two reasons for 
focusing primarily on male animals: first, in humans ASD is a male dominant disorder 
that is 4-5 times more likely in males than females (Wingate et al., 2014), and second, 
male rats spend more time engaging in a variety of social behaviours than females 
(Meaney & Stewart, 1981), making them better candidates to observe potential social 
deficits. Animals were housed in rectangular Plexiglas cages (40 cm x 25 cm x 12 cm), 
with pine bedding. An animal technician cared for the rats and performed euthanasia on 
the animals when their role in the experiment had come to an end. All procedures in this 
chapter were approved by the Victoria University of Wellington Animal Ethics 
Committee. 
 
Breeding  
The current thesis employed two distinct breeding procedures, one for each 
environmental risk factor (the second breeding procedure will be described in the next 
chapter on VPA). When modelling the first environmental risk factor, maternal infection, 
wild-type Wistar mothers were mated with either wild-type males or homozygous SERT 
knockout males. Once mated (defined as the day a vaginal plug was discovered) the 
females were removed from the males, housed individually, and subcutaneously injected 
with either LPS (0.5 mg/kg) or saline on GD 10 and 11. Thus, this created four groups of 
offspring for experimentation (Table 2):  
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Table 2. Experimental groups used in chapter 2. 
Group  Genotype Treatment 
1 Wild-type SAL 
2 Wild-type LPS 
3 Heterozygous SAL 
4 Heterozygous LPS 
 
In all of the following experiments, multiple litters were used to create the sample size 
for each experimental group. The reason for this was to reduce the chance of potentially 
abnormal litters representing an entire group. The sample sizes reported in these 
experiments indicate the number of individual rats, rather than litters.  
 
Data analysis 
IBM SPSS statistics version 22 was used for all statistical analyses in this chapter. The 
alpha level for statistical significance was set at p < .05.  
 
Experiment I (EXP-I): Social approach and novelty seeking in juveniles  
The purpose of this experiment was to investigate social approach and social novelty 
seeking behaviour in juvenile rats. Typically, rats are highly social creatures with the 
tendency to approach social cues, and prefer novel conspecifics over familiar ones 
(Lehman & Adams, 1977; Smith, Wilkins, Mogavero, & Veenema, 2015). The current 
paradigm aimed to exploit this typical behaviour in an experimental setting to see if the 
proposed model led to deficits in such behaviour – thus, the experiment was designed to 
be able to detect one of the three core behavioural hallmarks of ASD: a reduction in social 
behaviour. Juvenile animals were used for this experiment as ASD is a disorder detectable 
at a very young age and thus observing a social deficit in juveniles would more closely 
mimic the behavioural profile seen in patients.  
 
Method 
Animals 
EXP-I was performed on male and female juvenile rats (PND 24-30). In this experiment, 
stranger rats were also used; these strangers were untreated, Sprague Dawley, female 
juveniles (approximately PND 30), used solely for the purposes of a novel social cue. All 
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animals were moved into the experimental room 30 min before the experiment began. 
Lighting and temperature conditions were the same in the experimental room as they 
were in the housing room. The sample sizes for the experimental groups in this paradigm 
were as follows: wild-type + saline = 10; wild-type + LPS = 16; heterozygous + saline = 
17; heterozygous + LPS = 7. 
 
Apparatus  
The experiment took place in a standard open field circular arena (80 cm diameter, 45 cm 
height) with black flooring and walls. Two cylindrical small cages (11 cm diameter, 14 
cm height) were used to house the stranger rats during the appropriate phases (two and 
three) of the experiment. Ethovision XT v9.0 video tracking software was used to 
determine the duration and frequency animals spent in the relevant areas of the open field. 
The floor and walls were wiped down with 75% ethanol before each new experimental 
animal was put into the open field in order to minimise scent carry-over from previous 
animals.  
 
Procedure 
The experiment employed an adapted version of the social approach and social novelty 
paradigm described in Jones et al (2010) and Nadler et al (2004). The current experiment 
consisted of three main phases: habituation, the social approach phase, and the social 
novelty phase. In the first phase of the experiment, animals were placed individually into 
the empty open field arena and left for 10 min to freely explore; this was done in order to 
habituate the animals to the new environment. 
The second phase of the experiment began immediately after habituation and its 
primary aim was to measure social approach behaviour. First, the rat was removed from 
the open field following habituation and two cylindrical wire mesh cages were placed in 
the open field (30 cm apart from each other), with one of the cylinders (A) containing a 
stranger pup, and the other cylinder (B) containing nothing at all and acting as a control, 
novel object. Next, the experimental rat was released back into the open field, now faced 
with the two new environmental stimuli: a social cue (A) and a non-social cue (B). The 
rat was then left for 10 min to freely explore its environment and time spent with its nose 
or mid-point within 5 cm of each cylinder was recorded. Degree of sociability was 
calculated as the time spent next to the social cylinder (A) relative to the time spent 
investigating both cylinders (A + B). Spending time next to the social cylinder was 
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inferred as a sign of sociability and the greater the amount of time spent, the greater the 
degree of sociability.  
The third phase of the experiment began immediately after the end of phase two, and 
its primary purpose was to measure preference for a novel social stimulus. The reason 
there was no time delay between phase two and three is that an earlier experiment, using 
the same paradigm, conducted in our laboratory utilised a one hour gap between phase 
two and three but found no evidence of social novelty preference in any of the 
experimental groups (to be described later in EXP-III). Hypothesising that the lack of 
novelty preference may have been due to the one hour time delay, the delay was 
eliminated in the current experiment. The set-up of the open field in phase three was 
almost the same as in phase two, except this time in cylinder (B), which previously 
contained nothing, a new stranger pup was placed. Thus, cylinder (A) now housed the 
familiar pup from phase two, and cylinder (B) housed a new stranger pup. The 
experimental rat was then released back into the open field and again given 10 min to 
freely explore the arena and time spent in the proximity of each cylinder was recorded. 
Degree of social novelty seeking was calculated as the time spent next to the new-social 
cylinder (B) relative to the time spent investigating both cylinders (A + B). Spending time 
next to cylinder (B) was inferred as a sign of social novelty seeking behaviour.  
Experimental sessions were run in the morning, from 09:00 till 12:00. The primary 
outcomes of interest were: the percentage of total investigatory time spent investigating 
cylinder (A) in phase two and the percentage of total investigatory time spent 
investigating cylinder (B) in phase three. However, distance moved during habituation 
(phase one) was also calculated to control for any effect locomotion may have had on the 
social behaviour data.  
 
Results  
As this experiment involved both males and females, a one-way analysis of variance 
(ANOVA) was used to test the effect of sex on each of the three primary outcomes of 
interest. Results revealed there was no main effect of sex on distance moved in phase one: 
F(1, 48) = 1.218, p = .275; the mean percentage of time exploration occurring near 
cylinder (A) during phase two: F(1,48) = 1.509, p = .225; or the mean percentage of 
exploration occurring near cylinder (B) during phase three: F(1,48) = 3.002, p = .090. 
Thus, both sexes were pooled together for all future analyses.  
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A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on distance moved during phase one. Results indicated a significant main 
effect of genotype, F(1, 46) = 10.769, p = .002, with wild-types moving significantly 
more than heterozygous animals. There was no main effect of treatment type F(1, 46) = 
.065, p = .801. However, there was a significant interaction between genotype and 
treatment type F(1, 46) = 17.218, p < .001. Specifically, LPS exposure significantly 
increased locomotion in wild-types (p = .008) but significantly decreased locomotion in 
heterozygous animals (p = .006). (See Fig. 1).  
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the mean percentage of exploration time occurring near cylinder (A) 
during phase two. Results indicated there was no main effect of genotype, F(1, 46) = 
.524, p = .473, or treatment type F(1, 46) = .028, p = .867. In addition, there was no 
significant interaction between genotype and treatment type F(1, 46) = 1.884, p = .176. 
(See Fig. 2). One sample t-tests were performed to determine whether the experimental 
groups displayed a significant preference for the social cue (preference was inferred when 
the percentage of exploration next to (A) was significantly higher than 50%). Results 
indicated that all groups except wild-type saline-treated animals displayed a significant 
preference for the social cue.  
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the mean percentage of exploration time occurring near cylinder (B) 
during phase three. Results indicated a significant main effect of genotype, F(1, 46) = 
6.205, p = .016, with wild-types exploring cylinder (B) a higher percent of the time than 
heterozygous animals. However, there was no main effect of treatment type F(1, 46) = 
.1.273, p = .265, and no significant interaction between genotype and treatment type F(1, 
46) = .002, p = .965. (See Fig. 3). One sample t-tests were performed to determine 
whether the experimental groups displayed a significant preference for the novel social 
cue (preference was inferred when the percentage of exploration next to (B) was 
significantly higher than 50%). Results indicated that only wild-type LPS-treated animals 
displayed a significant preference for social novelty.  
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Figure 2. EXP-I: Effects of SERT genotype and LPS treatment in 
juveniles on the mean percentage of exploration time near the social 
cylinder (A) in phase two. Bars represent the mean (+SEM). 
Figure 1. EXP-I: Effects of SERT genotype and LPS treatment in 
juveniles on the distance moved during habituation. Lines represent 
the mean. 
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Figure 3. EXP-I: Effects of SERT genotype and LPS treatment in 
juveniles on the mean percentage of exploration time near the novel 
social cylinder (B) in phase three. Bars represent the mean (+SEM). 
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Experiment II (EXP-II): Social motivation in adolescents 
The purpose of this experiment was to investigate social motivation in adolescent rats. 
Typically, rats are highly social animals that find socialisation rewarding (Peartree et al., 
2012; Thiel, Okun, & Neisewander, 2008). The current paradigm aimed to exploit this 
typical behaviour in an experimental setting to see if the proposed model led to deficits in 
social motivation – thus, the experiment was designed to be able to detect one of the three 
core behavioural hallmarks of ASD: a reduction in social behaviour.  
 
Method 
Animals 
EXP-II was performed using male adolescent rats (PND 35-45). All animals were moved 
into the experimental room 30 min before the experiment began each day. The sample 
sizes for the experimental groups in this paradigm were as follows: wild-type + saline = 
9; wild-type + LPS = 9; heterozygous + saline = 13; heterozygous + LPS = 15.  
 
Apparatus 
The experiment took place in a conditioned place preference box (Panlab/Harvard 
instruments) comprised of two main chambers (40 cm x 34 cm x 45 cm) and a connecting 
starting chamber (25 cm x 13 cm x 45 cm). The two main chambers differed both visually 
(spotted vs. stripy walls; black vs. grey floor colour) and texturally (smooth vs. rough 
flooring); moreover, olfactory cues (essential oils) were added to the original box so that 
one chamber (A) smelled like rosemary and the other (B) like lemon (The Aromatherapy 
Company, New Zealand). Three drops of oil were added to the far corner of the 
respective chambers to make them even more distinguishable from each other. Rosemary 
and lemon smells were used because pilot research in our lab had previously found that 
although Wistar rats can distinguish easily between the two they tend to have no 
preference for either smell (data not shown). In short, chamber (A) had spotted walls, a 
black, smooth floor, and smelled like rosemary; whereas chamber (B) had stripy walls, a 
grey, rough floor, and smelled like lemon. The box was cleaned thoroughly and wiped 
down with 75% ethanol before each trial. Temperature conditions were the same as the 
housing room; however, lighting conditions differed. The room was dimly lit with only a 
lamp in order to promote locomotor activity and to make it easier to track the animals 
with the Ethovision software. Ethovision XT v9.0 video tracking software was used to 
determine the duration and frequency animals spent in each compartment. 
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Procedure 
The experiment used a conditioned place preference (CPP) paradigm based on the 
protocol described by Peartree et al (2012). The paradigm consisted of three main stages: 
habituation, conditioning, and testing. Each experimental block took 6 days to complete. 
In the first stage of the experiment animals were placed individually in the CPP box and 
given three habituation sessions of 10 min per day for 3 consecutive days. Each 
habituation session began at approximately the same time in the afternoon, at 13:30. The 
habituation sessions gave the rats a chance to freely explore the box and allowed the 
researcher to determine if there was a baseline preference for a particular chamber. 
Preference was calculated using the average time spent in each chamber across the last 
two habituation days – the least preferred chamber was calculated for each experimental 
animal for the purposes of the next stage in the experiment.  
The second stage of the experiment began on day 4 with 2 days of conditioning. 
Conditioning consisted of two 10 min sessions per day with a 6 hr interval separating the 
morning (beginning 09:30) and afternoon (beginning 15:30) sessions. During the 
conditioning stage, both of the main chambers were sealed off from one another in order 
to prevent free exploration throughout the whole box. In one session rats were paired with 
another rat (a foreign rat of the same sex and age) in their least preferred compartment 
(established during habituation). The pairing animals used for the social reward were not 
used for any other purpose in the experiment. In the other session, rats were placed alone 
in their preferred compartment. Session type (paired vs. alone) was counterbalanced, so 
that half the rats were paired in the morning session and the other half were alone in the 
morning session, and vice versa for the afternoon session. Moreover, animals that were 
paired in their morning session on the first day were conditioned alone in the morning 
session on the second day; likewise, animals conditioned alone in the first morning 
session of conditioning were paired in the second morning session of conditioning on the 
second day. Thus, each animal had a morning-alone, morning-social, afternoon-alone, 
and afternoon-social conditioning session. 
The third stage of the experiment was performed on day 6 when the animals were 
tested for a possible change in preference compared to the habituation stage. The rats 
were once again placed individually in the box for 10 min with the ability to freely 
explore both chambers and time spent in each chamber was recorded. An increased 
preference for their least preferred chamber following conditioning was interpreted as a 
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sign of social motivation, i.e., socialising was rewarding, and the larger the increase in 
preference, the more strongly rewarding socialising was to that animal.  
The primary outcome of interest was the degree to which social conditioning 
influenced subsequent time spent in an animal’s least preferred chamber. This outcome 
was measured by taking the percentage of time spent in the least preferred chamber 
during habituation and comparing this number to the percentage of time spent in that 
particular chamber in the third and final test stage of the experiment that followed 
conditioning. Thus, the change in percentage of time spent in the least preferred chamber 
was the outcome of most importance. In addition, distance moved during the first 
habituation session on day one was calculated.  
 
Results  
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the total distance moved during the first session of habituation. Results 
indicated there was no main effect of genotype, F(1, 42) = 1.92, p = .214, or treatment 
type F(1, 42) = .665, p = .419. However, there was a significant interaction between 
genotype and treatment type F(1, 42) = 13.634, p = .001. Specifically, LPS exposure 
significantly reduced locomotion in wild-types (p = .001), and increased locomotion in 
heterozygous animals, albeit not significantly (p = .054). This pattern of locomotion in 
adolescent rats was in contrast to the effect LPS had on juveniles’ locomotion in the 
previous experiment. (See Fig. 4). 
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the influence of social conditioning, as measured by the change in the 
percentage of time animals spent in their least preferred chamber (established during 
habituation) following conditioning. Results indicated there was no main effect of 
genotype, F(1, 42) = .040, p = .843, or treatment type F(1, 42) = .014, p = .905. Similarly, 
there was no significant interaction between genotype and treatment type F(1, 42) = 
2.064, p = .158. (See Fig. 5). In addition, one sample t-tests were performed to determine 
whether the experimental groups displayed a significant social conditioning effect 
(successful conditioning was inferred when the change in percentage of time spent in 
their least preferred chamber following conditioning was significantly higher than zero). 
Results indicated that only the heterozygous LPS-treated animals displayed a significant 
effect of social conditioning.  
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Figure 5. EXP-II: Effects of SERT genotype and LPS treatment on the 
rewarding properties of social conditioning. Data are expressed as the 
change in percentage of time spent in an animal’s least preferred 
chamber following a two day social-conditioning period. Bars 
represent the mean (+SEM). 
Figure 4. EXP-II: Effects of SERT genotype and LPS treatment on 
distance moved during the first habituation session. Lines represent 
the mean. 
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Experiment III (EXP-III): Social approach and novelty seeking in adults 
The purpose of this experiment was to investigate social approach and social novelty 
seeking behaviour in adult rats. This experiment was designed to be able to detect the 
same social deficits in adult rats that EXP-I aimed to identify in juveniles. The reason this 
experiment was performed in adults as well as juveniles was to assess whether any social 
deficits extended throughout the lifespan of the animal and thus mimic the profile of 
behavioural deficits observed in patients.  
 
Method 
Animals 
EXP-III was performed on adult male rats (PND 65-75). As in EXP-I stranger rats were 
also used; these strangers were untreated, Sprague Dawley, female juveniles 
(approximately PND 30). All animals were moved into the experimental room 30 min 
before the experiment began. Lighting and temperature conditions were the same in the 
experimental room as they were in the housing room. The sample sizes for the 
experimental groups in this paradigm were as follows: wild-type + saline = 12; wild-type 
+ LPS = 5; heterozygous + saline = 9; heterozygous + LPS = 14.  
  
Apparatus  
The experiment used the same open field arena, cylindrical wire mesh cages, and 
Ethovision video tracking software as EXP-I.  
 
Procedure 
EXP-III employed the same protocol described in EXP-I, but with a one hour delay 
between phase two (social approach phase) and phase three (social novelty phase). The 
primary outcomes of interest were: the percentage of total investigatory time spent 
investigating cylinder (A) in phase two and the percentage of total investigatory time 
spent investigating cylinder (B) in phase three. In addition, distance moved during 
habituation (phase one) was calculated.  
 
Results  
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on distance moved during phase one. Results indicated there was no main 
effect of genotype, F(1, 36) = .001, p = .973, or treatment type F(1, 36) = 1.045, p = .314. 
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Similarly, there was no significant interaction between genotype and treatment type F(1, 
36) = .629, p = .433. (See Fig. 6). 
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the mean percentage of exploration time occurring near cylinder (A) 
during phase two. Results indicated there was no main effect of genotype, F(1, 36) = 
1.158, p = .289, or treatment type F(1, 36) = 1.334, p = .256. Similarly, there was no 
significant interaction between genotype and treatment type F(1, 36) = .023, p = .881. 
(See Fig. 7). One sample t-tests were performed to determine whether the experimental 
groups displayed a significant preference for the social cue (preference was inferred when 
the percentage of exploration next to A was significantly higher than 50%). Results 
indicated that all groups except heterozygous saline-treated animals displayed a 
significant preference for the social cue.  
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the mean percentage of exploration time occurring near cylinder (B) 
during phase three. Results indicated there was no main effect of genotype, F(1, 36) = 
.255, p = .617, or treatment type F(1, 36) = .000, p = .995. Again, there was no significant 
interaction between genotype and treatment type F(1, 36) = .441, p = .511. (See Fig. 8). 
One sample t-tests were performed to determine whether the experimental groups 
displayed a significant preference for the novel social cue (preference was inferred when 
the percentage of exploration next to B was significantly higher than 50%). Results 
indicated that no experimental groups displayed a significant preference for social 
novelty.  
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Figure 7. EXP-III: Effects of SERT genotype and LPS treatment in 
adults on the mean percentage of exploration time near the social 
cylinder (A) in phase two. Bars represent the mean (+SEM). 
Figure 6. EXP-III: Effects of SERT genotype and LPS treatment in 
adults on distance moved during habituation. Lines represent the 
mean. 
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Figure 8. EXP-III: Effects of SERT genotype and LPS treatment in 
adults on the mean percentage of exploration time near the novel 
social cylinder (B) in phase three. Bars represent the mean (+SEM). 
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Experiment IV (EXP-IV): Olfactory-choice paradigm in adults  
The purpose of this experiment was to investigate preference for social olfactory cues in 
adult rats. Typically, rats are highly social animals that will vigorously investigate a 
social cue and the smell of a novel rat (Lehman & Adams, 1977). The current paradigm 
aimed to exploit this typical behaviour in an experimental setting to see if the proposed 
model led to deficits in such behaviour – thus, the experiment was designed to be able to 
detect one of the three core behavioural hallmarks of ASD: a reduction in social 
behaviour.  
 
Method 
Animals 
EXP-IV was performed on male adult rats (PND 90+). As in EXP-II, the experimental 
room was dimly lit with a lamp and was thus darker than their housing room. 
Temperature conditions were the same as their housing room. All animals were moved to 
the experimental room 30 min prior to any testing. The sample sizes for the experimental 
groups in this paradigm were as follows: wild-type + saline = 9; wild-type + LPS = 6; 
heterozygous + saline = 10; heterozygous + LPS = 12. 
 
Apparatus 
The experiment took place in a clean cage identical to the standard housing cages of the 
animals except that no food or water was accessible in the testing cage. Before the 
introduction of any new rat to the paradigm, fresh bedding was placed in the clean cage 
and the roof of the cage was wiped down with 75% ethanol to remove all prior olfactory 
cues. Cotton swabs (15 cm) suspended from the roof of the cage were used as the source 
of social and non-social olfactory cues. The social odour was obtained using soiled 
bedding from a cage housing foreign male rats – the swab was dragged in a zig-zag 
pattern along the bottom of the dirty cage. The non-social odour was obtained using 
banana extract (Hansells, Auckland, NZ; 1:100 dilution). A stop watch was used during 
the session to measure the time spent investigating each cue. Testing sessions were also 
recorded with a video camera in order to double-check measured times.  
 
Procedure 
The experiment employed an adapted version of the olfactory habituation/dishabituation 
paradigm described by Crawley et al (2007). In essence, the experiment is an olfactory-
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choice paradigm, giving rats the choice between a social olfactory cue and a non-social 
olfactory cue and measuring the time spent investigating each of the cues. The experiment 
consisted of two phases: habituation and the test session.  
In the first phase of the experiment, animals were taken from their home cage and 
placed in a fresh cage by themselves. The new cage was the same as their housing cage, 
except with fresh bedding, no food or drink to access, and two 15 cm cotton swabs 
suspended from the roof of the cage. Both these swabs were fresh and contained no traces 
of odour. The experimental animal was left to freely explore the cage for 5 min.  
The second phase of the experiment began immediately after habituation and its 
primary aim was to investigate sociability, as measured by time-spent sniffing social or 
non-social odours. The two swabs during the habituation phase were discarded and 
replaced with two new swabs, one of which contained a banana odour (non-social) and 
the other the smell of another cage of animals (social). In order to obtain the banana 
odour, the swab was dipped into a 1:100 solution of banana extract. In order to obtain the 
social smell, the swab was dragged in a zig-zag pattern along the bottom of a dirty, 
freshly-soiled cage which had previously housed a litter of foreign males. The animal was 
then allowed 5 min to freely roam around the cage, and time spent investigating each cue 
was recorded. Investigatory behaviour was defined as the rat’s nose being within 
approximately 2 cm of the head of the cotton swab, or if the rat grabbed the head of the 
swab with a forepaw. Time spent next to each cotton swab was interpreted as a measure 
of interest in that particular odour, thus spending time sniffing the social odour was 
inferred as a sign of sociability – the higher the amount of time spent, the greater the 
degree of sociability. If experimental groups exhibited an ASD-related phenotype they 
would be expected to show a reduced preference for the social swab. Experimental 
sessions were run in the morning, from 09:00 till 12:00. The primary outcomes of interest 
were: the total time spent investigating both olfactory cues and the percentage of total 
investigatory time spent sniffing the social cue.  
 
Results  
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the total time investigating both olfactory cues combined. Results 
indicated there was a main effect of genotype F(1, 33) = 7.960, p = .008, with wild-types 
spending significantly more cumulative investigatory time than heterozygous animals. 
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There was no main effect of treatment type F(1, 33) = .110, p = .742. Similarly, there was 
no significant interaction between genotype and treatment type F(1, 33) = .000, p = .990. 
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the total time investigating the social olfactory cue. Results indicated 
there was no main effect of genotype, F(1, 33) = 1.492, p = .231, or treatment type F(1, 
33) = 1.439, p = .239. Similarly, there was no significant interaction between genotype 
and treatment type F(1, 33) = 1.062, p = .310. (See Fig. 9). 
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the total time investigating the banana olfactory cue. Results indicated 
there was a main effect of genotype, F(1, 33) = 7.203, p = .011, with wild-types spending 
more time sniffing the banana swab than heterozygous animals. There was no main effect 
of treatment type F(1, 33) = 1.010, p = .322. In addition, there was no significant 
interaction between genotype and treatment type F(1, 33) = .264, p = .611. (See Fig. 9). 
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the percentage of total investigatory time spent sniffing the social swab. 
Results indicated there was a main effect of genotype, F(1, 33) = 4.395, p = .044, with 
wild-types spending a lower percentage of time investigating the social swab than 
heterozygous animals. There was a main effect of treatment type F(1, 33) = 4.697, p = 
.038, with LPS-treated animals spending a lower percentage of time investigating the 
social cue than saline-treated animals. There was no significant interaction between 
genotype and treatment type F(1, 33) = .093, p = .763. (See Fig. 10). In addition, one 
sample t-tests were performed to determine whether the experimental groups displayed a 
significant preference for the social cue (preference was inferred when the percentage of 
total investigatory time next to the social cue was significantly higher than 50%). Results 
indicated that no experimental group statistically preferred the social olfactory cue over 
the banana olfactory cue. 
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Figure 9. EXP-IV: Effects of SERT genotype and LPS treatment in 
adults on the total time spent investigating each of the olfactory cues. 
Bars represent the mean (+SEM). 
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Figure 10. EXP-IV: Effects of SERT genotype and LPS treatment in 
adults on the percentage of total sniffing exploration spent 
investigating the social cue. Bars represent the mean (+SEM). 
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Discussion 
The purpose of this chapter was to investigate the effects of LPS on social behaviour in 
Wistar rats and to test the hypothesis that rats with a genetically compromised SERT 
function would show an increased vulnerability to the impact of a maternal immune 
activation encountered during foetal development. Four paradigms were run at different 
stages of the animals’ lives with the aim of detecting ASD-like social deficits. 
Collectively, the data from this chapter produced three key findings: first, no gene-
environment interactions were observed for any measure of social behaviour across the 
four paradigms. Second, both SERT genotype and LPS treatment influenced social 
behaviour on at least some measures of social behaviour. Third, several gene-
environment interactions were found in relation to locomotor activity.  
The most important finding in the current chapter was that no gene-environment 
interaction was observed on any measure of social behaviour. Thus, the data provide 
support for the null hypothesis: that there is no interaction between SERT genotype and 
maternal immune activation on social behaviour in rats. This conclusion presents two 
distinct interpretations: first, it is in fact true there is no interaction; or second, the 
experimental conditions failed to detect real interactions at play (a type II error). The 
failure to detect a real interaction at play could occur for a number of reasons, including a 
ceiling or floor effect of either the gene or environmental risk factor being used, or the 
experimental paradigms themselves not being subtle enough to detect an interaction.  
The interpretation that seems most consistent with the data is the first one: that there is 
no interaction between SERT genotype and maternal immune activation on social 
behaviour in rats. First, although the four paradigms described in this chapter investigated 
social behaviour in different ways and at different developmental age points in the 
animals, the data consistently demonstrated there was no gene-environment interaction on 
any of the measures of social behaviour. The fact that all the data across a wide range of 
measures points to the same conclusion is strong evidence that there is no 
gene-environment interaction at play.  
Second, a ceiling/floor effect of either the genotype or the environmental factor seems 
unlikely given the fact only moderate genetic and environmental insults were used. For 
instance, these experiments focused on heterozygous SERT rats, which only have a 40% 
reduction in SERT proteins (Homberg, Olivier, et al., 2007; Kalueff, Ren-Patterson, et al., 
2007). In behavioural studies published so far, heterozygous rats produce either no or 
only small effects compared to wild-types (Olivier et al., 2008). Moreover, in the present 
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study, when a significant genotype effect was found (EXP-I: heterozygous animals 
displayed lower novelty seeking than wild-types) the effect was only small, leaving room 
for environmental influences. Likewise, with respect to the environmental risk factor, two 
injections of LPS (0.5 mg/kg s.c.) spaced over 24 hr were used – this dose represents a 
moderate dose compared to others used in the literature. For instance, Kirsten, Taricano, 
Maiorka, et al. (2010) used a much lower dose (0.1 mg/kg i.p. once), while Basta-Kaim et 
al. (2012) used much higher doses (1 mg/kg s.c every second day from GD 7 until birth). 
In addition, when main effects of treatment were found (EXP-IV: LPS-treated rats 
demonstrated less interest in a social olfactory cue than saline-treated rats), these effects 
were only moderate and left room for the potential influence of genotype.  
Finally, both in EXP-I and II a significant gene-environment interaction was found, 
albeit in relation to locomotion, indicating these two variables do interact on at least some 
behavioural measures. Overall, it seems likely that SERT genotype does not interact with 
prenatal LPS exposure, at least in the paradigms used in the current chapter (which are 
well validated paradigms for investigating social behaviour) (Bambini-Junior et al., 2011; 
Crawley, 2007; McFarlane et al., 2008; Moy et al., 2007; Peartree et al., 2012; Silverman, 
Yang, Lord, & Crawley, 2010).  
There were two experiments investigating social approach and social novelty seeking 
in this chapter, one in juveniles (EXP-I) and one in adults (EXP-III). Both experiments 
demonstrated similar patterns of social approach behaviour in phase two, with almost 
universal preference for the social cue over the empty cylinder and very little difference 
between the experimental groups. However in phase three, EXP-I showed an effect of 
genotype, with heterozygous animals demonstrating significantly less social novelty 
seeking behaviour than wild-types. In contrast, there was no genotype effect on social 
novelty seeking in EXP-III, as heterozygous animals displayed the same degree of social 
novelty seeking as wild-types. Although this study is the first to investigate social 
behaviour in heterozygous rats, previous research has shown that juvenile homozygous 
SERT knockout rats show a reduction in play behaviour (Homberg, Schiepers, et al., 
2007). Thus, the results from EXP-I support the idea that a genetic reduction in SERT 
functioning can reduce certain aspects of social behaviour in young rats. The fact that 
there was no genotype effect in EXP-III indicates that the genotype effect is transient and 
that heterozygous animals have normal levels of social behaviour in adulthood. These 
findings are supported by Moy et al. (2009) who investigated adult SERT knockout mice 
in the social approach/novelty seeking paradigm and found no difference between wild-
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type and heterozygous SERT mice in phase two or three. In addition, the results from 
EXP-IV further support the idea that adult heterozygous rats do not show a deficit in 
social behaviour. In fact, in this experiment heterozygous animals actually spent a higher 
percentage of time investigating the social cue than wild-types.  
It should be noted that in addition to the animals’ age there was another difference 
between EXP-I and III. Specifically, EXP-III had a one hour gap between phase two and 
three whereas EXP-I did not. However, it seems unlikely that the lack of a genotype 
effect was due to the one hour delay.  
Interestingly, there was a lack of preference for social novelty found in both EXP-I 
and III. In fact, across both experiments only wild-type LPS-treated juveniles displayed a 
significant preference for the novel social cue over the familiar social cue in phase three. 
Although preference for social novelty has been demonstrated in both mice and rats 
(Bambini-Junior et al., 2011; McFarlane et al., 2008; Moy et al., 2004; Moy et al., 2007), 
it is by no means a universal finding and there is significant precedent for the 
observations in this thesis (Moy et al., 2009; Moy et al., 2007; Roullet et al., 2010). The 
initial paradigm performed (EXP-III) included a one hour gap between phases two and 
three. This gap was considered as a potential explanation for the low degree of social 
novelty seeking and was thus excluded in the paradigm investigating juveniles (EXP-I). 
However, even EXP-I found a low degree of social novelty seeking, suggesting the one 
hour delay was not the reason for the low preference for social novelty. Previous research 
has demonstrated preference for social novelty to be related to the strain of animal used in 
the experiment, with some strains exhibiting no preference for social novelty (Moy et al., 
2007). Thus, the lack of social novelty observed in the current thesis may be accounted 
for by the strain or species of animals used, and/or the differences in protocol compared 
with previous studies using a similar paradigm. A key difference in protocol is that the 
current thesis used a round open field with the cylinders at opposing ends, whereas other 
studies have used a three-chambered box with the cylinders separated by a middle 
chamber.  
In addition, previous research has indicated that the parameters used for assessing 
social approach/novelty seeking can have an important influence on the overall 
conclusion. Thus, while many studies use ‘time spent in the chamber’ others have more 
specifically assessed ‘time spent sniffing the cylinder.’ It was suggested that ‘time spent 
sniffing the cylinder’ may be the more sensitive measure of social approach behaviour 
(Moy et al., 2007). For instance, measuring ‘time spent sniffing the cylinder’ allowed for 
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the detection of social approach behaviour in the BALB/cByJ, BTBR T+tf/J, and 
129S1/SvImJ inbred mouse strains in one study, and the male and female Slc6a4-null 
mice and female heterozygous Slc6a4 mice in another study, that was not detected using 
the ‘time spent in the chamber’ measure (Moy et al., 2009; Moy et al., 2007).  
However, these authors found no evidence for an increased sensitivity when 
measuring social novelty seeking via the ‘time spent sniffing’ calculation. The current 
thesis did not use chambers, but instead measured time spent (nose-point and mid-point of 
the animal) in the immediate proximity (within 5 cm) of the cylinder and thus represents a 
measure more in line with the sniffing measure used in previous studies.  
EXP-II investigated the rewarding properties of social behaviour in a CPP paradigm. 
Aside from the fact EXP-II did not find a genotype effect, treatment effect, or gene-
environment interaction, the experiment also found limited evidence for the rewarding 
properties of social behaviour in a CPP paradigm, with only heterozygous LPS-treated 
animals displaying evidence of social conditioning. These findings are in contrast to 
previous research that has observed social behaviour to be rewarding in a CPP paradigm 
(Calcagnetti & Schechter, 1992; Peartree et al., 2012; Van den Berg et al., 1999). Several 
factors may have contributed to the surprising CPP results in EXP-II.  
First, the animals were not socially isolated before the conditioning phase due to 
limited cage space in the laboratory and thus social behaviour may not have been as 
rewarding as possible. The data provided by Kirsten, Taricano, Maiorka, et al. (2010) 
support this idea – these authors found that only by increasing the motivation for social 
behaviour through isolation were the differences between control animals and LPS-
treated animals able to be identified.  
Second, the ‘pairing’ animal is important to the social value of the social conditioning 
and EXP-II could not always use an ideal social pair (Trezza, Damsteegt, & 
Vanderschuren, 2009). In this experiment, animals were paired with foreign rats of the 
same sex, strain, and age, but breeding issues meant the paired rat was not always the 
same treatment and genotype as the experimental rat, which would have been ideal. The 
reason the pairing rat is important is that the interaction between two rats is key to the 
rewarding value of a social interaction. For example, if the pairing rat is unresponsive to 
play then social conditioning will not be as rewarding for the experimental rat and will 
likely not induce a positive change in preference in the CPP box. Considering EXP-I 
found social deficits in heterozygous rats it is possible that pairing wild-type rats with 
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heterozygous rats during the conditioning phase may have been less rewarding for the 
wild-types than expected.  
Finally, despite the experiment being performed in dim lighting conditions, it was also 
performed during the animals’ ‘light phase’ and not during the peak social activity that 
occurs in their ‘dark phase.’ These described limitations may partly explain why no 
significant social conditioning was found in wild-type rats. In turn, this lack of effect on 
the control group may partly explain why no significant main effects or an interaction was 
observed, as our genetic and environmental risk factors were expected to decrease the 
degree of social conditioning. Nonetheless, it is surprising to find that heterozygous LPS-
treated animals were the only group to display evidence of social conditioning and the 
reason for this finding remains unclear. Future research using a CPP paradigm to assess 
social behaviour would benefit from social isolation, appropriate pairing of animals, and 
experimentation during the animals’ dark phase.   
In EXP-IV the preference of rats for a social vs. non-social odour was investigated, 
based on similar paradigms in mice (Crawley et al., 2007; Ryan, Young, Crawley, 
Bodfish, & Moy, 2010). Surprisingly, none of the experimental groups showed a 
significant preference for the social over the banana olfactory cue. This is in contrast to 
prior research observing several different strains of mice to be significantly more 
interested in novel social olfactory cues than novel banana olfactory cues (Crawley et al., 
2007). However, these previous experiments presented the cues sequentially whereas in 
EXP-IV both cues were deliberately presented simultaneously to more directly assess 
choice behaviour in the rats. Perhaps presenting the cues sequentially might have led to a 
different outcome. Moreover, to the best of our knowledge, this is the first time a study of 
this kind was performed using rats and thus it is at least possible that rats show less 
preference for a social olfactory cue, or, alternatively, that banana may not have been the 
ideal non-social cue in rats that it was in mice. The difference in protocol, combined with 
the different species of animals used across the experiments, may partially account for 
these divergent findings. 
Collectively, the data presented in this chapter suggest that our LPS treatment 
protocol provided only a small effect on social behaviour. Although EXP-IV observed 
that LPS had detrimental effects on social behaviour in adulthood, this was the only 
experiment in the chapter to find such an effect. In fact, the remaining three experiments 
(I, II, and III) found no effect of LPS on social behaviour. These findings are not too 
surprising considering a moderate dose of LPS was deliberately chosen in order to detect 
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an interaction. The findings reported here support those by Xuan and Hampson (2014) 
who similarly observed social behaviour equivalent to controls in rodents prenatally 
treated with LPS. Nonetheless, many studies have reported a reduction in social 
behaviour following foetal exposure to a maternal immune response (Bauman et al., 
2014; Kirsten, Taricano, Maiorka, et al., 2010; Shi et al., 2003). 
Evidently, the question of whether a maternal immune activation influences social 
behaviour provides diverse answers. The explanation for this diversity is likely that social 
behaviour is a nuanced class of behaviours, made up of several subcomponents, prone to 
subtle differences in experimental design and thus contrasting findings from experiments 
that are not exact replications are to be expected. Therefore, contrasting findings are 
unlikely to be due to one specific reason, but instead may be a combination of the type of 
social behaviour being investigated (social approach, social novelty, etc), experimental 
animals being used (age, strain, species, and sex), immunogen being administered (type, 
method, timing, and dose), and the paradigm and protocol utilised. Protocol differences 
that may provide the biggest influence on social behaviour data may be the method of 
housing the animals (grouped vs. individual housing), and whether the animals are 
investigated in their light or dark phase.  
Interestingly, the data from this chapter indicated LPS treatment produced alterations 
in locomotor activity that depended on both SERT genotype and the age of the animals. 
Briefly, while in juveniles LPS increased locomotion in wild-types but decreased 
locomotion in heterozygous animals (EXP-I), no such effect was seen in adult animals 
(EXP-III). Interestingly, in EXP-II in adolescents, LPS decreased locomotion in wild-
types and increased locomotion in heterozygous animals. However, EXP-II had a 
completely different experimental design (three compartments that differed in texture, 
smell, and visual cues) and thus it is difficult to compare this with the other two 
experiments. Nonetheless, EXP-I and III show that the LPS dosage was active enough to 
influence some aspects of behaviour, that these risk factors can in fact interact, and that 
the influence of LPS on locomotion depends on both the age and genotype of the animal 
but that these effects extinguish in adulthood.  
Although this is the first study to investigate prenatal LPS in heterozygous rats, the 
influence prenatal LPS had in wild-types in EXP-I and III (an increase in locomotor 
activity in juveniles, but no effect in adults) is consistent with previous literature (Lin, 
Lin, & Wang, 2012; Wischhof, Irrsack, Osorio, & Koch, 2015). However, it should be 
acknowledged that a wide range of different effects on locomotion following prenatal 
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LPS have been reported, likely due to the large diversity in LPS treatment schedules 
(Harvey & Boksa, 2014; Kirsten, Taricano, Flório, Palermo-Neto, & Bernardi, 2010; 
Stigger et al., 2013).  
  
Conclusion 
Taken together, the results of these four experiments indicate that there was no interaction 
between SERT genotype and maternal immune activation on social behaviour in rats. 
Although the data show that both SERT genotype and LPS treatment can independently 
influence social behaviour on at least some measures, the effect of genotype was 
dependent on the specific parameter and the majority of data suggested LPS had little 
effect. These small/moderate effects were not too surprising considering moderate genetic 
and environmental insults were deliberately chosen for the purposes of detecting an 
interaction. Thus, these findings lend only some support to previous literature suggesting 
both a compromised SERT genotype and maternal immune activation/maternal infection 
lead to social deficits in animals (Bauman et al., 2014; Homberg, Schiepers, et al., 2007; 
Shi et al., 2003; Shi et al., 2009). However, the results in this chapter do seem to resemble 
human research in this field i.e., there is an inconsistent 5-HTTLPR genotype association 
with ASD, and although maternal infection increased the likelihood of ASD in children, 
the overall odds of developing ASD are still low (Atladóttir et al., 2010; Devlin et al., 
2005). Interestingly, there was evidence to suggest LPS treatment produced behavioural 
outcomes relating to locomotion that depended on both SERT genotype and the age of the 
animal.  
In summary, the data from this chapter did not provide initial face validity for a SERT 
reduction-maternal immune activation gene-environment model for ASD, but 
importantly, the data did demonstrate that these two risk factors can interact on certain 
behavioural measures and have independent effects on specific social parameters. Claims 
of the risks provided by SERT genotype and maternal immune activation in the 
development of ASD should be made with caution.  
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CHAPTER 3: PRENATAL VALPROATE AND BEHAVIOUR 
 
VPA is a mood-stabilizing drug used for epilepsy, migraine, bipolar, and other mood 
disorders. Moreover, its uniquely diverse properties mean it is also being trialled as a 
treatment in a variety of diseases including cancer, HIV, and Alzheimer’s disease 
(Avallone et al., 2014; Brodie & Brandes, 2014; Grishina et al., 2015; Hu et al., 2011; 
Lehrman et al., 2005; Qing et al., 2008). A complete explanation of the molecular 
mechanisms underlying VPA’s wide-ranging effects is currently lacking; however, the 
preponderance of evidence suggests HDAC-I and oxidative stress are two important 
mechanisms through which VPA exerts its teratogenic influence (Ranger & Ellenbroek, 
2015). The reason VPA’s mechanistic action is unclear is that VPA works via many 
different mechanisms, produces a multitude of outcomes, interacts with a variety of 
neurotransmitters, enzymes, and proteins, and the mechanism of influence can change 
depending on the dose and timing of usage (Bollino et al., 2015; Fathe et al., 2014; Jeong 
et al., 2003; Johannessen & Johannessen, 2003; Lloyd, 2013).  
Despite its prophylactic properties, VPA is a teratogenic agent that can damage 
developing foetuses and potentially lead to severe consequences throughout life, 
including congenital malformations and neurodevelopmental deficits (Christensen et al., 
2013; Diav-Citrin et al., 2008; Koren et al., 2006; Morrow et al., 2006). Indeed, an 
increasing amount of data from both humans and animals suggest that prenatal exposure 
to VPA is a clear environmental risk factor for ASD (Christensen et al., 2013; Moore et 
al., 2000; Rasalam et al., 2005; Schneider & Przewlocki, 2005). The most recent large-
scale population-based study conducted in Denmark found that individuals prenatally 
exposed to VPA had a risk factor of 4.42% for ASD, whereas controls not exposed to 
VPA had a risk factor of 1.53% – indicating a near 3 fold increased risk for ASD in those 
prenatally exposed to VPA (Christensen et al., 2013).  
The purpose of this chapter was to investigate the behavioural consequences of a 400 
mg/kg dose of VPA administered subcutaneously at GD 12 and to see if the behavioural 
response was dependent on SERT genotype. This VPA schedule was chosen for two 
reasons: first, it has been used before (Kim et al., 2011), and second it represents a 
moderate dose within the context of the literature – an important point when attempting to 
identify a potential interaction. ASD is characterised by three core deficits: a reduction in 
social behaviour, impaired communication, and an increase in repetitive 
behaviour/stereotypy. Multiple behavioural paradigms aimed at investigating all three of 
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these core dysfunctions are included in this chapter. These experiments were designed to 
be able to detect ASD-like phenotypes in rats, using species-relevant behaviours. The data 
from these experiments helped determine the face validity of a SERT reduction-prenatal 
exposure to VPA gene-environment model for ASD. These experiments tested the 
hypothesis that rats with a genetically compromised SERT function would show an 
increased vulnerability to the impact of prenatal exposure to VPA. 
 
Animals 
The types of animals used in this chapter were identical to the animals used in chapter 2. 
In brief, all experimental animals were Wistar rats that varied according to their genotype. 
The genotypes of interest were wild-type and heterozygous SERT knockout rats. All rats 
were group housed in a temperature-controlled room (temperature: 21± 2
o
C; 55% 
humidity) and kept on 12 hr light-dark cycles (lights on at 07:00) with food and water 
available ad libitum. Pups were weaned at PND 21, and then housed with sex-matched 
littermates in standard Plexiglas cages (40 cm x 25 cm x 12 cm), with pine bedding. An 
animal technician cared for the rats and euthanised the animals when their role in the 
experiment had come to an end. All procedures in this chapter were approved by the 
Victoria University of Wellington Animal Ethics Committee. 
 
Breeding  
Rather than mating wild-type mothers with wild-type or homozygous males as in chapter 
2, instead heterozygous mothers and heterozygous fathers were mated. The reason for 
using this new breeding method was primarily the low success rate of breeding using the 
first technique. The switch to using heterozygous parents appeared to increase the success 
rate of breeding.  
Once a heterozygous mother successfully mated (defined as the day a vaginal plug 
was discovered, GD 0) she was removed from the male, housed individually, and 
subcutaneously injected with either VPA (400 mg/kg) or saline on GD 12. This new 
technique created the four experimental groups for this chapter (Table 3): 
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Table 3. Experimental groups used in chapter 3. 
Group Genotype Treatment 
1 Wild-type SAL 
2 Wild-type VPA 
3 Heterozygous SAL 
4 Heterozygous VPA 
 
In addition, because this new technique did not guarantee one particular genotype in 
the offspring as with the first technique, within a few days of weaning (PND 21) rats were 
ear-punched and the tissues subsequently genotyped by a commercial genotyping 
company (Transnetyx, Cordova, TN, USA). 
In all of the following experiments, multiple litters were used to create the sample size 
for each experimental group. The reason for this was to reduce the chance of potentially 
abnormal litters representing an entire group. The sample sizes reported in these 
experiments are indicative of individual rats (except where otherwise indicated). 
 
Data analysis 
IBM SPSS statistics version 22 was used for all statistical analyses in this chapter. The 
alpha level for statistical significance was set at p < .05. 
  
Experiment V (EXP-V): Ultrasonic vocalisations in pups  
The purpose of this experiment was to investigate ultrasonic vocalisation (USV) 
communication in PND 7 rats. Although rat communication is not perfectly understood, 
much is known about the way they communicate. Rats emit USVs as a means of 
communication and the frequency of these USVs depends on a variety of factors, 
including the age of the animal, its emotional state, and environmental variables 
(Brudzynski, 2013; Brudzynski, Kehoe, & Callahan, 1999; Insel, Hill, & Mayor, 1986). 
Various situations throughout a rat’s life can induce the rat to emit USVs, including: 
separation from the nest, interaction with a predator, social, sexual, and aggressive 
behaviour, engagement in cooperative behaviour with a conspecific, courtship, and 
exploration (Barfield, Auerbach, Geyer, & McIntosh, 1979; Blanchard, Blanchard, 
Agullana, & Weiss, 1991; Burgdorf et al., 2008; Knutson, Burgdorf, & Panksepp, 1998; 
Łopuch & Popik, 2011; Wöhr & Scattoni, 2013; Wöhr & Schwarting, 2007).  
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In pups, USVs are a vital means of communication and play a significant role in 
survival. Previous research has demonstrated that pups separated from their mothers will 
reliably emit USVs, most likely as a way of helping her to locate them and return them to 
the safety and warmth of the nest. The isolation-induced USVs emitted by the pup 
indicate a negative affective experience and may be similar to human infant cries for help 
(Shair et al., 2015). These ‘retrieval’ or ‘distress’ calls are effective in eliciting maternal 
search behaviour both when the pup emits the call in real time and when it is simply an 
audio play-back of a call (Allin & Banks, 1972; Brunelli, Shair, & Hofer, 1994; Farrell & 
Alberts, 2002; Smotherman, Bell, Starzec, Elias, & Zachman, 1974; Wöhr & Scattoni, 
2013). The current paradigm aimed to exploit this typical method of communication in an 
experimental setting to see if the proposed model led to deficits in this type of 
communication – thus, the experiment was designed to be able to detect one of the three 
core behavioural hallmarks of ASD: impaired communication.  
 
Method 
Animals 
EXP-V was performed using male and female pups at PND 7. As this age was prior to the 
weaning process (PND 21), the animals were still housed with their mother and siblings. 
Thus, the entire home cage including the mother and litter was moved to the experimental 
room 30 min prior to experimentation. Lighting and temperature conditions were the 
same in the experimental room as in the housing room. Food and water were available ad 
libitum. The sample sizes for the experimental groups in this paradigm were as follows: 
wild-type + saline = 7; wild-type + VPA = 6; heterozygous + saline = 17; heterozygous + 
VPA = 11.  
 
Apparatus 
EXP-V took place in a cylindrical wire mesh cage (11 cm diameter, 14 cm height) lined 
with fresh pine bedding and a specialised ultrasonic microphone (Ultravox) placed 
directly above the cage, approximately 15 cm from the animal. Noldus Ultravox XT 
software and technology was used to record pup USVs and Raven Pro 1.5 was used to 
detect the calls.  
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Procedure 
Essentially, this experiment involved separating a pup from its mother and then 
measuring the pup’s USVs for a 5 min period. Specifically, an individual pup was taken 
from its home cage and placed inside the wire mesh cage lined with pine bedding. After a 
delay of 10 s, the ultrasonic microphone placed above the cage was turned on and 
recorded USVs for the next 5 min. The 10 s delay was used to control for the immediate 
effects of handling. During the 5 min period of USV recording, the experimenter left the 
room to ensure minimal noise was picked up by the microphone. Once this period was 
completed, the pup was removed from the wire mesh cage and its role in the experiment 
was complete. The primary outcomes of interest were the total number of USV emissions, 
or ‘calls,’ produced by the pup during the experiment, and the mean duration of these 
calls.  
 
Results  
As this experiment involved both males and females, initially one-way ANOVAs were 
used to test the effect of sex on the primary outcomes of interest. Results revealed there 
was no main effect of sex on the number of total calls: F(1, 40) = .499, p = .484; or the 
mean duration of these calls: F(1, 40) = 1.224, p = .275. Thus, both sexes were pooled 
together for all future analyses. 
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the total number of calls. Results indicated there was no main effect of 
genotype, F(1, 38) = .002, p = .961, or treatment type F(1, 38) = .266, p = .609. Similarly, 
there was no significant interaction between genotype and treatment type F(1, 38) = 
3.200, p = .082. (See Fig. 11). 
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the mean duration of calls. Results indicated there was no main effect 
of genotype, F(1, 38) = 2.636, p = .113, or treatment type F(1, 38) = 1.140, p = .292. 
Similarly, there was no significant interaction between genotype and treatment type F(1, 
38) = .006, p = .940. (See Fig. 12). 
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Figure 11. EXP-V: Effects of SERT genotype and VPA treatment on 
the total number of USV calls emitted by PND 7 pups during a 5 min 
isolation period. Bars represent the mean (+SEM). 
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Figure 12. EXP-V: Effects of SERT genotype and VPA treatment on 
the mean duration of USV calls emitted by PND 7 pups during a 5 
min isolation period. Bars represent the mean (+SEM). 
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Experiment VI (EXP-VI): Social interaction following isolation in adults 
The purpose of this experiment was to investigate social interaction in adult rats 
following a brief period of isolation. Typically, rats engage in social interaction and will 
actively interact with a novel conspecific (Grant, 1963; Lehman & Adams, 1977), 
particularly after a period of short-term isolation (Niesink & Van Ree, 1982). The current 
paradigm aimed to exploit this typical behaviour in an experimental setting to see if the 
proposed model led to deficits in social interaction. Thus, the experiment was designed to 
detect one of the three core behavioural hallmarks of ASD: a reduction in social 
behaviour.  
 
Method 
Animals 
EXP-VI was performed using adult male rats (PND 90+). It is important to note that this 
experiment investigated pairs of animals, rather than individual animals. For this 
paradigm each rat was taken from its home cage and individually housed in a clean cage 
in the experimental room the day before experimentation to optimise social interaction. 
Specifically, rats were isolated at midday and experimentation began at 10:00am the 
following day. Food and water were available ad libitum during this period of isolation. 
Lighting and temperature conditions were the same in the experimental room as they 
were in the housing room. This paradigm used 5 wild-type saline pairs, 4 wild-type VPA 
pairs, 11 heterozygous saline pairs, and 11 heterozygous VPA pairs.  
 
Apparatus 
The experiment took place in the same standard open field circular arena (80 cm in 
diameter, 45 cm in height) with black flooring and walls as used in previous experiments. 
Ethovision XT v9.0 video tracking software was used to investigate animal social 
interactions. The arena was washed with warm water and wiped down with 75% ethanol 
before each new pair of experimental animals was put into the open field; this was done 
in order to minimise scent carry-over from previous animals.  
 
Procedure 
Essentially, this experiment involved pairing animals of identical genotype and prenatal 
treatment, but from different litters, following a period of isolation (approximately 24 hr) 
and examining their social interaction for 30 min.  
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Animals were placed at opposite ends of the open field and video was recorded for 30 
min. Active and passive social behaviours were manually scored using Ethovision XT 
v9.0 software. Active social behaviours were defined as: at least one animal in the pair 
actively investigating the other, either through sniffing, following, passing, mounting, 
grooming, or attacking its partner. Passive social behaviour was defined as both animals 
disengaged from active social behaviours but still within close proximity of each other, 
suggesting they still prefer social contact even if they are not directly interacting. A pair 
was defined as being in close proximity if a rat’s body was within touching distance of 
the other rat’s tail. The primary outcomes of interest were: total duration of both active 
and passive social behaviours, and the frequency of both active and passive social 
behaviours.  
 
Results  
Active Duration 
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the total duration of active social behaviour. Results indicated there was 
no main effect of genotype, F(1, 27) = .034, p = .856, or treatment type F(1, 27) = 1.458, 
p = .238. However, there was a significant interaction between genotype and treatment 
type F(1, 27) = 4.674, p = .040. (See Fig. 13).  
 
Active Frequency 
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the frequency of active social behaviour. Results indicated there was no 
main effect of genotype, F(1, 27) = .077, p = .783, or treatment type F(1, 27) = .641, p = 
.430. However, there was a significant interaction between genotype and treatment type 
F(1, 27) = 6.614, p = .016. (See Fig. 14). 
 
Passive Duration 
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the total duration of passive social behaviour. Results indicated there 
was no main effect of genotype, F(1, 27) = .690, p = .414, or treatment type F(1, 27) = 
3.317, p = .080. Similarly, there was no significant interaction between genotype and 
treatment type F(1, 27) = .403, p = .531. (See Fig. 15). 
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Passive Frequency 
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the frequency of passive social behaviour. Results indicated there was 
no main effect of genotype, F(1, 27) = .002, p = .961, or treatment type F(1, 27) = 1.701, 
p = .203. Similarly, there was no significant interaction between genotype and treatment 
type F(1, 27) = .265, p = .611. (See Fig. 16). 
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Figure 13. EXP-VI: Effects of SERT genotype and VPA treatment on 
the total duration of active social behaviour in adult pairs following a 
period of isolation. Bars represent the mean (+SEM). 
Figure 14. EXP-VI: Effects of SERT genotype and VPA treatment on 
the frequency of active social behaviour in adult pairs following a 
period of isolation. Bars represent the mean (+SEM). 
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Figure 16. EXP-VI: Effects of SERT genotype and VPA treatment on 
the frequency of passive social behaviour in adult pairs following a 
period of isolation. Bars represent the mean (+SEM). 
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Figure 15. EXP-VI: Effects of SERT genotype and VPA treatment on 
the total duration of passive social behaviour in adult pairs following a 
period of isolation. Bars represent the mean (+SEM). 
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Experiment VII (EXP-VII): Scent marking in adults  
The purpose of this experiment was to investigate scent marking communication in adult 
rats. In addition to the emission of USVs, rodents can communicate through olfactory 
signals, or scent marking (Arakawa, Blanchard, Arakawa, Dunlap, & Blanchard, 2008; 
Wöhr & Scattoni, 2013). Scent marking is a form of communication whereby the animal 
deposits urinary pheromones, used to convey information in a variety of domains 
including territorial and fighting behaviour, sexual and social behaviour, and predator 
identification. Typically, male rodents will produce scent marks in the presence of a 
female urinary cue (Adams, 1976; Wöhr, Roullet, & Crawley, 2011; Wöhr & Scattoni, 
2013). The current paradigm aimed to exploit this typical behaviour in an experimental 
setting to see if the proposed model led to deficits in this type of communication. Thus, 
the experiment was designed to be able to detect one of the three core behavioural 
hallmarks of ASD: impaired communication.  
 
Methods 
Animals 
EXP-VII used adult male rats as experimental animals (PND 90 +). However, female 
adult rats were also used in the socialisation phase that preceded the experimental phase. 
The sample sizes for the experimental groups in this paradigm were as follows: wild-type 
+ saline = 8; wild-type + VPA = 5; heterozygous + saline = 8; heterozygous + VPA = 7. 
 
Apparatus 
The experiment took place in a standard open field circular arena (80 cm in diameter, 45 
cm in height) with black flooring and walls. A clean, regular housing polycarbonate cage 
was used during the socialisation phase in which male rats were exposed to foreign 
female animals. Lemon essence (The Aromatherapy Company, New Zealand) was used 
as the novel smell competing with the social smell of female urine; both of these odours 
were pipetted onto pieces of circular standard filter paper. The open field was cleaned 
with a 70% ethanol solution before new experimental animals were introduced to the 
paradigm. Ninhydrin spray was used to identify scent markings left by the animals during 
the experimental procedure.  
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Procedure 
The procedure for this experiment was adapted from the scent marking paradigm 
described by Wöhr et al. (2011). The experiment was divided into three distinct phases: 
the socialisation, habituation, and experimental phases. The socialisation phase consisted 
of placing an individual male rat in a fresh cage with a foreign female rat of an identical 
strain and leaving them there for 5 min. The purpose of this phase was to ensure the 
experimental male rats had been directly exposed to female smell before the next phase of 
the experiment. It must be remembered that male rats had only been housed with other 
males since weaning at PND 21.  
The habituation phase came 6-9 days later. Experimental rats were placed in an open 
field for 20 min in order to habituate to the novel environment. The purpose of this phase 
was to reduce the potential effect of anxiety in the experimental phase. Following 20 min 
free exploration, the rat was removed temporarily whilst the open field was cleaned of 
urine and faeces.  
Immediately following the cleaning of the open field, the experimental phase 
commenced. Two pieces of filter paper were placed on either side of the open field, one 
containing 30 μl of lemon essence, and the other containing 30 μl of adult female urine. 
The rat was then placed back into the open field and left to freely explore for 5 min. At 
the end of this 5 min exploration period the rat was removed and placed back in its home 
cage – its role in the experiment complete. The filter paper was then removed and left to 
dry for an hour so it could be analysed later for scent markings. Scent markings near the 
cues were interpreted as signs of communication, thus the more scent markings there 
were, the more communicative that animal was interpreted as being. The primary 
outcomes of interest were: the percentage of scent marks made next to the urinary cue and 
the total number of scent marks.  
 
Scent marking analysis 
After the experimental phase the filter paper was removed and left to dry for an hour. 
Once dried, the filter paper was sprayed with ninhydrin spray and left for 24 hr in order to 
illuminate the scent markings on the paper. Ninhydrin spray reacts with the ammonia in 
urine to produce a distinguishable purple colour that can be observed for analysis (Laskar, 
Bhattacharya, & Basak, 1991). The ninhydrin spray illuminated scent markings, pools of 
urine, sneeze markings, and footprints. The scent markings were counted using 
transparent grid paper, each of the squares 1 cm x 1 cm. Scent marks were defined as 
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marks smaller than four 1 cm grids, unless they had obvious visual characteristics of 
footprints or sneezes. Marks larger than four 1 cm grids were defined as urine pools and 
not included in the analysis.  
 
Urine Collection 
Urine was collected from female strain-matched rats in the oestrus phase of the 
reproductive cycle. To determine whether the females were in the oestrus phase, they 
were picked up gently by the base of the tail and the genital region was visually 
inspected. A female was defined as being in the oestrus phase when a reddish and relaxed 
vagina was observed. In order to collect urine, the female rat was held over a container 
and its stomach was rubbed to encourage urination. Fresh urine was always used for 
experimentation – no more than 60 min old. 
 
Results 
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the percentage of overall scent marks made next to the urinary cue. 
Results indicated that there was no main effect of genotype, F(1, 24) = 3.834, p = .062, or 
treatment type F(1, 24) = .781, p = .386. Similarly, there was no significant interaction 
between genotype and treatment type F(1, 24) = 2.663, p = .116. (See Fig. 17). One 
sample t-tests were performed to determine whether the experimental groups displayed a 
significant preference for marking next to the urinary cue (preference was inferred when 
the percentage of scent marks was significantly higher than 50%). Results indicated that 
no group displayed statistical preference for scent marking next to the urinary cue. 
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the total number of scent marks. Results indicated there was no main 
effect of genotype, F(1, 24) = .000, p = .983. However, there was a main effect of 
treatment type F(1, 24) = 4.763, p = .039, with saline-treated animals marking 
significantly more than VPA-treated animals. There was no significant interaction 
between genotype and treatment type F(1, 24) = .835, p = .370. (See Fig. 18). 
  
 86 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
40
WT HET
N
u
m
b
er
 
Genotype 
SAL
VPA
Figure 18. EXP-VII: Effects of SERT genotype and VPA treatment on 
the total number of scent marks produced during the experimental 
phase. Bars represent the mean (+SEM). 
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Figure 17. EXP-VII: Effects of SERT genotype and VPA treatment on 
the percentage of scent markings produced next to the urinary social 
cue. Data are expressed as a percentage of the number of scent 
markings produced next to both cues combined. Bars represent the 
mean (+SEM). 
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Experiment VIII (EXP-VIII): Social approach and novelty seeking in adolescents  
The purpose of this experiment was to investigate social approach and social novelty 
seeking behaviour in adolescent rats. This experiment was designed to be able to detect 
the same social deficits in adolescent rats that EXP-I and III aimed to identify in juveniles 
and adults, respectively. EXP-VIII was performed in adolescents so that these social 
behaviours could be evaluated at three different developmental stages.  
 
Method 
Animals 
EXP-VIII was performed using adolescent male rats (PND 35-60). As in EXP-I stranger 
rats were also used; these strangers were untreated, Sprague Dawley, female juveniles 
(approximately PND 30). All animals were moved into the experimental room 30 min 
before the experiment began. Lighting and temperature conditions were the same in the 
experimental room as they were in the housing room. The sample sizes for the 
experimental groups in this paradigm were as follows: wild-type + saline = 7; wild-type + 
VPA = 8; heterozygous + saline = 10; heterozygous + VPA = 18.  
 
Apparatus  
EXP-VIII used the same open field arena, cylindrical wire mesh cages, and Ethovision 
XT v9.0 video tracking software as EXP-I and III, described in chapter 2. In addition, a 
tennis ball was used as an inanimate novel object in phase two.  
 
Procedure 
EXP-VIII employed the same protocol described in EXP-I, with one key difference: there 
was a novel inanimate object placed in the empty cylindrical cage (B) during phase two. 
The reason for this adaptation was to control for the possibility of a ceiling effect of the 
social cue in phase two. As both EXP-I and III did not observe a social deficit in phase 
two, it is possible that the difference between a novel rat in a cage and an empty cage was 
simply too large, meaning a social deficit would need to be drastic to reveal a difference 
in an experimental group. Thus, in the current experiment the comparison was between a 
novel rat and a novel inanimate object (a tennis ball).  
The primary outcomes of interest were: the percentage of total investigatory time 
spent investigating cylinder (A) in phase two and the percentage of total investigatory 
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time spent investigating cylinder (B) in phase three. Distance moved during habituation 
(phase one) was also calculated.  
 
Results 
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on distance moved during phase one. Results indicated there was no main 
effect of genotype, F(1, 39) = .563, p = .458, or treatment type F(1, 39) = .028, p = .867. 
Similarly, there was no significant interaction between genotype and treatment type F(1, 
39) = 2.050, p = .160.  
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the mean percentage of exploration time occurring near cylinder (A) 
during phase two. Results indicated there was no main effect of genotype, F(1, 39) = 
.771, p = .385, or treatment type F(1, 39) = .073, p = .789. Similarly, there was no 
significant interaction between genotype and treatment type F(1, 36) = 1.506, p = .227. 
(See Fig. 19). One sample t-tests were performed to determine whether the experimental 
groups displayed a significant preference for the social cue (preference was inferred when 
the percentage of exploration time next to (A) was significantly higher than 50%). Results 
indicated that all groups except the heterozygous saline-treated animals displayed a 
significant preference for the social cue.  
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the mean percentage of exploration time occurring near cylinder (B) 
during phase three. Results indicated there was no main effect of genotype, F(1, 39) = 
2.378, p = .131, or treatment type F(1, 39) = 1.472, p = .232. Again, there was no 
significant interaction between genotype and treatment type F(1, 39) = 1.271, p = .266. 
(See Fig. 20). One sample t-tests were performed to determine whether the experimental 
groups displayed a significant preference for the novel social cue (preference was inferred 
when the percentage of exploration time next to (B) was significantly higher than 50%). 
Results indicated that no experimental groups displayed a significant preference for the 
novel social cue. 
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Figure 20.  EXP-VIII: Effects of SERT genotype and VPA treatment 
in adolescents on the mean percentage of exploration time near the 
novel social cylinder (B) in phase three. Bars represent the mean 
(+SEM). 
Figure 19. EXP-VIII: Effects of SERT genotype and VPA treatment 
in adolescents on the mean percentage of exploration time near the 
social cylinder (A) in phase two. Bars represent the mean (+SEM). 
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Figure 21. Summary of EXP-I, III, and XIII: mean percentage of exploration spent near the social 
cylinder in phase two for juvenile, adolescent, and adult animals, treated with saline, LPS, or VPA. 
Bars represent the mean (+SEM). 
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Experiment IX (EXP-IX): Repetitive behaviour in juveniles 
The purpose of this experiment was to investigate repetitive behaviour in juvenile rats. 
Typically, rats are highly exploratory animals with a tendency to investigate all novel 
cues in a new environment (Sara, Dyon-Laurent, & Hervé, 1995). The current paradigm 
aimed to exploit this typical behaviour in an experimental setting to see if the proposed 
model led to deficits in such behaviour. Thus, the experiment was designed to be able to 
detect one of the three core behavioural hallmarks of ASD: increased repetitive 
behaviour. Juvenile animals were used as ASD is a disorder detectable at a very young 
age and thus observing repetitive behaviour in juveniles would more closely mimic the 
behavioural profile seen in patients.  
 
Methods 
Animals 
EXP-IX was performed using juvenile (PND 22-30) male and female rats. Animals were 
habituated to the experimental room for 30 min before beginning the experiment. The 
sample sizes for the experimental groups in this paradigm were as follows: wild-type + 
saline = 9; wild-type + VPA = 13; heterozygous + saline = 31; heterozygous + VPA = 15.  
 
Apparatus 
The experiment took place inside a standard Plexiglas locomotor activity box (42 cm x 42 
cm x 30 cm), with a 16-hole steel hole-board apparatus placed on the floor of the activity 
box (Med Associates). Effectively, the hole-board apparatus provided a novel floor with 
16 identical holes (20 mm in diameter, in a square 4 x 4 orientation) for the rat to be able 
to poke its nose inside. Each time the rat poked its nose inside a hole, the event was 
recorded by a computer program (Med Associates). The activity boxes were cleaned with 
70% ethanol before the introduction of any new rat to the paradigm.  
 
Procedure 
First, rats were placed inside the locomotor activity boxes without the hole-board 
apparatus inside and left to freely explore their novel experimental environment for 5 
min. The purpose of this stage was to habituate the rats to the locomotor boxes to reduce 
any effect anxiety may play in the experiment. Next, the rats were removed from the box, 
the hole-board apparatus was inserted, and the rats were reintroduced to the box and left 
to freely explore for 15 min. Nose-pokes into each hole were recorded. Re-entries (nose-
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pokes) into a previously explored hole were interpreted as a measure of repetitive 
behaviour and/or stereotypy. Behaviourally, a rat with an ASD phenotype would be 
expected to produce more re-entries than typical rats.  
The primary outcomes of interest were: the number of novel nose-pokes and the 
number of re-entries into a previously explored hole. Locomotor activity was unable to be 
measured due to a technical fault in the computer program monitoring the activity boxes.  
 
Results  
As this experiment involved both males and females, initially one-way ANOVAs were 
used to test the effect of sex on the primary outcomes of interest. Results revealed there 
was no main effect of sex on the number of novel nose-pokes: F(1, 66) = 1.903, p = .172; 
the number of re-entries: F(1, 66) = .005, p = .944; or the total number of nose-pokes: 
F(1, 66) = .194, p = .661. Thus, both sexes were pooled together for all future analyses. 
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the number of novel nose-pokes. Results indicated there was no main 
effect of genotype, F(1, 64) = 1.789, p = .187, or treatment type F(1, 64) = 2.191, p = 
.144. Similarly, there was no significant interaction between genotype and treatment type 
F(1, 64) = 2.357, p = .130. (See Fig. 22). 
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the number of re-entries into a previously explored hole. Results 
indicated there was no main effect of genotype, F(1, 64) = .742, p = .392, or treatment 
type F(1, 64) = .172, p = .680. However, there was a significant interaction between 
genotype and treatment type F(1, 64) = 7.897, p = .007. Specifically, prenatal exposure to 
VPA increased the number of re-entries in wild-types (p = .055), but significantly 
decreased the number in heterozygous animals (p = .050). (See Fig. 23).  
A 2 x 2 (gene x environment) ANOVA tested the effects of the SERT genotype and 
treatment type on the total number of nose-pokes. Results indicated there was no main 
effect of genotype, F(1, 64) = 1.126, p = .293, or treatment type F(1, 64) = .567, p = .454. 
However, there was a significant interaction between genotype and treatment type F(1, 
64) = 7.002, p = .010. (See Fig. 24). Specifically, prenatal exposure to VPA significantly 
increased the total number of nose-pokes in wild-types (p = .050), and decreased the total 
number of nose-pokes in heterozygous animals, albeit not significantly (p = .113).  
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Figure 22. EXP-IX: Effects of SERT genotype and VPA treatment in 
juveniles on the number of novel nose-pokes performed during a 15 
min period. Bars represent the mean (+SEM). 
0
2
4
6
8
10
12
14
16
18
WT HET
N
u
m
b
er
 o
f 
re
-e
n
tr
ie
s 
Genotype 
SAL
VPA
Figure 23. Effects of SERT genotype and VPA treatment in juveniles 
on the number of re-entries into a previously explored hole performed 
during a 15 min period. Bars represent the mean (+SEM). 
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Figure 24. EXP-IX: Effects of SERT genotype and VPA treatment in 
juveniles on the total number of nose-pokes performed during a 15 
min period. Bars represent the mean (+SEM). 
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Discussion 
The purpose of this chapter was to investigate the effects of prenatal exposure to VPA on 
the three core behavioural domains of ASD and to test the hypothesis that rats with a 
genetically compromised SERT function would show an increased vulnerability to the 
impact of this prenatal exposure to VPA. Five different experiments (V, VI, VII, VIII, 
IX), including measures of social behaviour, communication, and repetitive behaviour 
were performed with the aim of detecting ASD-like deficits. Collectively, the data from 
this chapter produced three key findings: first, gene-environment interactions were 
observed on some measures of social behaviour and repetitive behaviour, but not on 
measures of communication. Second, of the interactions observed, none were in 
accordance with the pattern expected by the hypothesis; in fact, heterozygous animals 
seemed more resilient to the effects of VPA. Third, VPA is particularly sensitive to 
experimental variables.  
In order to identify a potential interaction, a moderate dose of VPA (400 mg/kg) was 
used, relative to previous literature. For instance Cohen et al. (2013) used a similar lower 
dose (350 mg/kg) while others have used much higher doses (800 mg/kg) (Miyazaki et 
al., 2005; Narita et al., 2002). VPA was administered at GD 12 as this timing is widely 
used throughout the literature and is a critical period in which VPA exposure can lead to 
ASD-like deficits in rats (Kim et al., 2011).  
 
Social Behaviour 
Two experiments (EXP-VI and VIII) were performed to investigate the first diagnostic 
criterion of ASD: a reduction in social behaviour. EXP-VI investigated social interaction 
in adult rats following a brief period of isolation. A significant gene-environment 
interaction between SERT genotype and prenatal exposure to VPA was found on both 
measures of active social behaviour. Specifically, prenatal exposure to VPA reduced the 
duration and frequency of active social behaviour in wild-types, but did not influence 
active social behaviour in heterozygous animals. The pattern of this interaction was at 
odds with the hypothesis that predicted an exaggerated detrimental influence of VPA on 
social behaviour in heterozygous animals. In fact, if anything, VPA treatment actually 
tended to increase the frequency of active social behaviour in heterozygous animals, 
albeit not significantly. No gene-environment interactions were observed for measures of 
passive social behaviour.  
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These findings support previous literature demonstrating that prenatal exposure to 
VPA can have a detrimental influence on aspects of social behaviour in rats (Bambini-
Junior et al., 2011; Schneider & Przewlocki, 2005), and furthermore, EXP-VI shows for 
the first time that VPA’s influence on social behaviour depends on SERT genotype. 
However, the data provide no evidence for the hypothesis that a compromised SERT 
function will leave animals more vulnerable to prenatal VPA exposure. Rather, the data 
suggest that a compromised SERT genotype may actually be protective against prenatal 
VPA exposure, at least with regards to active social behaviour. Although speculative, the 
data also indicate the possibility that VPA exposure may even be desirable for rats with a 
compromised SERT function, at least with regards to the frequency of active social 
behaviour, as VPA treatment actually led to a small (albeit non-significant) increase in 
active social behaviour. 
That VPA can demonstrate prosocial properties given the right experimental 
conditions has been reported before. Several recent papers have observed increased social 
behaviours in rats following prenatal exposure to VPA. In fact, these prosocial effects 
were even demonstrated in multiple rat strains (Long Evans and Wistar) and at different 
doses (350 mg/kg and 600 mg/kg) (Cohen et al., 2013; Štefánik et al., 2015). The variety 
of outcomes in research investigating prenatal VPA treatment and social behaviour 
demonstrates how sensitive VPA is to experimental variables.  
One more important point can be gleaned from EXP-VI: the fact there was an 
interaction but no main effect of gene or environment alone highlights the importance of 
gene-environment research. As mentioned in chapter 1, ignoring interactions can lead to 
both genetic and environmental factors being underestimated or, at worst, dismissed. 
Combining these risk factors in this experiment revealed the importance of SERT 
genotype in active social behaviour that may have been overlooked when looking at the 
genotype in isolation.  
EXP-VIII was the second paradigm investigating social behaviour in this chapter. 
Specifically, EXP-VIII investigated social approach and social novelty seeking behaviour 
in adolescents. No gene-environment interaction or main effect of genotype or treatment 
on either of the measures of social behaviour was found. The procedure in this 
experiment was adapted from EXP-I and III to include an inanimate object in the 
opposing cylinder (B) in phase two. This adaptation was designed to control for the 
possibility (evoked by results in EXP-I and III) that the social cue in phase two was 
simply too strong, when compared to a totally empty cylinder, to detect social deficits 
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using moderate genetic and environmental insults. Despite the different non-social 
stimulus, preference remained high for the social cue amongst all animals, suggesting 
these animals simply do not have a deficit in social approach behaviour (See Fig. 21 for a 
summary of all phase two results from this thesis). In addition, previous research has 
detected differences in social approach behaviour in phase two without the addition of 
high valence cues in competition with the novel animal (Bambini-Junior et al., 2011; 
McFarlane et al., 2008; Moy et al., 2007).  
Animals in EXP-VIII displayed a lack of social novelty. In fact, no experimental 
group displayed a significant preference for the novel social cue over the familiar social 
cue. Several studies using this approach/novelty paradigm have observed preference for 
social novelty in a variety of rodent strains (Bambini-Junior et al., 2011; Moy et al., 
2007). However, not all studies using this paradigm have observed preference for social 
novelty, indicating the type of animal/strain investigated and the specific protocol used 
may have an important influence on the outcome (Moy et al., 2007; Roullet et al., 2010). 
As described in chapter 1, a vast range of even subtle experimental details can lead to 
differing outcomes when investigating VPA (Roullet et al., 2013). Thus, it is possible that 
the lack of social novelty seeking observed in EXP-VIII was a combination of the type of 
animals used, the dose and timing of VPA, the way VPA was administered, and the use of 
an open field over the more traditional three-chambered box. 
That being said, the data from this thesis indicate that social approach and social 
novelty are two distinct aspects of social behaviour that do not necessarily correlate. This 
idea is in line with previous research. For instance, Moy et al. (2007) investigated these 
two behaviours across ten different inbred mouse strains and found that the rank order for 
the degree of social approach did not match up with the rank order for the degree of social 
novelty. Moreover, the data from this thesis show that social approach differs 
fundamentally from social interaction (EXP-VI) and thus, from an animal modelling 
perspective, it is important to include both paradigms in order to encompass multiple 
aspects of social behaviour. 
Collectively, the data from EXP-VI and VIII demonstrate that prenatal exposure to 
400 mg/kg of VPA administered subcutaneously at GD 12 can reduce certain measures of 
social behaviour in wild-types, but not in heterozygous animals. The influence of VPA 
shown here in wild-types is consistent with the majority of previous research in this field 
(Bambini-Junior et al., 2011; Schneider & Przewlocki, 2005). However, as this thesis is 
the first extensive investigation of social behaviour in heterozygous rats, the finding that 
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heterozygous rats appear resilient to the disruptive effect of VPA to social behaviour is 
novel. Overall, no main effect of SERT genotype on social behaviour was observed in 
this chapter. This finding is in accordance with previous research which, despite finding 
reductions in play behaviour in homozygous rats, actually found non-playful facets of 
social behaviour, such as active social behaviour, to be unaffected in homozygous rats 
(Homberg, Schiepers, et al., 2007). In studies published to date, heterozygous rats have 
produced either no or only small effects when behaviourally compared to wild-types 
(Olivier et al., 2008).  
In summary, the experiments investigating social behaviour in this chapter suggest 
that there is an interaction between SERT genotype and prenatal exposure to valproate on 
some measures of social behaviour, although not in the pattern predicted by the 
hypothesis. The fact that not all measures of social behaviour were influenced by VPA 
demonstrates the diversity of social behaviours and the specificity of VPA’s influence.  
 
Communication 
There were two experiments (EXP-V and VII) included in this chapter designed to assess 
the second diagnostic criterion of ASD: impaired communication. EXP-V investigated 
USV communication in PND 7 rats and EXP-VII investigated scent marking in adult rats. 
Across these two paradigms there was no interaction between SERT genotype and 
prenatal exposure to VPA observed on any measure of communication. Thus, the data do 
not support the hypothesis that a compromised SERT function will leave animals more 
vulnerable to the detrimental impact of prenatal VPA exposure, at least with regards to 
communication. There are several reasons to trust this conclusion. First, a number of 
different communication measures at different stages of life were investigated and all the 
data indicate there is no interaction between SERT genotype and prenatal exposure to 
VPA. Second, only moderate genetic and environmental insults were used (heterozygous 
animals and 400 mg/kg VPA), suggesting a ceiling/floor effect of the genetic and 
environmental manipulations is unlikely. In support of this point, when a main effect of 
treatment was found (EXP-VII: VPA-treated animals produced fewer scent marks than 
saline-treated animals) the effect was only moderate and left room for the potential 
influence of the genotype. Finally, EXP-VI demonstrated that SERT genotype and 
prenatal exposure to VPA can interact on certain behavioural measures. Taken together, 
the data suggest it is likely that the SERT genotype does not interact with prenatal 
exposure to VPA with regard to the communication paradigms used in this chapter.  
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Overall, the data from these communication paradigms showed no significant effect of 
SERT genotype. Although to the best of our knowledge no previous literature has 
investigated the impact of SERT genotype on communication in rats, significant evidence 
does implicate the role of 5-HT in rodent communication (Wöhr, van Gaalen, & 
Schwarting, 2015). For instance, SSRI drugs acting on the SERT have been demonstrated 
to significantly reduce USV calling in pups (Winslow & Insel, 1990; Zimmerberg & 
Germeyan, 2015). In addition, mice with genetically modified serotonergic systems have 
produced alterations in isolation-induced USVs. Specifically, mouse pups with a genetic 
deletion of the 5-HT1b receptor emit fewer isolation-induced USVs than wild-type 
controls (Brunner, Buhot, Hen, & Hofer, 1999; El-Khodor et al., 2004). In addition, 
studies investigating mouse pups with a genetic deletion of the 5-HT1a receptor have 
observed both decreases (Weller et al., 2003) and increases (Zanettini et al., 2010) in 
isolation-induced USVs. Finally, mice lacking any brain 5-HT (tryptophan hydroxylase 2 
knockout mice) have shown deficits in both USV and scent marking behaviour (Kane et 
al., 2012; Mosienko et al., 2015).  
Thus, given the importance of 5-HT in communication, it is surprising no significant 
effect of SERT genotype was found on any measure of communication in this chapter. 
One explanation for this might be the use of a more moderate genetic insult used here 
than in previous studies. For instance, the current chapter used heterozygous SERT rats 
whereas previous research used full knockouts of 5-HT1a, 5-HT1b, and tryptophan 
hydroxylase 2 (El-Khodor et al., 2004; Kane et al., 2012; Mosienko et al., 2015; Weller et 
al., 2003).  
In addition, some of these previously mentioned genetic mouse models and 
pharmacological substances that have disrupted USVs via the serotonergic system may 
have done so through the anxiolytic outcome of these manipulations rather than through a 
true disruption in communication. Although the main interpretation of the isolation-
induced USV paradigm in ASD modelling is that fewer vocalisations are indicative of a 
reduced ability to communicate, an alternative interpretation is that fewer vocalisations 
simply indicates a lowered response to a stressful environment, or, in other words, 
reduced anxiety (Malkova et al., 2012). Indeed, the role of anxiety in isolation-induced 
USVs has been demonstrated, with pup USVs decreasing following administration of 
anxiolytic compounds and increasing after administration of anxiogenic compounds 
(Hodgson, Guthrie, & Varty, 2008; Insel et al., 1986). Moreover, 5-HT1b and tryptophan 
hydroxylase 2 knockout mice both display decreased levels of anxiety, consistent with 
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the fact they display a decrease in isolation-induced USVs (Mosienko et al., 2012; 
Zhuang et al., 1999).  
Thus, in the current chapter, the fact rats with a compromised SERT genotype did not 
have altered levels of communication, may simply reflect the fact heterozygous rats do 
not have a big enough genetic insult to disrupt communication on the one hand, and do 
not exhibit reduced levels of anxiety on the other hand. Data from the other behavioural 
experiments in this chapter support the claim that these experimental animals are unlikely 
to differ in terms of anxiety. For instance, EXP-VIII found no genotype effect on 
locomotor activity during habituation and EXP-IX found no genotype effect on novel 
nose-pokes in an exploration paradigm. If there were real differences in anxiety between 
the experimental groups, it is reasonable to expect they would have been detected by 
either one of these measures. 
Collectively, the data from EXP-V and VII showed that prenatal exposure to 400 
mg/kg of VPA subcutaneously administered at GD 12 reduced communication abilities in 
adult rats but not in pups. Specifically, VPA exposure was able to reduce overall scent 
marking in adults, but did not statistically influence USV emissions in pups. To the best 
of our knowledge, EXP-VII was the first to investigate prenatal VPA exposure in a scent 
marking paradigm and in this respect the data constitute a novel finding that support 
previous literature showing other types of communicatory deficits in VPA-exposed 
animals (Gandal et al., 2010). Moreover, this finding puts the VPA model in line with 
other well-validated models of ASD in rodents, such as maternal immune activation 
models and the BTBR T+tf/J mouse model, that have demonstrated reduced scent 
marking in similar paradigms (Malkova et al., 2012; Wöhr et al., 2011). In contrast, it was 
surprising VPA exposure did not alter USV calls in pups, as has been found in prior 
research. For instance, both Moldrich et al. (2013) and Gandal et al. (2010) found prenatal 
VPA exposure to reduce USVs in pups isolated from their mothers. However, both these 
previous papers used mice and a higher dose of VPA (600 mg/kg), which may partially 
explain the divergent findings.  
Interestingly, EXP-VII revealed that no experimental group had a preference for 
marking next to the urinary cue over the lemon cue. Previous research in mice has shown 
preference for scent marking near urinary cues over non-social cues (Kane et al., 2012). 
However, there are several possible explanations for these discrepant findings: first, due 
to the inherent difficulties of visually identifying a female rat in oestrus it was hard to 
guarantee the female urine was definitely oestrus cycle urine. Second, there may be 
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fundamental species differences between rats and mice in their reaction for social odours. 
Third, Kane et al. (2012) presented the cues sequentially and used phosphate-buffered 
saline as the non-social cue whereas in EXP-VII the cues were presented simultaneously 
and lemon was used as the non-social cue. Subsequent studies will be required to address 
these explanations.  
In summary, the experiments investigating communication in this chapter suggest that 
there is no interaction between SERT reduction and prenatal exposure to VPA. However, 
prenatal exposure to VPA did influence certain aspects of communication. That VPA did 
not influence all measures of communication once again demonstrates the specificity of 
VPA’s influence and its sensitivity to experimental variables.  
 
Repetitive Behaviour 
EXP-IX was designed to assess the last diagnostic criterion of ASD: repetitive behaviour.  
A significant gene-environment interaction between SERT genotype and prenatal 
exposure to VPA was observed on the primary measure of repetitive behaviour: re-entries 
into nose holes previously explored. Specifically, prenatal exposure to VPA increased 
repetitive behaviour in wild-types, but significantly decreased repetitive behaviour in 
heterozygous animals. The pattern of this interaction was at odds with the hypothesis that 
predicted an exaggerated effect of VPA on repetitive behaviour in heterozygous animals. 
Echoing the results found in EXP-VI on social behaviour, EXP-IX suggests that a 
compromised SERT genotype may actually be protective against certain ASD-like 
phenotypes induced by VPA, in this case repetitive behaviour.  
In addition to observing a novel gene-environment interaction, the data from EXP-IX 
were consistent with previous research analysing only one of these variables: SERT 
genotype or prenatal VPA. For instance, despite just missing statistical significance (p = 
.055), the influence of VPA on wild-type rats in this study appears consistent with 
previous research which demonstrated that prenatal exposure to VPA increased repetitive 
behaviour in rodents (Gandal et al., 2010; Mehta et al., 2011; Schneider et al., 2008). 
Moreover, when analysing just the saline-treated animals, heterozygous-saline animals 
performed significantly more re-entries into previously explored holes than wild-type-
saline animals (p = .022). This finding is in accordance with previous literature 
investigating the impact of SERT genotype on repetitive behaviours. For instance, Kyzar 
et al. (2012) found heterozygous SERT mice to have increased levels of self-grooming 
behaviour, a common measure of repetitive behaviour in animal models of ASD.  
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Interestingly, the gene-environment interaction observed in EXP-IX was specific to 
the type of nose-poking that reflected ASD-like behaviour (re-entries), and did not occur 
on the novel nose-pokes measure which controlled for general exploratory behaviour and 
anxiety. Thus, this particular gene-environment model showed a very specific effect on 
one of the three behavioural hallmarks of ASD: repetitive behaviour.  
 
Conclusion 
Taken together, the results of these five experiments indicated that SERT genotype 
interacted with prenatal exposure to VPA on some measures of social behaviour and 
repetitive behaviour, but not communication. However, prenatal exposure to VPA was 
able to independently influence certain aspects of communication. Despite the 
observation of multiple gene-environment interactions, none were in accordance with the 
pattern predicted by the hypothesis. Instead, VPA tended to have a more detrimental 
effect on the wild-type animals, whereas a compromised SERT genotype seemed to offer 
protection against some of these effects.  
There were several instances in this chapter where VPA did not exert the expected 
ASD-like influence (for example, EXP-VIII did not find a reduction in social approach 
behaviour in VPA-exposed animals). This fact suggests three important points: first, more 
detailed analysis of the prenatal VPA model is required; second, the selected VPA dose 
indeed had a moderate effect; and third, the experimental details involved in a prenatal 
VPA model are of critical importance to the outcome (Cohen et al., 2013; Roullet et al., 
2013; Štefánik et al., 2015). In fact, a range of experimental variables have been shown to 
influence the outcome of VPA, including the timing and dose (Roullet et al., 2013). The 
work in this chapter adds SERT genotype to the expansive list of variables that can 
influence or determine the outcome of prenatal exposure to VPA.  
In summary, this chapter provided an extensive investigation into the behavioural 
effects of prenatal VPA and its potential interaction with SERT genotype in rats. Taken 
together, the data suggest that prenatal exposure to 400 mg/kg of VPA produces a diverse 
set of outcomes, some of which are consistent with an ASD-phenotype, and some of 
which are not. These findings seem consistent with the human context, where, although 
prenatal VPA exposure significantly increases the risk of ASD in children (Christensen et 
al., 2013), the overall risk of developing ASD is still very low.  
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CHAPTER 4: THE BIOCHEMICAL AND IMMUNOLOGICAL 
CONSEQUENCES OF PRENATAL EXPOSURE TO VALPROATE 
 
Although the three core diagnostic criteria of ASD are all behavioural, individuals with 
ASD often have altered biochemical and immunological profiles as well. For instance, 
elevated levels of pro-inflammatory cytokines and hyperserotonemia are well replicated 
findings among patients (Chez et al., 2007; Devlin et al., 2005; Jyonouchi et al., 2001; 
Lam et al., 2006; Li et al., 2009; Vargas et al., 2005). There is a significant amount of 
research investigating potential biomarkers for ASD and recent findings may hold 
promise (Yang et al., 2015). Understanding the chemical underpinnings of ASD will 
provide several benefits, but most importantly it will enable significant progress in the 
development of pharmacological treatments and allow for simpler diagnoses in patients.  
This chapter focused on two different biochemical processes that have been associated 
with ASD: a dysregulation in BDNF gene expression and an increased level of the 
proinflammatory cytokine IL-6.  
 
BDNF 
BDNF is a small protein encoded by the similarly named BDNF gene. This protein 
belongs to the family of neurotrophins (themselves, within the class of growth factors) 
and plays a critical role in the development, growth, differentiation, synaptic plasticity, 
and survival of various neuronal populations in both the peripheral and central nervous 
systems (Allen et al., 2013; Binder & Scharfman, 2004; Nickl-Jockschat & Michel, 2011; 
Pruunsild, Kazantseva, Aid, Palm, & Timmusk, 2007; Zhang, Jiang, & Lu, 2014).  
The structure of the BDNF gene is highly complex (Aid, Kazantseva, Piirsoo, Palm, 
& Timmusk, 2007; Homberg, Molteni, Calabrese, & Riva, 2014; Pruunsild et al., 2007; 
Timmusk et al., 1993). The most recent description of the BDNF gene in rodents 
identified at least eight 5′ noncoding exons and one protein coding 3′ exon, with all 5′ 
noncoding exons controlled by different promoters (Aid et al., 2007). There are 11 
different transcripts of the BDNF gene, and in each transcript a 5′ exon is spliced to the 
protein coding exon (Aid et al., 2007; Vicario et al., 2015). Adding to the complexity, 
these BDNF variants show brain region-specific expression and are differentially 
regulated by DNA methylation and histone deacetylation (Aid et al., 2007).  
With respect to the current thesis, it is important to note that BDNF plays a 
particularly strong role in the function of serotonergic neurons and interacts with the 
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SERT in the development of mood disorders (Homberg et al., 2014; Martinowich & Lu, 
2008). Significantly reduced BDNF expression has been observed in adult rats with a 
compromised SERT function (Calabrese et al., 2013; Calabrese et al., 2010; Molteni et 
al., 2010). Moreover, BDNF is a known target of VPA (Almeida, Roby, & Krueger, 
2014; Fukuchi et al., 2009; Jeon et al., 2006; Roullet et al., 2010; Yasuda, Liang, 
Marinova, Yahyavi, & Chuang, 2009). Due to its multi-functionality, BDNF has been 
implicated in the pathogenesis of a number of neurological diseases and psychiatric 
disorders, including depression, schizophrenia, Huntington’s, Alzheimer’s, and 
Parkinson’s disease (Homberg et al., 2014; Martinowich & Lu, 2008; Schumacher et al., 
2005; Zuccato & Cattaneo, 2009).  
BDNF plays a significant role in neurodevelopment and thus has become the focus of 
increasing attention in ASD research (Nickl-Jockschat & Michel, 2011). Unusual patterns 
of brain growth in ASD patients have led to the hypothesis that early BDNF hyperactivity 
may play a role in the aetiology of ASD (Tsai, 2005). Specifically, patients with ASD 
have demonstrated abnormal overgrowth of the brain in the early stages of life followed 
by a period of significantly slowed growth (Courchesne, Carper, & Akshoomoff, 2003; 
Courchesne et al., 2001).  
A wealth of research has investigated the association between BDNF expression and 
ASD. Following the consistent pattern of biological associations in the ASD literature, a 
dysregulation of BDNF, as opposed to too much or too little, is evident in ASD patients. 
For instance, elevated levels of BDNF have been found in the peripheral blood (Nelson et 
al., 2001), plasma (Bryn et al., 2015; Correia et al., 2010), and serum (Connolly et al., 
2006; Miyazaki et al., 2004; Ricci et al., 2013; Zhang et al., 2014) of ASD patients, 
relative to healthy controls. In contrast, reduced levels of BDNF have also been found in 
the blood of ASD patients, relative to healthy controls (Abdallah et al., 2013; Taurines et 
al., 2014).  
Interestingly, BDNF has been linked to both the severity of ASD and the age of the 
patient. Specifically, while mildly autistic patients were found to have elevated levels of 
serum BDNF relative to controls, severely autistic patients did not (Al-Ayadhi, 2012). 
With regards to age, although one study found no overall difference in serum BDNF 
between patients and controls, when the study population was divided by age (above and 
below 6 years old) it was found that BDNF was significantly elevated in ASD patients 
below the age of 6, and significantly decreased in ASD patients above the age of 6, 
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relative to their age-matched control counterparts (Mansour, Mohamed, Azam, & 
Henedy, 2010).  
Taken together, the data investigating the association between BDNF and ASD 
suggest that BDNF likely plays a role in the pathogenesis of this disorder. At this stage 
the preponderance of evidence points towards an increased level of BDNF (at least in the 
early stages of life), but the heterogeneity of ASD coupled with several contrasting 
findings indicates that a more general dysregulation of BDNF may be at play. 
In accordance with human findings, rodent models of ASD have observed alterations 
of BDNF in either direction following prenatal treatment with VPA. For instance, 
Almeida et al. (2014) found that a prenatal dose of VPA (400 mg/kg i.p) at GD 12.5 
increased BDNF in mouse foetal whole brains. In addition, Roullet et al. (2010) found 
regional-specific deficits in BDNF in adult mice prenatally exposed to a 800 mg/kg dose 
of VPA at GD 11. Specifically, these authors found reduced BDNF in the somatosensory 
cortex, but no change in the hippocampus. Finally, chronic postnatal treatment with VPA 
led to increased BDNF in both the hippocampus and the frontal cortex (Einat et al., 2003). 
The goal in the current chapter was to extend these previous works and to see if VPA-
induced alterations in BDNF are dependent on SERT genotype.  
 
IL-6 
Interleukins are a group of cytokines of critical importance to the immune system. IL-6 is 
one of the key interleukins that helps the communication process between the central 
nervous system (CNS) and the immune system. IL-6 is a multifunctional cytokine, 
capable of crossing the blood-brain-barrier, that plays a role in brain development, host 
defence, and numerous diseases (Banks, Kastin, & Gutierrez, 1994; Ferretti & Hollander, 
2015; van der Poll et al., 1997; Wei, Alberts, & Li, 2013).  
Evidence for IL-6’s role in ASD has been mounting, with elevated levels of IL-6 
being found in plasma, peripheral blood monocytes, lymphoblasts, and in the brain of 
ASD patients (Ashwood et al., 2011; Enstrom, Onore, Van de Water, & Ashwood, 2010; 
Li et al., 2009; Malik et al., 2011; Wei et al., 2013; Wei et al., 2012; Wei et al., 2011; 
Yang et al., 2015). Recent hypotheses speculate that IL-6 elevation may play a role in 
ASD symptomatology via its detrimental impact on neuronal plasticity and 
neuroanatomical structures (Wei et al., 2013; Wei et al., 2012). Taken together, the data 
suggest IL-6 is a potential biomarker and/or promising target for intervention in ASD.  
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The influence VPA has on levels of IL-6 is unclear. For instance, although treatment 
with VPA was seen to elevate blood levels of IL-6 in humans (Shiah, Yatham, Yeh, & 
Ravindran, 2005; Verrotti et al., 2001), other investigators have found both no change and 
decreased levels of IL-6 in response to VPA (Guenther et al., 2014; Steinborn et al., 
2014). Further, VPA inhibited LPS-induced IL-6 in THP-1 cells (Ichiyama et al., 2000), 
and supressed expression of IL-6 following intra-cerebral haemorrhage induction in rats 
(Sinn et al., 2007). The differential effects of VPA on IL-6 support the previously 
described idea that the effects of VPA strongly depend on the specific experimental 
variables used in each study. That being said, to the best of our knowledge, no prior 
studies have investigated changes in IL-6 using a prenatal exposure to VPA rat model. In 
fact, only a minority of studies using the prenatal VPA model have investigated any 
immunological measures at all (Schneider et al., 2008). In addition, if prenatal exposure 
to VPA were to alter IL-6 in rats, there is reason to believe SERT genotype may modulate 
this alteration, since Macchi et al. (2013) found heterozygous SERT rats had an 
exaggerated IL-6 gene expression following a postnatal immune challenge.  
The purpose of this chapter was to investigate the biochemical and immunological 
consequences of a 400 mg/kg dose of VPA subcutaneously administered at GD 12 and to 
see if the response was dependent upon SERT genotype. In addition to the three core 
behavioural characteristics that characterise ASD, there are several biochemical findings 
that are consistently observed in patients with ASD, including a dysregulation in BDNF 
gene expression and an increased level of the proinflammatory cytokine IL-6. Assays 
aimed at investigating these two particular biochemical/immunological profiles are 
included in this chapter. The purpose of these assays was to assess whether the proposed 
gene-environment model could produce biochemical/immunological changes consistent 
with those found in human patients with ASD. These experiments were designed to 
extend the behavioural data included in this thesis, thus providing a more in depth 
evaluation of the face validity of the SERT reduction-prenatal exposure to VPA model. 
These experiments tested the hypothesis that rats with a genetically compromised SERT 
function would show an increased vulnerability to the impact of prenatal exposure to 
VPA and that this would be reflected in their biochemical and immunological profiles. 
 
Breeding 
The same breeding procedure as chapter 3 was used. In short, this involved mating 
heterozygous SERT knockout females with heterozygous SERT knockout males, and 
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separating the females once successfully mated (defined as presence of vaginal plug, GD 
0). The pregnant mothers were then administered 400 mg/kg VPA or saline 
subcutaneously at GD 12. The offspring of these mothers were the experimental animals 
for this chapter. All procedures in this chapter were approved by the Victoria University 
of Wellington Animal Ethics Committee. 
Again, the experiments performed in this chapter used multiple litters to create the 
sample size for each experimental group. The reason for this was to reduce the chance of 
potentially abnormal litters representing an entire group. The sample sizes reported in 
these experiments are indicative of individual rats.  
 
Experiment X (EXP-X): BDNF mRNA expression in the hippocampus and frontal 
lobe 
The purpose of this experiment was to investigate BDNF gene expression changes in the 
brains of PND 7 rats. This experiment was conducted to evaluate whether prenatal 
exposure to VPA could mimic a consistently replicated finding in the biochemical 
profiles of ASD patients (dysregulation of the BDNF gene) and if the biochemical 
response depended on SERT genotype. To achieve this aim, total BDNF mRNA (exon 
IX) was measured in both the hippocampus and the frontal lobe. Then, due to the 
complex transcriptional structure of the BDNF gene (11 distinct transcripts from different 
promoters) (Aid et al., 2007), several prominent transcripts were measured to investigate 
which BDNF exon contributed to the alterations in total BDNF. Specifically, BDNF IV 
and BDNF VI were investigated due to their prominent expression in these brain regions, 
their well characterised promoter regions, and the previous work demonstrating 
compromised SERT genotype can alter these transcripts (Calabrese et al., 2013; 
Calabrese et al., 2010; Molteni et al., 2010). The collection of brain samples for this 
experiment was performed at Victoria University of Wellington, and the analyses of these 
samples were carried out during an overseas research stay at the University of Milan, 
Italy.  
 
Methods 
Animals 
Experimental animals were infant (PND 7) male and female Wistar rats treated with 
either saline or VPA at GD 12. Female rats were used due to the low numbers of males in 
some experimental groups. Wild-type and heterozygous knockout animals were used for 
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the biochemical investigations. Animals were kept in standard Plexiglas cages with their 
mother and littermates in a temperature-controlled room (temperature: 21± 2
o
C; 55% 
humidity) on 12 hr light-dark cycles (lights on at 07:00) with food and water available ad 
libitum. On PND 7 animals were sacrificed for brain extraction. The sample sizes for the 
experimental groups in this experiment were as follows: wild-type + saline = 9; wild-type 
+ VPA = 5; heterozygous + saline = 20; heterozygous + VPA = 14. 
 
Brain Extraction 
At PND 7 animals were gassed using carbon dioxide, decapitated with a guillotine, and 
then had their brains extracted using standard surgical tools, including scissors, pliers, and 
a spatula. Their fresh brains were rinsed in distilled water and then dissected immediately 
on an ice-chilled glass-tray using a razor blade and forceps. The hippocampus and frontal 
lobe were collected and stored immediately at -80
o
C. The remaining brain tissue was 
discarded. The frontal lobe was taken by making a coronal cut one quarter of the way 
along the brain from the anterior tip – the olfactory bulbs were removed from this 
resulting region and were not included as a part of the frontal lobe. Following brain 
extraction, a tail snip was taken from each animal’s body for the purposes of genotyping 
(Transnetyx, Cordova, TN, USA). The frozen brain samples were then shipped under dry-
ice to the Department of Pharmacological and Biomolecular Sciences at the University of 
Milan, Italy to be analysed using real-time polymerase chain reaction (RT-PCR).  
 
Apparatus 
The experiments were carried out at the Department of Pharmacological and 
Biomolecular Sciences at the University of Milan. The laboratory in this department had 
the necessary facilities and equipment to conduct RT-PCR experiments. In addition to the 
standard compounds used in the single-step guanidinium-isothiocyanate-phenol-
chloroform extraction method, PureZol RNA isolation reagent (Bio-Rad Laboratories) 
and a tissue lyser (TissueLyser II, QIAGEN) were used during RNA isolation; a 
Nanodrop1000 spectrophotometer (Thermo Scientific) was used during quantification; 
and a TaqMan qRT–PCR instrument (CFX384 real time system, Bio-Rad Laboratories) 
was used for the thermal cycling and RT-PCR analysis. Probe and primer sequences for 
the housekeeping gene (36B4) were purchased from Eurofins MGW-Operon (Germany). 
The use of 36B4 as a housekeeping gene when investigating BDNF is in line with 
previous research (Fumagalli et al., 2012). TaqMan Gene expression assays were 
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purchased from Applied Biosystems, Life Technologies. IBM SPSS statistics version 22 
was used for all statistical analyses.  
  
 
RNA preparation and quantification of BDNF mRNA expression using RT-PCR 
The following procedure was completed in accordance with the established protocols 
developed in the Department of Pharmacological and Biomolecular Sciences at the 
University of Milan (Calabrese et al., 2013; Fumagalli et al., 2012). 
 
RNA isolation 
Total ribonucleic acid (RNA) was isolated by the single-step guanidinium-isothiocyanate-
phenol-chloroform extraction method (Chomczynski & Sacchi, 1987) using PureZol 
RNA isolation reagent (Bio-Rad Laboratories) according to the manufacturer’s 
instructions and then quantified using a NanoDrop1000 spectrophotometer. The specifics 
were performed as follows: 
The first step was to homogenise and disrupt the samples. The samples were 
homogenised and disrupted by being placed in Eppendorf tubes that included a stainless 
steel bead and PureZol RNA isolation reagent. The amount of PureZol in the Eppendorf 
tubes depended on the size of the sample (1 ml of PureZol for every 50-100 mg of tissue). 
These Eppendorf tubes were then put in a tissuelyser (TissueLyser II, QIAGEN) and 
shaken at 30 Hz for 30 s.  
Next, the samples were removed from the lyser and left at room temperature for 5 min 
to achieve complete dissociation of the nucleoprotein complexes. Next, chloroform 
(CHCl₃) was added to the Eppendorf tubes (1/5th of the amount of PureZOL used in step 
one), and the tubes were shaken vigorously for 15 s. This was then followed by another 5 
min room-temperature incubation period.  
In the next step, the stainless steel beads were removed from the Eppendorf tubes and 
the tubes centrifuged at 12,000 RCF for 15 min at 4
o
C. Following this centrifugation, the 
mixture separated into three phases: the aqueous phase, the interphase, and the organic 
phase. RNA is found in the aqueous phase, whilst the interphase and organic phase 
contain the DNA and proteins. As much of the aqueous phase as possible was then 
transferred into a new set of ribonuclease (RNase)-free Eppendorf tubes. In order to avoid 
disrupting the interphase and organic phase and thus contaminating the RNA, some of the 
aqueous phase was intentionally left behind.  
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In the next step, isopropanol was added to the aqueous phase; the amount added 
approximately equal to the total aqueous phase already contained in the Eppendorf tubes. 
These tubes were then vortexed and stored at -20
o
C overnight. The following day the 
Eppendorf tubes were removed from the -20
o
C freezer, vortexed, and then centrifuged 
(12,000 RCF for 20 min at 4
o
C). After centrifugation the RNA appeared as a white pellet 
on the bottom of each Eppendorf tube. The supernatant was carefully discarded using a 
vacuum and beaker.  
In the next step the pellets were washed with 75% ethanol – 1 ml of 75% ethanol for 
every 1 ml of PureZol used in step one was added to the Eppendorf tubes. The solution 
was then centrifuged, (12,000 RCF for 10 min at 4
o
C) and again the supernatant was 
carefully discarded using a vacuum and beaker.  
The final step in the RNA isolation process was to resuspend the pellets in RNase-free 
diethylpyrocarbonate (DEPC)-treated water. Approximately 20 μl of DEPC-treated water 
was added to the Eppendorf tubes and pipetted up and down 15 times to ensure the 
resuspension of the pellets. The samples were then stored at -20
o
C to await quantification. 
 
Quantification and DNAse Treatment 
Samples were taken from the -20
o
C freezer, vortexed, and then quantified to assess the 
concentration of RNA and their purity using a NanoDrop1000 spectrophotometer. The 
samples were then processed for RT-PCR to assess the levels of BDNF mRNA. 
Deoxyribonuclease (DNAse) treatment was performed on an aliquot of each sample that 
contained 5 μg of RNA (determined per sample via the results of the initial 
quantification) in order to destroy any possible remaining elements of DNA that may be 
in the RNA sample. Briefly, a 30 μl mixture of DNase (3 μl), 10x reaction buffer with 
magnesium chloride (MgCl₂) (3 μl), DEPC-treated H20 (24 μl – size of the sample), and 
the required aliquot of the sample were added to a new Eppendorf tube. This solution was 
centrifuged briefly at 10,000 RCF (to get all the contents to the bottom of the Eppendorf 
tube) then put in a thermoblock for 30 min at 37
o
C. Next, 3 μl of 
ethylenediaminetetraacetic acid (EDTA) was added to the Eppendorf tube, after which it 
was centrifuged and then once again put in the thermoblock – this time for 10 min at 
65
o
C. This final step combined with the EDTA inactivated the DNase. Following DNase 
treatment, a second quantification using the NanoDrop1000 spectrophotometer was 
performed on the samples. This quantification provided the final average concentration 
figures with which to create the sample dilution plate for RT-PCR.  
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The samples were diluted with sterile and apyrogen (RNase-free) H20 so that each 
sample had a ratio of 10 ng of RNA per 1 μl of sample. RNA was then analysed by a 
TaqMan qRT–PCR instrument (CFX384 real time system, Bio-Rad Laboratories) using 
the iScriptTM one-step RT–PCR kit for probes (Bio-Rad Laboratories). Samples were run 
in 384-well plates that were sealed, briefly vortexed, and centrifuged. Samples were run 
in triplicate as multiplexed reactions with a normalising internal control, or housekeeping 
gene (36B4). Each well contained 1 μl of sample and 1.5 μls of ‘mix.’ The ‘mix’ was a 
different recipe for each gene being investigated but the core components of the recipe 
were: the primers and probe for the housekeeping gene, the primers and probe for the 
target gene, 2x reaction mix, and Iscript reverse transcriptase. Probe and primer 
sequences for the 36B4 housekeeping gene were bought from Eurofins MWG-Operon 
(Germany). TaqMan gene expression assays (Applied Biosystems, Life Technologies) 
were used to analyse some of the most prominent transcripts of BDNF; their IDs are as 
follows (See Table 4): BDNF IV = Rn01484927_m1; and BDNF VI = Rn01484928_m1. 
Probe and primers for total BDNF were designed in Milan with the following specifics:  
 
Probe: TGTGGTTTGTTGCCGTTGCCAAG 
Forward Primer: AAGTCTGCATTACATTCCTCGA 
Reverse Primer: GTTTTCTGAAAGAGGGACAGTTTAT 
 
The TaqMan qRT-PCR instrument that conducted the thermal cycling used the 
following protocol: a 10 min incubation period at 50
o
C (RNA retrotranscription), 
followed by 5 min at 95
o
C (TaqMan polymerase activation). Next, 39 cycles of PCR were 
performed with each cycle consisting of heating the samples at 95
o
C for 10 s to enable 
melting, and then at 60
o
C for 30 s to enable the annealing and extension reactions.  
Four different RT-PCR experiments were performed. Three of these experiments used 
RNA isolated from the hippocampus samples and calculated total BDNF, BDNF IV, and 
BDNF VI. The last experiment used RNA isolated from the frontal lobe samples and 
calculated total BDNF. Transcripts IV and VI were not investigated for the frontal lobe 
due to the time constraints on my overseas research-stay in Milan. The primary outcome 
of interest was gene expression change for the specific target gene being investigated. A 
comparative cycle threshold (Ct) method was used to calculate the relative target gene 
expression. 
 
 112 
 
 
 
Table 4. Gene expression assays for total BDNF, BDNF IV, and BDNF VI. 
Gene Assay ID 
Total BDNF 
 
 
Probe TGTGGTTTGTTGCCGTTGCCAAG 
Forward Primer AAGTCTGCATTACATTCCTCGA 
Reverse Primer GTTTTCTGAAAGAGGGACAGTTTAT 
BDNF IV 
 
 
 
Rn01484927_m1 
BDNF VI Rn01484928_m1 
 
Results 
A 2 x 2 (gene x environment) ANOVA tested the effects of SERT genotype and treatment 
type on total BDNF mRNA expression in the hippocampus of PND 7 rats. Results 
indicated there was no main effect of genotype, F(1, 44) = 3.624, p = .064. There was a 
main effect of treatment type F(1, 44) = 9.238, p = .004, with VPA decreasing total 
BDNF mRNA expression. However, there was no significant interaction between 
genotype and treatment type F(1, 44) = .566, p = .456. (See Fig. 25). 
A 2 x 2 (gene x environment) ANOVA tested the effects of SERT genotype and 
treatment type on BDNF IV mRNA expression in the hippocampus of PND 7 rats. 
Results indicated that there was a main effect of genotype, F(1, 44) = 4.694, p = .036, 
with heterozygous animals exhibiting higher levels of BDNF IV. In addition, there was a 
main effect of treatment type F(1, 44) = 32.381, p < .001, with VPA increasing BDNF IV 
mRNA expression. Lastly, there was no significant interaction between genotype and 
treatment type F(1, 44) = 1.498, p = .228. (See Fig. 26).  
A 2 x 2 (gene x environment) ANOVA tested the effects of SERT genotype and 
treatment type on BDNF VI mRNA expression in the hippocampus of PND 7 rats. 
Results indicated there was no main effect of genotype, F(1, 44) = 1.665, p = .204, or 
treatment type F(1, 44) = .269, p = .607. In addition, there was no significant interaction 
between genotype and treatment type F(1, 44) = 1.241, p = .271. (See Fig. 27).  
A 2 x 2 (gene x environment) ANOVA tested the effects of SERT genotype and 
treatment type on total BDNF mRNA expression in the frontal lobe of PND 7 rats. 
Results indicated there was no main effect of genotype, F(1, 44) = 1.628, p = .209. 
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However, there was a main effect of treatment type F(1, 44) = 15.155, p < .001, with 
VPA increasing total BDNF mRNA expression. Lastly, there was no significant 
interaction between genotype and treatment type F(1, 44) = .903, p = .347. (See Fig. 28). 
(See Table 5 for a summary of these results; for the RT-PCR amplification graphs from 
the total BDNF analyses see figures 30-33 in appendix). 
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Table 5. Two-way ANOVA results of the effects of SERT genotype and VPA treatment on various BDNF 
transcripts in both the hippocampus and the frontal lobe. * p < .05. 
Target SERT Genotype VPA Treatment GxE Interaction 
Hippocampus    
Total BDNF F(1, 44) = 3.624, p = .064 F(1, 44) = 9.238, p = .004* F(1, 44) = .566, p = .456 
BDNF IV F(1, 44) = 4.694, p = .036* F(1, 44) = 32.381, p < .001* F(1, 44) = 1.498, p = .228 
BDNF VI F(1, 44) = 1.665, p = .204 F(1, 44) = .269, p = .607 F(1, 44) = 1.241, p = .271 
Frontal Lobe    
Total BDNF F(1, 44) = 1.628, p = .209 F(1, 44) = 15.155, p < .001* F(1, 44) = .903, p = .347 
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Figure 25. EXP-X: Effects of SERT genotype and VPA treatment on 
total BDNF mRNA levels in the hippocampus of PND 7 rats. Data are 
expressed as a percentage of control (wild-type saline-treated rats) 
values. Bars represent the mean (+SEM). 
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Figure 26. EXP-X: Effects of SERT genotype and VPA treatment on 
BDNF IV mRNA levels in the hippocampus of PND 7 rats. Data are 
expressed as a percentage of control (wild-type saline-treated rats) 
values. Bars represent the mean (+SEM). 
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Figure 27. EXP-X: Effects of SERT genotype and VPA treatment on 
BDNF VI mRNA levels in the hippocampus of PND 7 rats. Data are 
expressed as a percentage of control (wild-type saline-treated rats) 
values. Bars represent the mean (+SEM). 
Figure 28. EXP-X: Effects of SERT genotype and VPA treatment on 
total BDNF mRNA levels in the frontal lobe of PND 7 rats. Data are 
expressed as a percentage of control (wild-type saline-treated rats) 
values. Bars represent the mean (+SEM). 
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Experiment XI (EXP-XI): IL-6 in serum 
The purpose of this experiment was to investigate IL-6 levels in the serum of PND 7 rats. 
This experiment was conducted to evaluate whether prenatal exposure to VPA could 
mimic a consistently replicated finding in the immunological profiles of ASD patients 
(elevated levels of IL-6) and if the immunological response depended on SERT genotype.  
 
Methods 
Animals 
Experimental animals were infant (PND 7) male and female Wistar rats treated with 
either saline or VPA at GD 12. Wild-type and heterozygous SERT knockout animals 
were used for this immunological investigation. Animals were kept in standard Plexiglas 
cages with their mother and littermates in a temperature-controlled room (temperature: 
21± 2
o
C; 55% humidity) on 12 hr light-dark cycles (lights on at 07:00) with food and 
water available ad libitum. On PND 7 animals were sacrificed to obtain a serum sample. 
 
Serum collection  
Animals were decapitated and as much blood as possible was collected from the neck and 
placed into an Eppendorf tube. A tail snip was taken from each animal’s body for 
genotyping. The blood was then left at room temperature for 24 hr for the coagulation 
process to take place. Following this, the blood was then centrifuged at 2000 RPM for 10 
min to fully separate the serum from the rest of the blood-matter. Next, the serum was 
pipetted out of the Eppendorf tube and into a new Eppendorf tube and immediately stored 
at -80
o
C. The serum samples were used specifically for the immunological analysis of 
IL-6.  
 
Apparatus 
The experiment was performed using a commercial LEGEND MAX Rat IL-6 sandwich 
ELISA kit with precoated plates (Biolegend, CA, USA). An Enspire 2300 microplate 
reader (PerkinElmer) was used to measure the absorbance rate of the samples.  
 
Procedure 
The ELISA kit was performed in accordance with the manufacturer’s instructions (to be 
described below). The unknown IL-6 concentrations in the serum samples were 
calculated using a standard curve generated from known reference IL-6 concentrations 
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(‘standards’) provided in the kit. Samples and IL-6 standards were run in duplicate in a 
96-well ELISA plate.  
An initial optimisation pilot experiment demonstrated that the provided rat IL-6 
standards (beginning at 1200 pg/ml) were too large to detect the levels of IL-6 in the 
current experimental animals. Thus, these standards were diluted further with the aim of 
providing a more accurate detection of IL-6. These new rat IL-6 standard concentrations 
were prepared in separate tubes so that there were eight different concentrations to 
eventually be placed in the final 96-well plate: 20 pg/ml, 10 pg/ml, 5 pg/ml, 2.5 pg/ml, 
1.25 pg/ml, .625 pg/ml, .3125 pg/ml, and 0 pg/ml (the blank).  
To begin, the plate was washed four times with 300 μl of wash buffer per well. 
Remaining buffer was blotted by tapping the plate upside down on absorbent paper. This 
washing technique was the standardised technique during this experiment.  
Next, 50 μl of Matrix C was added to the wells designated for the standards and 50 μl 
of Assay Buffer A was added to the wells designated for the samples. Subsequently, 50 μl 
of standard or serum sample was added to the wells containing Matrix C or Assay Buffer 
A, respectively. The plate was then left to incubate at room temperature for 2 hr. Next, the 
contents of the plate were discarded and the plate was washed four times as previously 
described.  
Next, 100 μl of rat IL-6 detection antibody solution was added to each well. The plate 
was then left to incubate at room temperature for 1 hr. Again, the contents of the plate 
were discarded and the plate washed four times as previously described.  
Next, 100 μl of Avidin-HRP A solution was added to each well and the plate left to 
incubate at room temperature for 30 min. Again, the contents of the plate were discarded 
and the plate washed five times as previously described. In order to minimise background 
noise, in this washing cycle the wells were soaked for approximately 45 s in the wash 
buffer during each wash. 
Next, 100 μl of substrate solution F was added to each well and left to incubate in the 
dark for 10 min. Wells containing IL-6 turned blue – the more intense the colour the 
higher the concentration of IL-6. This colour reaction was stopped by adding 100 μl of 
stop solution to each well. This solution changed the colour from blue to yellow. Finally, 
the plate was analysed by a microplate reader (PerkinElmer) reading at 450 nm within a 
few minutes of adding the stop solution.  
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Results 
The level of IL-6 in the serum samples was too low to be reliably detected using this 
ELISA kit. As seen by the standard curve (See Fig. 29), accurate measurements of IL-6 
below 5 pg/ml were not possible and as all the samples fell below this range (See Table 6, 
appendix) all that can be concluded is that the samples produced very low levels of IL-6, 
somewhere within the range of 0-5 pg/ml. 
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Figure 29. Standard curve. Black line represents the mean absorbance rate of 
each standard dilution (+SEM). The red line is the trend line. Values below 5 
pg/ml are undetectable by the kit. 
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Discussion 
The purpose of this chapter was to investigate the effects of prenatal exposure to VPA on 
the biochemical and immunological profiles of Wistar rats and to test the hypothesis that 
rats with a genetically compromised SERT function would show an increased 
vulnerability to the impact of this prenatal exposure. BDNF gene expression levels were 
measured in brain samples (EXP-X) and IL-6 levels were measured in serum (EXP-XI), 
both with the aim of detecting ASD-like biochemical and immunological profiles. EXP-X 
produced several key findings: first, no gene-environment interactions were observed 
with regard to BDNF expression levels. Second, compromised SERT genotype did not 
impact total BDNF levels, but did influence specific transcripts. Third, region-specific 
effects of VPA were found on total BDNF. Fourth, VPA differentially impacted BDNF 
transcripts within the same brain region. Together, these results are indicative of BDNF’s 
complex transcriptional regulation and the extreme specificity with which VPA interacts 
with the brain. In EXP-XI the levels of IL-6 were undetectably low, suggesting this model 
may not produce physiologically relevant changes in IL-6.  
The most important finding in the current chapter was that no gene-environment 
interactions were observed with regard to BDNF expression levels in either the 
hippocampus or frontal lobe. Thus, the data provide support for the null hypothesis: that 
there is no interaction between SERT genotype and prenatal exposure to VPA on BDNF 
expression. There are several reasons to trust this conclusion. First, multiple variants of 
BDNF in multiple different brain regions were investigated, and all of the data suggest 
that there is no interaction between SERT genotype and prenatal exposure to VPA. 
Second, there does not appear to be a ceiling/floor effect of the genetic or environmental 
factor considering only moderate genetic and environmental insults were used 
(heterozygous animals and 400 mg/kg VPA). In support of this idea, when main effects of 
genotype and treatment were found (for instance the main effect of VPA on total BDNF 
and main effect of SERT genotype on BDNF IV in the hippocampus), these effects were 
not extreme and left room for the potential influence of the other variable. Third, data 
from the current thesis have demonstrated that these gene and environmental risk factors 
can in fact interact, albeit on behavioural measures. Overall, it seems likely that SERT 
genotype does not interact with prenatal exposure to VPA with regard to BDNF gene 
expression at PND 7.  
EXP-X found no genotype effect on total BDNF mRNA in either the hippocampus or 
the frontal lobe of PND 7 rats. With regards to the lack of genotype effect in the 
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hippocampus, this result mirrors previous literature that also found no significant 
difference in total BDNF between wild-types and heterozygous rats, albeit in adult 
animals (Molteni et al., 2010). Although Calabrese et al. (2013) found a reduction in total 
BDNF mRNA in homozygous adult rats when looking specifically at the ventral 
hippocampus, no heterozygous animals were included in their study and even these 
homozygous rats did not differ in total BDNF mRNA when the dorsal region of the 
hippocampus was investigated. Moreover, the significant reductions in total BDNF 
observed in the ventral hippocampus in homozygous adults were not found when 
investigating homozygous PND 7 rats (Calabrese et al., 2013). Thus, it is not surprising 
that EXP-X, investigating the entire hippocampus in the more moderate heterozygous rats 
at PND 7, did not find a genotype effect. 
With respect to the frontal lobe, although previous work has found reduced total 
BDNF in the prefrontal cortex of PND 7 rats with a compromised SERT function, these 
investigations compared homozygous rats with wild-types and did not include the more 
moderate heterozygous genotype (Calabrese et al., 2013). In addition, research that did 
find reduced total BDNF in heterozygous animals observed so only in adult rats (Molteni 
et al., 2010). Finally, both these previous studies examined the ‘prefrontal cortex,’ which 
fundamentally differs from the less specific ‘frontal lobe’ region targeted in this thesis. In 
fact, data from Calabrese et al. (2010) support this point: these authors analysed total 
BDNF in both the ‘prefrontal cortex’ and the ‘frontal cortex,’ and found opposing effects 
of SERT genotype in each region. Specifically, total BDNF was downregulated in 
homozygous animals in the prefrontal cortex, but upregulated in homozygous animals in 
the frontal cortex. These findings emphasise the region-specific effects SERT genotype 
can have on total BDNF.  
Although EXP-X found no effect of SERT genotype on total BDNF, an investigation 
of several prominent transcripts within the hippocampus revealed that SERT genotype did 
affect specific BDNF transcripts. For instance, in the hippocampus BDNF IV was 
upregulated in heterozygous animals relative to wild-types, whereas no genotype effect 
was found for BDNF VI. These findings support previous work suggesting that BDNF 
transcripts are differentially regulated (Aid et al., 2007; Pattabiraman et al., 2005). 
The observation that heterozygous animals displayed upregulated BDNF IV, whilst 
having no significant upregulation of total BDNF is surprising. Previous research has 
found consistent patterns of direction between total BDNF and BDNF IV, suggesting 
BDNF IV is a primary driver of total BDNF. For example, both Molteni et al. (2010) and 
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Calabrese et al. (2013) found reductions in total BDNF and BDNF IV in homozygous 
adult animals. Moreover, where differences in total BDNF were not found in these 
previous studies, differences in BDNF IV were not found either. For instance, Molteni et 
al. (2010) found no difference in total BDNF or BDNF IV in adult heterozygous animals. 
In addition, Calabrese et al. (2013) found no difference in total BDNF or BDNF IV in 
PND 7 homozygous animals. In fact, consistent with the idea that BDNF IV may be a 
primary driver of total BDNF, Calabrese et al. (2013) only observed decreases in BDNF 
IV in homozygous animals from PND 21 onwards, which may explain why they found a 
decrease in total BDNF in adult animals but not PND 7 animals. Although the data in 
EXP-X seem to show a mismatch between total BDNF and BDNF IV within the 
hippocampus, a closer look at the statistical analyses reveals that heterozygous animals 
did have higher levels of total BDNF, but the difference was just short of significance (p 
= .064). Thus, the perceived mismatch between total BDNF and BDNF IV may be more 
related to a slightly larger variability in total BDNF levels in the heterozygous animals 
than a true inconsistency. Finally, the current finding of heterozygous animals displaying 
no difference in BDNF VI is in agreement with previous reports (Molteni et al., 2010). 
Another key finding from EXP-X was that region-specific effects of VPA were found 
on total BDNF. Specifically, VPA significantly decreased total BDNF in the 
hippocampus, but significantly increased total BDNF in the frontal lobe. These findings 
are in accordance with previous research that has demonstrated VPA can induce both 
increases and decreases in total BDNF mRNA, depending on the region investigated 
(Almeida et al., 2014; Roullet et al., 2010). However, a vast range of experimental 
variables including the VPA treatment schedule, region of the brain investigated, and the 
age, strain, and species of the animal used, likely modulate the effects of prenatal VPA on 
BDNF gene expression and lead to differences amongst the literature. Taken together, the 
data from this chapter and previous papers suggest that prenatal exposure to VPA is able 
to produce dysregulation in BDNF gene expression in specific brain regions – reminiscent 
of the dysregulation seen in the blood of human patients.  
 Finally, EXP-X showed that VPA differentially impacted BDNF transcripts within 
the hippocampus. Specifically, BDNF IV was upregulated, but BDNF VI was unaffected 
by VPA. The observation that VPA can regulate BDNF expression in a transcript-specific 
manner is consistent with previous research. For instance, Almeida et al. (2014) found 
prenatal exposure to VPA increased specific BDNF transcripts (I, IV, VI) but not others, 
in foetal whole brains of mice. In addition, Yasuda et al. (2009) found VPA treatment 
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increased the level of BDNF IV (but not I, II, or VI) in rat cortical neuronal cultures. As 
discussed in chapter 1 of this thesis, VPA is an HDAC-I with the ability to regulate the 
expression of a wide number of genes (Lloyd, 2013). Literature investigating the effects 
of other HDAC-Is (such as TSA or sodium butyrate) on BDNF expression suggests that 
the mechanism by which VPA alters specific BDNF transcript expression is likely 
through the inhibition of HDAC. For instance, Yasuda et al. (2009) were able to find 
similar increases in BDNF IV using TSA and sodium butyrate that they found using 
VPA. In addition, Aid et al. (2007) found TSA increased the expression of specific BDNF 
transcripts (III, VII, IXA) in rat C6 glioma cells. Together, the findings here and 
elsewhere suggest that histone deacetylation may play a role in the regulation of BDNF 
expression. 
Although EXP-X observed a VPA-induced increase in BDNF IV and no effect of 
VPA on BDNF VI, total BDNF in the hippocampus actually decreased. This finding was 
unexpected as typically the BDNF IV and VI transcripts have been seen as primary 
drivers of the level of total BDNF, particularly within the hippocampus (Calabrese et al., 
2013). For instance, Almeida et al. (2014) found the VPA-induced increase in total BDNF 
to be associated with a 13 and 15 fold increase in the BDNF IV and VI transcripts, 
respectively. However, these authors analysed foetal whole brains in mice just 3 hr after 
being exposed to VPA and thus a number of experimental differences may account for the 
divergent effects of VPA on BDNF IV and VI. The data from EXP-X indicate that 
transcripts other than the IV and the VI are likely to account for the VPA-induced 
decrease in total BDNF mRNA in the hippocampus of PND 7 rats. Future research would 
benefit from an analysis of all BDNF transcripts.  
EXP-XI aimed to measure IL-6 in serum. However, levels of IL-6 were too low (< 5 
pg/ml) to be accurately detected in all experimental groups. The undetectably low amount 
of IL-6 reported here is in accordance with previous research finding undetectably low 
levels of IL-6 in control animals (Clark, Rinker, Lessov, Hazel, & Eckenstein, 1999; 
Givalois et al., 1994; Ulich, Guo, Remick, Del Castillo, & Yin, 1991). Thus, the moderate 
genetic and environmental manipulations used in this thesis do not seem to produce 
relevant (i.e., above background) increases in IL-6, relative to controls. More sensitive 
measures of IL-6 detection, such as a cytometric bead array, would be necessary for 
future research aiming to determine the precise levels of IL-6 in a prenatal exposure to 
VPA rat model. Nonetheless, based on the low levels of IL-6 reported here, prenatal 
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exposure to a moderate dose of VPA (400 mg/kg) does not produce physiologically 
relevant changes in IL-6 in either wild-type or heterozygous SERT rats, at least at PND 7.  
 
Conclusion   
Taken together, the data in this chapter show there is no interaction between SERT 
genotype and prenatal exposure to VPA on BDNF expression levels. However, SERT 
genotype and prenatal exposure to VPA demonstrated independent main effects on BDNF 
expression that were parameter-specific. Interestingly, prenatal exposure to VPA 
dysregulated BDNF expression in different ways, depending on the brain region 
investigated – once again highlighting the specificity of VPA’s influence and its 
sensitivity to experimental variables. Finally, this SERT reduction-prenatal exposure to 
VPA model left levels of IL-6 undisturbed.  
With the inclusion of the work in this chapter, the current thesis has provided an 
investigation of behavioural, biochemical, and immunological domains in the hopes of 
observing ASD-like symptomatology and determining the validity of the proposed gene-
environment model for ASD. 
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CHAPTER 5: GENERAL DISCUSSION 
 
 ASD is a pervasive neurodevelopmental disorder characterised by social, 
communicative, and behavioural deficits. The apparent increase in prevalence over the 
past 20 years, the enormous burden to the patient and society, and the lack of effective 
pharmacological treatments have made ASD an increasing focus of research. Animal 
models play a major role in this research process, as they allow for the testing of specific 
hypotheses and the identification of novel therapies (Bauman et al., 2010). However, the 
recent rate of animal research translating into novel pharmacological therapies has been 
poor, particularly in the field of neuroscience (Kola & Landis, 2004). This low rate has 
prompted debate over the merit of animal research in general, and caused several major 
pharmaceutical companies to drastically reduce, or cut all together, animal research in 
areas with particularly low rates of success (Chandler, 2013; McGonigle & Ruggeri, 
2014). Thus, there is an urgent need for improved animal models (Kola & Landis, 2004; 
McGonigle & Ruggeri, 2014; Seok et al., 2013).  
It is now well understood that ASD develops as a result of an interaction between both 
genetic and environmental influences. However, most existing animal models for this 
disorder only take into account one of these aetiological contributors and have largely 
ignored looking at an interaction. There are a number of problems with this traditional 
modelling approach, but most prominent is the lack of construct validity involved in 
mimicking only one aspect of the aetiological process. For instance, one of the best 
models that currently exists for ASD is the prenatal exposure to VPA model that has been 
used in this thesis, yet this model only factors in one environmental influence and ignores 
the substantial contribution of genetic factors. In addition, VPA is likely only one of 
many environmental factors that interact with genotype in the development of ASD. 
Thus, the construct validity of even the best models are limited (Ranger & Ellenbroek, 
2015). Given that construct validity may be the most important element of an animal 
model (van der Staay et al., 2009), steps are needed to improve the construct validity of 
animal models in this field. To improve the construct validity of ASD animal models one 
suggestion is to develop models that take a gene-environment interaction approach – an 
approach that is particularly lacking in preclinical ASD research. 
The current thesis used two previously established environmental-based models for 
ASD and combined each of them with a genetic animal model that mimicked a genotype 
associated with ASD. The overall purpose was to develop a novel animal model for ASD 
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that demonstrated higher construct validity than traditional models due to its gene-
environment approach. Specifically, in chapter 2 a maternal immune activation model 
(prenatal administration of LPS) was combined with a SERT knockout model and in 
chapters 3 and 4 a prenatal exposure to VPA model (prenatal administration of VPA) was 
combined with a SERT knockout model. These chapters tested the hypothesis that rats 
with a genetically compromised SERT function will be more vulnerable to the impacts of 
different environmental risk factors.  
Collectively, the data from this thesis show that although both LPS and VPA 
interacted with SERT genotype on certain behavioural measures, only the prenatal 
exposure to VPA model interacted with SERT genotype on behavioural measures related 
to ASD. Specifically, the interaction between LPS and SERT genotype was only found on 
non-ASD type behaviours (locomotion), whereas prenatal exposure to VPA interacted 
with SERT on two of the three core dysfunctions in ASD: social behaviour and repetitive 
behaviour. Contrary to expectation, however, the data did not support the hypothesis that 
rats with a genetically compromised SERT function would be more vulnerable to the 
impacts of prenatal exposure to VPA. In fact, rats with a compromised SERT function 
appeared more resilient to the ASD-like effects of VPA. Extrapolating these findings to 
the human condition, the data presented in this thesis predict individuals with the S allele 
of the 5-HTTLPR may be more resilient to the ASD-related influence of prenatal VPA. 
Future research investigating the 5-HTTLPR genotype of ASD patients prenatally 
exposed to VPA would be required to test this prediction.  
The reason rats with a compromised SERT genotype showed resilience, rather 
than vulnerability, to certain ASD-like effects of prenatal exposure to VPA is unclear.  
However, based on the considerable evidence demonstrating VPA’s high sensitivity for 
experimental variables, a possible explanation for these unexpected findings is simply 
that the combination of experimental variables in this thesis were novel and therefore one 
could expect the unexpected. An alternative explanation might be that the timing of the 
VPA dose was wrong for detecting vulnerability. As outlined in chapter 1, the timing of 
VPA administration significantly influences the long term responses to this drug.  
Previous research demonstrated that a prenatal dose of VPA at GD 12 reliably produces 
ASD-like deficits in normal, wild-type rodents, and thus was an obvious choice for the 
current thesis. However, perhaps GD 12 is not the optimal day where the hypothesised 
enhanced vulnerability of heterozygous rats is exposed. In line with this idea are findings 
that prenatal VPA at GD 9 significantly impacts on the serotonergic system (Dufour-
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Rainfray et al., 2010; Miyazaki et al., 2005; Narita et al., 2002). It is at least conceivable 
that VPA administration earlier than GD 12 may more strongly interact with the SERT 
genotype and expose the enhanced vulnerability hypothesised in this thesis. Future studies 
investigating the role of timing using a gene-environment approach would be needed to 
evaluate this suggestion. Although speculative at this point in time, should an enhanced 
vulnerability be found following an earlier dose of VPA, this would again emphasise the 
importance of tightly controlling the experimental variables when administering VPA.  
 
Limitations 
The overall goal of this thesis was to contribute to the development of animal models for 
ASD that possess higher construct validity and translatability to the human condition. To 
this aim, existing environmental animal models for ASD were crossed with a SERT 
knockout model. Thus, limitations in the typical methods of modelling maternal immune 
activation and prenatal exposure to VPA are present in the current thesis. Most notably, 
although strong face validity for the prenatal VPA model has been repeatedly observed, 
the typical treatment schedule used in this model does not quite mimic the human 
experience. Specifically, this thesis (and previous research) administered a single 
exposure of VPA during pregnancy, whereas in human pregnancies women typically take 
VPA for a prolonged period of time. More research investigating chronic VPA exposure 
in animals would be beneficial as it would increase the construct validity of the model by 
more accurately mimicking the human experience – this is especially important given the 
vital role that timing plays in response to VPA. A recent study investigating chronic 
exposure to low doses of VPA in rats reported disturbances in brain organisation 
equivalent to patients with ASD, thus supporting the suggestion for more work of this 
kind (Sabers et al., 2015). 
Even though gene-environment approaches will likely improve the construct validity 
of animal models of ASD, the limitations of these types of models, particularly within this 
field, must be acknowledged. The aetiology of ASD is complex and diverse, making it 
uniquely difficult to model the causal components of ASD in an animal model. For 
instance, genetic linkage studies have had enormous difficulty finding specific genetic 
factors that are consistently found to be associated with ASD and failed replications of 
initial discoveries are common. Most single genetic effects are small and it is likely the 
combination of many genes that is responsible for the overall effect of an individual’s 
genotype on their likelihood of developing ASD. Moreover, although certain 
 129 
 
environmental agents such as VPA have been linked to the development of ASD, the 
majority of patients have not been exposed to VPA and thus a combination of 
environmental factors likely interacts with a susceptible genotype to produce the deficits 
observed in ASD. Given that gene-environment models will usually follow the approach 
in this thesis (i.e, the combining of a genetic risk factor and an environmental risk factor 
in the same model) it will likely be impossible in practical terms to model the number of 
risk factors necessary to mimic the causal process in humans. In short, it seems that 
inherent in the limitation of the gene-environment approach in the field of ASD, is the 
complexity of ASD itself. This raises the question of whether the enormous complexity of 
ASD will pose an insurmountable challenge towards developing truly predictive animal 
models for this disorder. In addition, if the answer to this question is yes, what is an 
alternative strategy to solve this problem? 
 
Towards a better future 
Despite the first reports of ASD occurring over 70 years ago, this disorder is still poorly 
understood. The heterogeneous clinical profile and truly complex aetiology of ASD have 
proven serious obstacles for researchers working in this field. At this stage, it is evident 
that in addition to experiencing their disorder differently, individuals with ASD likely 
developed their disorder in different ways. Thus, it is probable that different clusters of 
patients will require different pharmacological treatments. Indeed, it has been argued that 
it is time to abandon the search for a single cause or cure for ASD and instead investigate 
the specific core symptoms separately (Happé, Ronald, & Plomin, 2006). In support of 
this argument, population-based data indicate that the three core domains of ASD may not 
represent a coherent triad but may simply be three mostly independent domains of 
impairment. For instance, Ronald, Happe, Bolton, et al. (2006) found that the three core 
domains of ASD are genetically heterogeneous and although deficits in one domain 
increased the likelihood of a deficit in another, this increased risk was relatively low 
overall. In other words, rather than one underlying genetic deficit explaining the triad of 
behavioural symptoms in ASD, different genes are responsible for the different core 
dysfunctions present in this disorder. This finding likely accounts for why these deficits 
are often found in isolation within the general population (Ronald, Happe, Price, Baron-
Cohen, & Plomin, 2006). If the different symptoms have different causes, it raises the 
question of whether ASD is even a unitary disorder at all. Although Ronald, Happe, 
Bolton, et al. (2006) found evidence for a small percentage of genes acting on multiple 
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parts of the triad, as Happé et al. (2006) argued, what is more interesting is the degree of 
separation. The degree of separation between the behavioural symptoms of ASD may 
explain why large scale genetic studies often provide inconsistent data when looking at 
ASD as a whole. For instance, although investigations into the role of the 5-HTTLPR in 
ASD provided remarkably heterogeneous findings overall (as described in chapter 1), 
when studies sub-grouped ASD by phenotype and genotype a clearer picture began to 
emerge (Brune et al., 2006; Kolevzon et al., 2014; Schauder et al., 2015; Tordjman et al., 
2001). A strong focus on researching ASD as a unitary disorder may be a significant 
reason why so little is known about this disorder despite decades of research. 
Interestingly, a similar conclusion was drawn by Arnedo et al. (2015) with regards to 
schizophrenia. After providing evidence that schizophrenia is comprised of distinct 
clinical syndromes with heterogeneous genetic architecture, these authors concluded that 
much of schizophrenia’s heritability has not been detected due to studies approaching 
schizophrenia as a whole, rather than using a more detailed analysis of patient phenotype 
(Arnedo et al., 2015).  
Although Happé et al. (2006) called for a fractionation of ASD’s triad of symptoms 
over 10 years ago, research has largely continued to approach this disorder as a whole (a 
disorder approach), in need of a singular explanation. In fact, the most recent edition of 
the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) actually moved in the 
opposite direction from a fractionation and grouped previously distinguished 
developmental disorders together (Association, 2013). It is time to start taking the 
suggestion offered by Happé et al. (2006) seriously and acknowledge the possibility that 
ASD may be an illusory triad.  
Approaching ASD as a unitary disorder (the disorder approach) should be abandoned 
and instead focus must move to the core symptoms as though they are independent 
impairments that simply co-exist in a number of people (a symptom approach). In this 
manner, the focus would shift from developing a model for ASD, towards developing 
different models for reduced sociability, reduced communication, and repetitive 
behaviour. In addition, effort should be made to model both genetic and environmental 
determinants of these symptoms. Under the traditional disorder approach, the 
heterogeneous aetiology and symptomatology of ASD pose insurmountable challenges to 
the development of good animal models for this disorder as it is impossible for a single 
animal model to mimic either all the causes or the range of symptoms. For instance, the 
prenatal exposure to VPA model cannot account for the majority of ASD cases that were 
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not induced by VPA. In addition, even though this model is credited with a very high 
degree of face validity, it cannot replicate the heterogeneity of symptoms observed in the 
clinical population. With the inability to create good, predictive animal models for ASD, 
it is not surprising that no effective pharmacological treatments have been developed.  
Following a symptom approach into the future would be beneficial for a variety of 
reasons. First, it would lower the complex demands of a traditional ASD animal model 
and thus increase the likelihood of a predictive model in the specific domain of interest, 
such as reduced social behaviour. Second, if successful models of these core domains 
were developed it would lead to the development of treatments that may be used across 
multiple disorders. For instance, reduced social behaviour is also present in other 
psychopathological disorders such as schizophrenia. In addition, these treatments would 
be of use to individuals who experience difficulties in just one of the three domains and 
are currently undiagnosed for this reason. This point is of particular importance given that 
extreme deficits in these areas can occur in isolation within the general population 
(Ronald, Happe, Price, et al., 2006). Finally, even if ASD does represent a true triad of 
symptoms and the fractionation of these symptoms has been exaggerated, the non-success 
of ASD models up until now suggests a symptom approach may still be a more efficient 
method of modelling. In general, an efficient method of solving complex problems is to 
break down the larger problem into smaller, more easily solvable, problems.  
In summary, the complexities of ASD’s symptomatology and aetiology may be 
fundamental obstacles to modelling this disorder. In fact, the great irony in this field may 
be that the biggest factor holding back progress in ASD research is the very fact that 
scientists are focusing on ASD. The best way forward may be to transition from a 
disorder approach toward a symptom approach.  
 
Conclusion 
The aim of this thesis was to develop a novel animal model for ASD that demonstrated 
higher construct validity than traditional models by using a gene-environment approach. 
To this aim, this thesis investigated the hypothesis that rats with a genetically 
compromised SERT function would be more vulnerable to the impacts of different 
environmental risk factors. The data show that rats with a genetically compromised SERT 
function are not more vulnerable to the impact of either a maternal immune activation 
encountered during foetal development or prenatal exposure to VPA, at least with regards 
to the behavioural, biochemical, and immunological measures of ASD-like 
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symptomatology employed in this thesis. On the contrary, rats with a genetically 
compromised SERT function actually appeared more resilient to some ASD-like 
outcomes, at least following prenatal exposure to VPA. Future attempts to improve 
animal models in this field should continue modelling both genetic and environmental 
risk factors, but would benefit from taking a symptom-based approach rather than the 
more traditional disorder-based approach.   
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Appendix 
  
Figure 30. Amplification graph for total BDNF in the 
hippocampus of PND 7 rats. 
Figure 31. Amplification graph for total BDNF in the 
frontal lobe of PND 7 rats. 
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Figure 32. Amplification graph for the housekeeping 
gene (36B4) in the hippocampus of PND 7 rats. 
Figure 33. Amplification graph for the housekeeping 
gene (36B4) in the frontal lobe of PND 7 rats. 
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Table 6. Absorbance (nm) values of the serum samples (minus the absorbance value of the 0 pg/ml 
standard, or 'the blank'). Each column represents an experimental group. Each cell represents a different 
sample. 
Wild-type Saline Wild-type VPA Heterozygous 
Saline 
Heterozygous VPA 
-0.0155 
 
-0.0205 
 
-0.0215 
 
-0.031 
 
-0.006 
 
-0.007 
 
-0.021 
 
-0.0175 
 
-0.0145 
 
-0.016 
 
-0.0235 
 
-0.0235 
 
-0.0285 
 
-0.0125 
 
-0.005 
 
-0.0235 
 
-0.0105 
 
-0.0215 
 
-0.0215 
 
-0.02 
 
-0.008 
 
 -0.009 
 
-0.014 
 
-0.0135 
 
 -0.023 
 
-0.028 
 
-0.024 
 
 -0.0165 
 
-0.0265 
 
-0.018 
 
  -0.026 
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